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Abstract
Glycine is the simplest and smallest amino acid present in human proteins. It has many important
roles in human as an intermediate of biosynthetic one carbon metabolism pathways, component of
structural proteins, and in the brain acting as the second major inhibitory neurotransmitter via the
activation of the glycine receptor (GlyR). Glycinergic neurons are present in various brain regions
including the forebrain and the retina, although highest densities can be found in the lower brain
regions of the central nervous system (CNS) such as the brain stem, where glycine is important in
the regulation of muscle contraction, sensory inputs, and others.
Given its diverse role, dysregulation in glycine biosynthesis and neurotranmission is implicated
in numerous conditions detrimental to human health such as some subtypes of glioma, as well as
genetic diseases caused by mutations to the components of the glycinergic synapse, for instance non-
ketotic hyperglycinemia (NHK) which leads to severe neurological problems. Moreover, the control
of glycine concentration time course via the inhibition of glycine reuptake has been suggested as a
potential novel treatment for several conditions, including schizophrenia, alcoholism, and others.
In order to advance the understanding of glycine regulation in the human CNS, computational
modelling of the various aspects of the glycinergic synapse were deployed. A metabolic model of
the CNS was constructed with the use of publicly available databases as a derivation of a generic
model of human metabolism, Recon2.2. The experimentally determined value of the human oxygen
to glucose index (OGI), indicating glucose brain consumption was used to validate the model via
the estimation of the background ATP demand which was similar to that reported in the scientific
literature.
In order to further contextualise the model to represent CNS metabolism, a method for the inte-
gration of single cell RNA-sequencing dataset containing the expression values of different types of
CNS cells was developed.
Flux Balance Analysis (FBA) methods were applied to the model in order to establish the most
likely pathways of glycine and ATP production across different CNS cell types, suggesting the com-
partmentalization of the serine/glycine metabolism in CNS cells. Furthermore, FBA was used to
assess whether serine or glycine can be used as main substrates in increasing cellular ATP and
biosynthetic demands, with the results suggesting that serine can be used for ATP formation by
the mitochondria via its breakdown to glycine, producing NADH for use in the Electron Transport
Chain (ETC).
Interactions between proteins composing the glycinergic synapse, including the glycine transporter
proteins 1 and 2 (GlyT1, GlyT2) which are responsible for the termination of signal via glycine re-
uptake determine the time course of glycine released upon stimulation, and therefore the inhibitory
post-synaptic currents (IPSC) Cl- currents via GlyR. For the purpose of increasing the understand-
ing of the events shaping the glycine time course, a kinetic model of the synapse was developed
iii
integrating previous experimental observations. The model was analysed by looking at the effects
of changing its parameters on the resulting amplitudes and decay time constants of glycine and the
resulting IPSC.
In addition, electrophysiological two electrode voltage clamp (TEVC) techniques were used in or-
der to characterize the effects of a newly identified NKH-causing mutation at position Ser 407 on
GlyT1 expressed in Xenopus laevis oocytes. The mutation lead to the inhibition of transport via
the GlyT1 as compared to wild type transporter, and the result was integrated into the kinetic
synapse model suggesting that the loss of GlyT1 function leads to a higher maximum concentration
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into four lobes, the brain stem, and the cerebellum. Although some brain regions
such as the somatomotor cortex are known to have very specific functions, much of
the higher order phenomena such as the understanding of sound is a result of the
neuronal networks connecting different brain regions which work in tandem. Adapted
from Wikimedia Commons: https://commons.wikimedia.org . . . . . . . . . . . . . 7
1.2 Transverse section of the spinal cord Grey matter which forms the center of
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inputs relayed from the periphery to the central nervous system. The ventral horn
neurons carry information from the brain to the periphery, synapsing onto skeletal
muscle cells. Adapted from Wikimedia Commons: https://commons.wikimedia.org . 9
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synaptic cleft, binding to the GlyR proteins present on the opposing neuron, which
allows an influx of Cl- ions leading to cell hyperpolarization. Glycine concentration
is reduced partially by passive diffusion away from the synaptic cleft, as well as active
reuptake by two transporter proteins, GlyT1 and GlyT2. Adapted from Wikimedia
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try matrix. System of the internal reactions can be represented mathematically in a
stoichiometry matrix, in which the rows describes metabolites and columns describe
reactions. Elements of the matrix are the stoichiometric coefficients, where the neg-
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is a product. If a metabolite does not take part in a reaction, the stoichiometric
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Glycine is the simplest amino acid with numerous function in mammals, where it is a component
of structural proteins, an intermediate metabolite of cellular biosynthetic pathways as well as in
the brain functioning as an inhibitory neurotransmitter. Although glycine or its precursor, serine,
can be supplied from the diet, due to their neuroactive properties uptake of these amino acids is
restricted by the blood brain barrier (BBB) and their de novo brain biosynthesis occurs inside the
organ.
Glycinergic inhibitory synapses are located mostly to the lower brain regions such as the brain stem
and the spinal cord, where glycine regulates the movement of skeletal muscles, breathing rhythms,
and others. Disruption of glycinergic neurotransmission resulting from mutations in proteins con-
trolling its concentration lead to rare conditions with severe phenotypes, for instance the inborn
metabolic condition, nonketotic hyperglycinemia (NKH) which results in death in over 50% of af-
fected individuals in the first neonatal week [3]. Furthermore, modulation of glycine time course
across the glycinergic synapse in different brain regions via the inhibition of its reuptake has been
proposed as a treatment for numerous conditions, including schizophrenia, alcoholism, and others
[4].
With respect to cellular metabolism overall, conversion of serine to glycine is the main source of one
carbon (1C) units used in the biosynthetic pathways of one carbon metabolism and thus pathways
of serine/glycine metabolism are implicated in a subset of cancers. In the brain, increased glycine
concentrations and correlated with the presence and stage of human gliomas [5, 6], and upregula-
tion of genes encoding enzymes related to serine/glycine has been found in a subset of cancers from
different tissues [7–10].
Much of what is known about glycine biosynthetic pathways specific to the brain is based on ra-
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diolabelled carbon incorporation studies and immunohistochemical staining of enzymes performed
between 1970s - 19s90s, with scant research performed on the topic in recent years. Given the
importance of glycine metabolism to human health, increasing the understanding of its initial
biosynthesis within the brain, as well as the interaction between proteins composing the glycinergic
synapse which regulate its concentration time course can aid in the design of novel chemotherapeu-
tic agents and neuromodulator compounds.
1.2 Glycine and the CNS
1.2.1 Brain composition and neuronal communication
The brain is composed of various cell types with by far the most important being the neuron, first
discovered by Cajal in 1886 and responsible for conducting information across the central nervous
system. Neurons are specialized cells, with extensions from the cell body (or the soma) called the
axons, which relay information away from the cell body and dendrites, which integrate incoming
signals towards the soma. The axons vary in length, with the longest being the sciatic nerve which
extends from the base of the spinal cord to the big toe of the foot and measures at around one
meter. Information is carried across the axon as an electrical impulse known as an action potential,
thus in order to prevent the dissipation of ionic flow and ensure speed of transmission, many axons
are coated in myelin, a fatty substance which insulates the cord along its length. Communication
in the form of electrical signals is enabled due to a difference in charge contained within the fluid
external to the cell and that within the cell cytosol. The resting voltage of a neuron is around
-70mV although varies according to the cell and is set up by the active transport of ions across the
compartments, as well as the presence of negatively charged proteins within the cell.
The synapse comes from the Greek word for ‘conjunction’ and is the site of communication between
two neurons. It is composed of the axon belonging to the presynaptic cell, a tiny space called the
synaptic cleft, and the dendrite of the opposing postsynaptic neuron. Transmission of signal across
the synapse is relayed via electrical or chemical means, with each having a specific advantage. The
electrical synapse directly transmits ionic fluxes from one cell to the other via the gap junction
made up of specialized proteins and is a faster method of talk, allowing cells to fire in unison.
The chemical synapse on the other hand is slower, and involves the release of a neurotransmitter
from the flattened structure of the axonal bouton, which binds to a neurotransmitter receptor pro-
tein on the opposing dendrite. Neurotransmitters available in the cytosol of the presynaptic cell are
packaged into synaptic vesicles which, triggered by an increase in Ca2+ concentrations in the soma,
fuse with the membrane and release the messenger across the synaptic cleft. There are two main
types of receptor proteins, the ligand gated ion channels (LGICs) which directly carry an ionic flux,
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and G-coupled receptor proteins which trigger the opening of a neighbouring ion channel protein.
Upon neurotransmitter binding, the LGIC protein changes its conformation and allows the flow of
ions into the postsynaptic neuron. Amino acids composing the pore of the protein determine the
electrochemical environment which favour the flow of differently charged ions. Excitatory chemical
synapses which form the majority within the CNS contain neurotransmitter receptors which favours
the flow of positively charged ions, leading to an increase in the cell voltage and thus the proba-
bility of cell depolarization. Inhibitory chemical synapses contain receptors which carry negatively
charged ions, leading to a decrease in the probability of neuronal firing. A single neuron contains
dendrites which forms connections with numerous other neurons, both excitatory and inhibitory
thus response is generated within the cell if there is a large net disbalance between inhibition and
excitation within a region of the soma.
Although it was originally thought that one neuron synthesizes and releases only one type of neuro-
transmitter, it is now known that many neurons co-release different neurotransmitters which may
be concentrated in separate, or the same synaptic vesicles. The list of neurotransmitters accepted
so far is still growing, with more than 20 classified neurotransmitters and more potential candidates
under review. Major categories include amino acid neurotransmitters or their derivatives (eg. glu-
tamate and glycine), peptides (eg. endorphins) and monoamines (eg. dopamine, serotonin).
Neurotransmitter receptors bind their respective agonist, but may also contain binding sites for
partial agonists such as other neurotransmitters which lead to a lower receptor response relative to
its response to the main agonist. They may also contain binding sites for other molecules which
modulate receptor function which may be native or non-native such as alcohols, anaesthetics, and
psychoactive substances like cannabis.
Apart from neurons, the brain is composed of different supporting cell types collectively termed the
glial cells which outnumber neurons, and constitute between 30-60% of the total mammalian brain
mass [11, 12]. Glial cells are further subdivided into four major classes, microglial cells, astrocytes,
oligodendrocytes and their precursor cells, NG2-glia [13]. These cells have many important func-
tions which are yet not fully understood. Astrocytes are by far the most studied glial cell type and
are important in providing metabolic support to neurons, as well as in the maintenance of ionic
gradients. Oligodendendrocytes secrete the myelin which ensheaths the neuronal axons of some
neurons but their function is thought to extend beyond that, also to include providing metabolic
support to neurons and others [14].
Brain tissue is divided into the grey and white matter, with the former composed of neuronal cell
bodies, dendrites, as well as supporting glial cells. White matter refers to the mass containing
myelinated axons as well as glial cells, including oligodendrocytes and others.
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1.2.2 Brain anatomy overview
The human brain weights around 3 pounds in the adult and its weight to body weight ratio is one of
the highest in mammals. Lower brain regions including the cerebellum and the brain stem control
the more primal functions shared across the animal kingdom whereas the outer layer, the cerebral
cortex, is the origin of more sophisticated activities, such as the understanding of consequence. The
cerebral cortex composes around 80% of the weight of the brain and is thought to have expanded
more recently in the course of human brain evolution in comparison to the lower brain region. The
highly developed cerebral cortex, and high brain to body mass ratio are an indicator of higher
intelligence in primates overall.
Communication between the brain and the rest of the body is mediated by neuronal connections
and has been classified into two distinct system, the peripheral and the central nervous systems
(PNS and CNS). The former includes the nerves outside of the brain as well as the spinal cord,
with the main function of relaying information between organs and limbs to the central nervous
system which is composed of the spinal cord and the brain.
The brain is enclosed in bone termed the cranium, which together with the bones protecting the
face form the skull. Between the cranium and the brain itself is the meninges, which is a three
layered tissue mass functioning as protective tissue as well as housing blood vessels and cavities
which allows the flow of cerebrospinal fluid (CSF). The latter is a clear fluid that is secreted by the
choroid plexus within the brain’s ventricular system, composed of four hollow spaces located to the
center of the brain and associated tubes which allow the flow of CSF around the brain. Its main
functions are to provide mechanical protection, increase the brains buoyancy thus protecting the
lower brain regions from the the effects of its mass, as well as being important in the clearance of
metabolic waste products and maintenance of cell homeostasis.
Anatomy of the brain can be generalised to three major sections, the cerebral cortex (or cerebrum),
composing the outer layer of the brain, the brain stem which resides in the deep mid-section of the
brain, and the cerebellum which lies in the back of the organ.
The cerebrum is composed of the right and left hemispheres joined by a tract of nerves named
the corpus callosum which communicates signals between the two hemispheres. Different rates of
expansion of the grey and white matter during embryonic development leads to an increase in the
surface of the organ in a compact form, leading to its wrinkled appearance. The tissue depth can be
divided into six cortical layers which contain different types and structural architectures of neurons
and supporting cells, and by region which distinguishes four major divisions, the frontal, paretial,
occipital and temporal lobes (Figure 1.1). Much of what is known about the functions attributed
to each of these areas come from observation of animal and human with injuries to a specific area,
as well as functional MRI (fMRI) studies which observe changes in regional blood flow in response
to stimuli or given task.
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Figure 1.1: Main regions of the human brain The brain can be divided into three major
areas, the cerebral cortex which forms the outer layer which is further subdivided into four lobes,
the brain stem, and the cerebellum. Although some brain regions such as the somatomotor cortex
are known to have very specific functions, much of the higher order phenomena such as the
understanding of sound is a result of the neuronal networks connecting different brain regions
which work in tandem. Adapted from Wikimedia Commons: https://commons.wikimedia.org
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The frontal lobe is located at the front of the brain and is the largest of all lobes. It is impli-
cated in a variety of human traits and abilities, including personality, decision making, emotional
responses, speech and language - for instance, patients with damage to the frontal lobe may perform
normally when testing for intellectual ability but have problems with emotional regulation.
Further towards the back of the organ lies the somatomotor cortex, which receives signals from the
lower brain regions and is responsible for conscious movement. It contains populations of neurons
which directly map onto different parts of the body- this specific mapping feature is also seen in
the neighbouring somatosensory complex which is involved in the processing of sensory signals from
the peripheral nervous system. The somatosensory cortex lies next to the paretial lobe, which is
involved in higher order functions such as sensorimotor planning, learning, spatial recognition, and
the ability to differentiate objects shapes and relationships in space.
The occipital lobe is the smallest out of all, and lies in the most posterior region of the brain. It is
the visual center of the brain, receiving and processing information from the retina and deals with
aspects of colour and object recognition, depth perception, facial recognition and others.
Lastly, the temporal lobe is located in the lower area on each side of the brain and is generally im-
plicated in processing of auditory and visual signals, important in language recognition, production
of speech and its perception, memory formation and others.
Deep in the core of the brain, above the brain stem lie the thalamus and the hypothalamus, which
are important for movement, perception, and vital bodily functions. The thalamus receives infor-
mation from the lower brain regions that make up the senses of touch, taste, hearing and sight,
then modulates and relays the information into the higher regions of the cerebral cortex. The
hypothalamus sits below the thalamus and is important in maintaining body homeostasis, such as
temperature control, sleep cycles, appetite and emotions. It controls the interactions between the
body’s nervous system and the endocrine system, receiving information from different areas of the
body and in turn stimulating organs and glands to release hormones.
The brain stem is composed of three sections, the pons, the midbrain and the medulla oblongata. It
is continuous with the spinal cord and is crucial in the regulation of autonomic body functions, for
example heart rate, breathing rhythms, as well the diameter of blood vessels. It is also important
in the integration of signals which control voluntary skeletal muscle movements.
Another major area controlling movement is the cerebellum, which is located to the back of the
brain and relays information from the motor area of the cerebral cortex to the spinal cord, whilst
also receiving impulses from the periphery. In result, it is crucial in the coordination of voluntary
muscle actions which work in maintaining posture, balance, as well as in the production of speech.
Extending from the brain stem is the spinal cord, mostly responsible for motor control of extremi-
ties as well as for relaying sensory signals from the rest of the body to the brain. It is a cylindrical
bundle of neurons and supporting cells running within the vertebral canal, surrounded by spinal
meninges filled with CSF which functions to protect the internal tissue. The interior of the spinal
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cord is composed of the grey matter, surrounded by white matter (Figure 1.2). Cross-sectional
anatomy of the grey matter divides the spinal cord into dorsal (posterior) and ventral (anterior)
horns, with a central canal in the middle that carries CSF from the ventricular system and trans-
ports nutrients to the surrounding tissue. Neurons within the dorsal horn receive sensory inputs
such as pain from the afferent dorsal axon nerve cells of the peripheral nervous system and relays
that information to the central nervous system. The ventral horn contains neurons which extend
their neuronal axons via the ventral root and further synapse to their respective body segment,









Figure 1.2: Transverse section of the spinal cord Grey matter which forms the center of the
tissue is divided into dorsal and ventral horns. Spinal nerves couples emerge from the space
between two vertebrae on each side of the spine. The dorsal horn contains neuronal cells incoming
from the dorsal root ganglion and carries sensory inputs relayed from the periphery to the central
nervous system. The ventral horn neurons carry information from the brain to the periphery,
synapsing onto skeletal muscle cells. Adapted from Wikimedia Commons:
https://commons.wikimedia.org
1.2.3 Brain energy metabolism
The average human adult brain comprises around 2% of body weight, yet accounts for 20% of the
oxygen consumption [15, 16], a proxy for the total amount of energy utilization by this relatively
small organ. The biochemical pathways of the ATP production in brain are the same as for other
human cells, involving the oxidation of glucose via glycolysis, and subsequently mitochondrial ox-
idative phosphorylation.
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Early studies of in vivo cerebral metabolism based on measurements of the arterio-venous differ-
ences in oxygen and glucose levels showed that glucose is consumed in nearly stoichiometric amounts
with the oxygen required for the complete oxidation of glucose [15]. The molar ratio consumption
of these substrates is the oxygen-to-glucose index (OGI), and is a widely used measure to describe
the fate of glucose in the brain, with a ratio of six suggesting that all glucose is utilized via the
mitochondrial oxidative pathways. A recent meta-analysis by Blazey et al. [17] showed that in
the human, experimentally recorded values of OGI range from 4.5 to 7.5, with a median of 5.5.
The discrepancy between this value and the theoretical value of six suggests glucose processing via
non-oxidative pathways, incomplete oxidation leading to a net release of lactate, or others. Value
of OGI above six suggest utilization of alternative energy substrates by the brain. Since the OGI
is close to the value of six, it is assumed that glucose is the near exclusive energy substrate for
cerebral ATP production overall.
Development of the 2-[14C]deoxyglucose (2-DG) tracer technique [18] allowed for the determination
of glucose utilization rates across all brain regions simultaneously in animal, and revealed that the
rate of glucose consumption is unequal across the brain [19], with the grey matter requiring more
ATP than white matter overall [19]. The majority of the metabolic energy consumption in the
grey matter is required to sustain processes occurring at chemical synapses which underlie neuronal
signalling. This includes restoration of ionic gradients necessary for the propagation of action po-
tentials, reuptake of neurotransmitter, and others. Since excitatory glutamatergic synapses are the
predominant type of chemical synapse, outnumbering inhibitory synapses by 9 to 1, glutamater-
gic neurotransmission is the major consumer of ATP in the brain. This has been supported by
studies showing a co-localization of mitochondria with the glutamatergic synapse components [20],
as well as the observations that glucose use correlates with the rates of conversion of glutamate
to glutamine [21]. Regional glucose consumption is linked to neuronal activation, and blocking
neuronal signalling via deep anaesthesia in the cortex leads to an 80-90% reduction in energy con-
sumption [21] showing that in the grey matter, neuronal activation is the major consumer of energy,
as opposed to cellular maintenance processes. Given the prevalence of glutamate in the brain, the
majority of research regarding brain energy utilization has focused on neurons and the supporting
glial cells which compose the glutamatergic synapse.
The Astrocyte-Neuronal Lactate Shuttle
Early studies using isolated cell cultures showed that CO2 production in neurons is greater than
that in the astrocyte [22, 23], suggesting a higher rate of mitochondrial oxidative phosphorylation
in the former. Pellerin and Magistretti [24] observed that upon stimulation with glutamate, astro-
cytes increase their rate of 2-DG phosphorylation and lactate release, which led these authors to
propose a mechanistic model for the metabolic cooperativity between these two cell types, named
the Astrocyte-Neuronal Lactate Shuttle (ANLS). This theory proposes that there is dissimilar pref-
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erence for the use of glucose and lactate to fuel energy production in astrocytes and neurons, which
work synergistically to support glutamatergic neurotransmission. Stimulated by glutamate uptake,
astrocytes oxidise glucose to lactate which is released into the extracellular environment. Lactate is
then taken up by the surrounding neurons which oxidise it for energy production. The authors state
that astrocytes have a higher activity of glycolysis in comparison to neurons, which produce ATP via
oxidative phosphorylation. According to the ANLS theory, neuronal glucose is primarily consumed
via the pentose phosphate pathway (PPP), which produces NADPH required for the reduction of
glutathione (GSH), necessary for the neutralization of reactive oxygen species (ROS) produced in
the oxidative mitochondrial pathways. Evidence supporting the theory was summarised in a review
by Magistretti and Allaman [25] and includes, amongst experimental observations, a summary of
the differential expression of genes encoding the enzymes of central metabolism which led the au-
thors to conclude that the enzymatic signature contained in these cells supports the ANLS.
However, no technique has yet been developed which may directly prove the theory in vivo, and
there exists multiple lines of evidence against the ANLS. Astrocytes contain high densities of mito-
chondria, and express enzymes of the Tricarboxylic acid Cycle (TCA) and well as those encoding
components of the Electron Transport Chain (ETC) [26] suggesting the activity of oxidative meta-
bolism. As opposed to the findings reported by Pellerin and Magistretti [24], other groups showed
that glutamate does not have an effect on 2-DG phosphorylation, and later studies utilizing in
vivo NMR spectroscopy showed that the fraction of oxygen utilization by astrocytes is similar to
the average volume fraction occupied by these cells in the brain [27, 28]. Another objection to
the ANLS theory states that it does not take into account the capability of astrocytes to oxidise
glucose-derived neurotransmitters, most notably glutamate [29–31] which is present in large con-
centrations intracellularly and may significantly contribute to the total ATP production in these
cells.
Transport of glucose and lactate is mediated by the monocarboxylate transporters (MCT) which
are expressed across various CNS cell types [32], thus utilization of lactate in one cell which orig-
inates from another may take place, but it remains underdetermined whether each cell type has
a preference for either substrate for the production of energy. As summed up in a recent review
by Dienel [33], it is likely that the metabolic pathways of energy production in the brain require
a more complex description, which depends on factors such as substrate availability, physiological
state of the cell, and others. These factors are difficult to control in the organism in vivo, and thus
computational modelling can greatly aid in the probing of questions pertinent to changes in the
metabolic pathways utilized by different CNS cell types.
Blood Brain Barrier
Metabolic pathways in the brain are dependent on the passage of oxygen, as well as carbon and
nitrogen sources from the circulating blood to the brain. The restrictive properties of brain mi-
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crovasculature, composed of endothelial cells held together by tight junctions, blood vessels, immune
system cells, astrocytes and others is collectively termed the blood brain barrier (BBB). Movement
of molecules across the BBB is a regulated process which allows for maintenance of CNS home-
ostasis and protection of the brain against pathogens, toxins, and disease. Hydrophilic substrates
such as glucose must transverse the BBB via carrier-mediated systems of transporters which are
asymmetrically expressed in the luminal (blood side) and abluminal (brain side) membranes of
the endothelial cells [34]. Glucose is transported across the BBB via the Glucose transport protein
(GLUT), but during starvation the brain can consume acetoacetate and hydroxybutyrate to support
its metabolic needs by uptake via monocarboxylate transporters, the expression of which increases
in response to prolonged fasting [35]. Uptake of amino acids is a tightly regulated process, mediated
by a system of facilitative amino acid transporters expressed on each side of the endothelial cell. In
general, movement of essential, neutral amino acids is greater than that of nonessential amino acids
and since the concentrations of all amino acids (except for glutamate) is higher in the circulating
blood than in the CSF, amino acids most likely leave the brain against a concentration gradient
[36]. The uptake of neurotransmitter amino acids such as glutamate and glycine is minimal, in
order to ensure no uncontrolled activation of their respective receptors, therefore these amino acids
are mostly synthesized within the brain rather than imported from blood circulation.
1.2.4 Glycine metabolism in the CNS
Pioneering experiments studying the role of glycine in the CNS by Aprison et al. [37] showed that
it is widely distributed across the brain, with highest concentrations found in the brain stem and
the spinal cord in the post mortem brains of vertebrates, which was later confirmed in autopsied
human brains by Perry et al. [38]. Measurements of the rate of labelled C14 atom incorporation
from glucose and serine into glycine by Shank et al. [39] showed that the ratio of carbon label from
glucose was similar to that obtained from serine, indicating that the latter is the primary source of
glycine in the CNS via the serine hydroxymethyltransferase (SHMT) catalyzed reaction. Another
potential source of glycine suspected at the time was from the transamination of glyoxylate by the
serine-pyruvate transaminase enzyme, which was shown in rat spinal cord extracts in vitro [40].
However, ratios of labelled serine and glycine derived from glucose as shown by Shank et al. [39]
suggested that this pathway does not significantly contribute to glycine biosynthesis in the brain in
vivo. In addition, expression of genes encoding the SHMT is high in comparison to those encoding
the transaminase enzyme in the brain, which has mostly been found in the human liver so far [41]
thus it is unlikely that glyoxylate is available in the brain.
Serine hydroxymethyltransferase catalyzes the reversible conversion of serine and tetrahydrofolate
into glycine and methylene-THF . Apart from its role in glycine metabolism, it is an important
enzyme in the reactions of one-carbon metabolism of folates in which it significantly contributes to
1.2. GLYCINE AND THE CNS 13
the availability of 1C units for the synthesis of purines, deoxythymidine monophosphate (dTMP),
as well as methionine which is adenylated to S-adenosyl methionine (SAM), a methylation cofactor
[42]. In humans, two genes encoding SHMT1 and SHMT2 are present encoding the cytoplasmic
and mitochondrial enzyme isoforms, respectively. This allows for the compartmentalization of folate
metabolism, thus metabolic pools involved in folate cycling can be regulated independently in the
cell. Experiments aiming to explain the function of SHMT compartmentalization showed that each
isoenzyme regulates a different cellular process - SHMT2 is mainly responsible for the biosynthesis
of glycine and 1C groups, whereas SHMT1 utilizes the mitochondrially-derived 1C groups for the
production of purines, methionine, and dTMP [43]. Mice deficient in SHMT2 experience respiratory
problems and die within the neonatal period [44], but those deficient in SHMT1 are viable, thus
only the former has been shown to be essential in rodent models [43].
Degradation of glycine in the CNS is mediated by the glycine cleavage system (GCS) which is com-
posed of four proteins loosely associated in the mitochondrial membrane which catalyze a rather
complex reaction resulting in the release of methylene-THF , CO2 and NH3 [45]. This reaction was
shown to be readily reversible in the rat liver mitochondria in vitro [45], although it is uncertain
if this may occur in vivo [46]. Although the expression of SHMT is not cell-specific, immunohisto-
chemical staining of the various regions of a rat brain by Sato et al. [47] showed that the P-protein
component of the GCS was confined to astrocytes, suggesting that glycine breakdown is mediated
exclusively by these cells.
Folate-cycling metabolic pathways are essential in cellular biosynthetic processes, thus the disrup-
tion of these pathways has long been identified as potential treatment against cancer. Antifolate
chemotherapeutic agents were the first class of antimetabolite drugs to be administered clinically
[48], and include currently widely used medications such as methotrexate and pemetrexed which af-
fect tetrahydrofolate biosynthesis [49]. It follows that serine/glycine metabolism has been identified
as a potential target for novel chemotherapy drug development, as has been previously reviewed
in several papers [50–52]. Relevant to brain malignancy, increased glycine concentrations are posi-
tively associated with the presence and stage of human gliomas [5, 6]. In addition, overexpression of
genes related to serine/glycine biosynthetic pathways, phosphoglycerate dehydrogenase (PHGDH),
SHMT2 and GCS has been found in a subset of human cancers [7–10], including gliomas [6, 53].
The ability of serine to support proliferation was shown in human cell cultures in in vitro [54], sug-
gesting that this amino acid may be capable of supporting not only biosynthetic, but also energy
production pathways in a cell although exactly how serine/glycine metabolic pathways support cell
proliferation is not known.
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1.2.5 Glycinergic neurotransmission
Following the studies by Aprison et al. [37] indicating high glycine concentrations in the ventral
horn of the spinal cord, subsequent electrophysiological experiments showed that glycine applica-
tion causes a hyperpolarization of motorneurons located in this region, which further implied that
glycine is an inhibitory neurotransmitter [55]. Glycine was found to increase Cl- ion conductance of
the neuronal membrane, and was inhibited by the alkaloid strychnine, the binding of which was Cl-
and glycine-dependent in the spinal cord of a rat [56]. Subsequently, the subunits composing the
rat glycine receptor (GlyR) protein were purified by affinity chromatography by Pfeiffer et al. [57],
establishing conclusive evidence for glycine’s role as an inhibitory neurotransmitter in the CNS.
High sequence homology with the nicotinic acetylcholine receptor (nAchR) led to the classification
of GlyR as a member of the Cys-loop family of ligand-gated ion channels (LGICs), which share
structural features [58]. LGICs can be expressed as homomeric or heteromeric proteins, composed
of five subunits arranged symmetrically in a ring with a central ion-conducting pore. They are
transmembrane proteins, containing an extracellular ligand-binding domain, a transmembrane do-
main, and an intracellular domain which takes part in receptor modulation [59]. The heteromeric
GlyR is composed of the α subunit, four isoforms of which have been identified [60] and the β
subunit, which is mainly involved in the anchoring of the receptor to the membrane via the protein
gephyrin [61] . Although α subunits can assemble to form functional homomeric GlyRs, expression
of which has been found in embryonic neurons [62], the distribution of the heteromeric receptor is
more widespread in the adult brain [63], thus it is likely to mediate majority of the glycine-induced
inhibition.
The glycinergic inhibitory synapse is composed of GlyR expressed in the membrane of the post-
synaptic neuron, as well as proteins conveying the events of glycine release and reuptake (Figure
1.3). Cytoplasmic glycine localized in the presynaptic neuron is concentrated in the synaptic vesi-
cle via the vesicular inhibitory amino acid transporter (VIAAT), which uptakes both glycine and
the other major inhibitory neurotransmitter, γ-aminobutyric acid (GABA). Inhibitory glycinergic
neurons may therefore utilize glycine only, or mixed neurotransmitter GABA and glycine which
is thought to be determined by the relative concentrations of each in the cytoplasm, affecting the
final concentrations in the synaptic vesicle [64]. Fusion of the synaptic vesicle is initiated by the
binding of Ca2+ ions, the concentrations of which increases following an action potential arrival in
the presynaptic cell. Upon release, glycine diffuses across the synaptic cleft, binding to the GlyR
present on the opposing neuron which increases its Cl- conductance.
Termination of this process is mediated partially by passive diffusion of glycine away from the
synapse, as well as the active reuptake by two transporter proteins, the glycine transporter 1 and
2 (GlyT1, GlyT2). Up to date, five variants of the GlyT1 (a-e) and three variants of GlyT2 (a-c)
have been identified which occur as a result of alternative gene promoter usage and/or splicing.
The glycine transporters are members of the SLC6 Na+ /Cl- -dependent neurotransmitter trans-
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porters family which also include transporters for other amino acids such as taurine, as well as
neurotransmitters dopamine, serotonin, and others [65]. The SLC6 Na+ /Cl- family proteins share
structural, and thus functional features which determine the mechanism of transport. Translocation
of ligand is coupled with Na+ and Cl- ions, utilizing the energy provided by their electrochemical
gradients to convey neurotransmitter transport. Although the types of ions co-transporter is the
same for all transporters across the family, the numbers of ions transported on each cycle differ.
Electrophysiological experiments in combination with radiolabelled glycine uptake studies by Roux
and Supplisson [66] showed that GlyT1 binds Na+ , Cl- and glycine in a 2:1:1, whereas GlyT2 in a
3:1:1 ratio. The difference in the stoichiometry has important implications, since the binding of the
extra Na+ by GlyT2 provides a bigger driving force for glycine reuptake by this protein, and affects
its ability for reverse glycine transport [66]. Indeed, the cellular distribution of each transporter
isoform, in combination with studies using pharmacological agents which inhibit reuptake suggest
that they have different roles in the CNS. GlyT1 is expressed across most regions of the brain, and is
located mostly to the glial cells surrounding the synapse. Across the inhibitory glycinergic synapses,
GlyT1 is thought to regulate the time course of the neurotransmitter transient. GlyT1-deficient
mice have respiratory defects and die within the first postnatal day. Measurements of the time
course of the inhibitory postsynaptic currents (IPSC) in the brain stem of these mice shows that
the IPSC decay time constant is increased, thus the phenotype is likely caused by over-inhibition
of the respiratory centers, due to increase glycine concentrations which persist for longer in the
synapse [67]. Apart from its role across the inhibitory synapses, in other regions of the brain such
as the forebrain GlyT1 is important in the regulation of N-methyl-D-aspartate (NMDA) receptor
which binds glycine as a co-substrate with glutamate [68]. On the other hand, GlyT2 expression
closely follows that of the GlyR [69], where it is thought to be mostly implicated in the refilling of
the presynaptic vesicle with glycine, necessary for effective uptake by the VIAAT [70], which has a
low affinity for glycine [71]. The amplitude of IPSC recorder from the spinal cords of mice deficient
in GlyT2 show a marked reduction, suggesting insufficient glycine concentrations in the presynaptic
cell.
1.2.6 Glycine and human health
Glycine receptor immunoreactivity was found to be particularly high in the lower brain regions
of the brain stem and the spinal cord, the retina [72] but also in the higher brain regions such
as the hippocampus and the forebrain structures of the cerebral cortex [73]. In the spinal cord,
glycinergic interneurons regulate motor control, such as via the reciprocal inhibition of excitatory
neurons coordinating the antagonistic relaxation of skeletal muscle [74].
Mutations in glycinergic synapse components, most notably GlyR, as well as GlyT2 results in hy-
perkplexia, which is characterised by uncontrolled startle reflex, as well as neonatal hypertonia in










Figure 1.3: Glycinergic inhibitory synapse Glycine available in the cytosol is packaged into
synaptic vesicles which fuse with the membrane releasing the neurotransmitter, triggered by an
increase in the concentration of Ca2+ ions. Glycine diffuses across the synaptic cleft, binding to
the GlyR proteins present on the opposing neuron, which allows an influx of Cl- ions leading to
cell hyperpolarization. Glycine concentration is reduced partially by passive diffusion away from
the synaptic cleft, as well as active reuptake by two transporter proteins, GlyT1 and GlyT2.
Adapted from Wikimedia Commons: https://commons.wikimedia.org
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response to tactile, auditory and other stimuli [75]. Although the onset of the condition may occur
at any age, it most often presents in early life, and in the neonatal period can cause severe apnea and
even death. As the disease progresses, life-threatening events subside but are replaced with startle
responses which present as muscle stiffenings in the affected individuals. The condition is caused
by reduced glycinergic inhibition, and current treatments include the use of benzodiazepines which
enhance GABA-mediated inhibitory action, compensating for the loss of glycinergic inhibition.
In the spinal cord, glycine is also involved in the regulation of the somatosensory system, and
reduction in the inhibitory neurotransmission is thought to contribute to the increased sensitivity
in neuropathic pain. Therefore, increasing glycine concentrations in these regions was identified
as a possible treatment option which may lead to analgesic effects in affected individuals. Since
the BBB restricts the uptake of glycine, research has focused on increasing its concentration in
the brain in situ, leading to the development of GlyT inhibitors, which act by decreasing glycine
reuptake during neurotransmission. Although various GlyT inhibitors have been shown to reduce
nociception in animal pain models, acute inhibition was also shown to cause side effects including
respiratory distress and at certain concentrations, an increase in nociception [76–78]. In addition,
it has been proposed that GlyT inhibitors could be used in order to control seizures in epileptic
patients unresponsive to currently available GABA therapy, as well as in the facilitation of con-
trolling alcoholism, obsessive compulsory disorders (OCD), and others via the dampening of the
dopaminergic reward systems in the nucleus accumbens of the midbrain.
Glycine is an essential co-agonist of the NMDA receptors which are critical in the cellular mecha-
nisms responsible for learning and memory, the disruption of which is thought to be implicated in
the pathophysiology of schizophrenia [4]. It was therefore hypothesized that regulation of glycine
concentrations across synapses containing NMDA receptor activity can be used to alleviate symp-
toms in patients, and the most advanced clinical trials of GlyT inhibitors were performed in the
pharmaceutical development of novel schizophrenia treatments. In the first instance, GlyT1 in-
hibitors were developed with the goal of increasing NMDA receptor activity in the forebrain, but
it has been since recognised that effects may also be relayed by inhibitory glycinergic circuits reg-
ulating dopamine and glutamate across various areas of the brain, alleviating negative symptoms
of schizophrenia in patients, such as poor working memory [4]. Although numerous compounds
were shown to be promising in controlling schizophrenia symptoms in animals models, bitopertin,
a GlyT1 inhibitor went the furthest in clinical trials, however phase III results show that it was
ineffective across a group size of roughly 600 schizophrenia patients as compared to placebo [79].
Dysregulation in glycinergic inhibition can also be caused by defects in enzymes involved in glycine
biosynthesis. Nonketotic hyperglycinemia (NKH) is an inborn condition which is characterised by
lethargy, hypotonia, and apnea in newborns with mortality rates at 50% within the first neonatal
week [3], with surviving infants experiencing severe motor and cognitive impairments. It is caused
by mutations in the GCS, responsible for glycine breakdown and thus the condition is recognised
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by the elevated glycine concentrations in the cerebrospinal fluid, which most likely leads to overac-
tivation of inhibitory glycinergic and excitatory NMDA synapses. To date, no effective treatments
for NKH have been developed [3].
Majority of patients presenting with NKH are born with mutations in the GCS components, al-
though recently a novel NKH-causing mutation was identified in a child which resides in the Ser
407 position of the GlyT1 [80]. This is the first time a mutation in the GlyT1 was linked to NKH,
and the functional effect of amino acid replacement at Ser 407 position of GlyT1 has not yet been
established.
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1.3 Computational modelling
1.3.1 Introduction
The application of mathematics to describe and study interactions within biological systems emerged
independently across various disciplines aiming to rigorously describe diverse phenomena including
laws governing biochemical reactions, electrical properties of neuronal cells, or the growth of pop-
ulations of a species. These systems differ widely, varying in their complexity with respect to the
number of interacting components, relative time scales in which events occur, and physical con-
strains they are under, leading to an equally wide range of theoretical descriptions and methods of
analysis. The overall goal of all, however is to develop a mathematical abstraction of a system based
on previous observation for the purpose of understanding the system and furthermore, predict its
future behaviours. Mathematical modelling also allows one to set up experiments in systems that
would prove difficult or otherwise impossible to perform in a laboratory setting, which is limited to
the techniques available.
Modern mathematical models describing protein interactions are rooted in principles derived from
the experimental observations in the late 19th and early 20th centuries. In 1864 Guldberg and
Waage described the law of mass action, which states that the rate of a chemical reaction in equi-






cD + dD (1.1)
where A and B are the substrates, C and D are products, a, b, c and d are the stoichiometric
coefficients describing the molar proportions of the species, and kf and kr are the reaction rate
constants. The order of reaction is related to how many molecules are changed in a reactions, thus





At equilibrium, the rates of the overall forward and reverse reactions are equal, thus there is no
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The equilibrium constant expresses the relationship between the concentrations of substrates
and products and remains the same regardless of the concentrations or absolute rates, at a given
temperature and pressure. Applying the law of mass balance, differential equations describing the
rate of reactant concentration changes over time can be written, for instance the rate of change of
C can be expressed as:
dC
dt
= Vf − Vr = kfAaBb − krCcDd (1.6)
This description of chemical reactions provide the foundation for deriving differential equations
that quantify the relationships between concentrations and reactions rates which can be measured
via experimental manipulation of variables in the equation.
Observations of enzyme-catalyzed reaction rates indicated features which did not follow the law of
mass action. It was noticed that the thermal stability of the enzyme is higher in the presence of
the subtrate than in its absence, leading to the idea of the enzyme-substrate complex. The enzyme
was not destroyed, even after catalysing the hydrolysis of a much higher weight of its substrate
than itself. Furthermore, there existed an optimal temperature at which the reaction proceeded the
fastest, unlike second-order kinetic reaction rates [81]. Amongst others, these observations led to
the description of biological catalysts and the kinetic reaction rate formalisms which followed. As
described by Cornish-Bowden [82], the equation describing the rate of progress of enzyme-catalyzed
reactions was first described by Henri, and the advantage of the use of the equation as well as further
experimental contributions achieved by Michaelis and Menten. The Michaelis Menten equation is





and describes the kinetics of saturable reactions involving a catalyst which converts product into
substrate, without itself taking part in the reaction. The parameters of the equation are Vmax , the
maximum forward rate of the reaction, S, the concentration of substrate and Km, the Michealis
constant. Enzyme catalysts function by increasing the speed of a reaction via lowering the activation
energy required for the reaction to proceed under given conditions, without affecting the equilibrium
of the reaction. They bind their substrates at the catalytic site at which the reaction occurs, and
may undergo some structural changes during the reaction progress but overall are not changed in
the reaction, thus are capable of catalysing multiple rounds of the reaction.
Although the Michaelis Menten equation could successfully fit reaction rate curves of many single-
substrate enzymes, it could not account for the sigmoidal shapes of rate curves observed for other
types of reactions. This type of curve implied a different method of regulation, with a higher
sensitivity of substrate to its protein. As previously, novel observations of how the rate of a reaction
changes according to the substrate concentrations lead to a need for a novel explanation. The first
model of cooperativity was proposed by Hill who used it to fit the rate of oxygen binding to
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It can be seen that this equation is very similar to the Michaelis Menten equation, with the exception
of the introduction of a new parameter, h, which is the Hill’s coefficient of cooperativity. The Hill
equation is a phenomenological model, meaning that it fitted the experimental observations but did
not provide a mechanistic interpretation for what happens between the substrate and protein. This
was offered by the development of mechanistic models of cooperativity, which were derived based
on the assumed sequence of substrate binding and the associated conformational changes that the
protein undertakes and include the Adair equation, the Koshland-Nemethy-Filmer (KNF) model,
as well as the Monod-Wyman-Changeux (MWC) model.
Cooperativity manifests as an apparent higher affinity of the enzyme to the substrate following the
binding of a preceeding substrate. It is an instance of allostery, which is the phenomena observed
when an effector binding at one site of the enzyme induces a change in the conformation of the
enzyme far away in space from its binding site. The MWC model [83] assumes that the enzyme
is composed of several subunits which possess at least one axis of symmetry that can exist in
different global conformational states even in the absence of any bound substrate. The affinity of
the substrate differs towards each global conformational state, and its binding shifts the equilibrium
towards one or the other conformational state, inducing a global concerted movement in all subunits.
This is in contrast to the KNF model, which assumes that the binding of ligand induces independent
conformational changes in protein subunits.
Since their conception, these well-known equations have been applied to describe the progress of
various types of proteins interacting with a substrate. The Michealis Menten equation, as well as
the Hill equation have the advantage of simplicity, and contain terms which can be easily interpreted
and compared between different protein-substrate interactions. Thus, outside of enzymology they
have found application in the field of quantitative pharmacology to describe the rates of transport of
substrates across biological membranes by transporter proteins, as well as ligand-receptor binding
reactions. Computational fitting of these equations to the reaction rates curves allows for the
estimation of the maximal reaction rate, as well as concentrations of substrate which produces
half-maximal effects, parameters that can be easily understood. In addition, the extension of these
equations by terms describing the action of inhibitors is used to directly compare the effects of
different compounds on the same protein, and has been applied in the field of drug discovery.
The MWC model has also seen wide use in biology. Experimental X-ray crystallography studies
have shown that numerous enzymes, as well as signalling and transport proteins are oligomeric
with one or more axis of symmetry [84], which is in agreement with the original MWC postulates.
Since its conception, the model has been applied to describe the activation of G-protein coupled
receptors [85], chaperones [86], and others [87]. Perhaps one of the earliest protein families the MWC
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was applied to were the ligand-gated ion channel receptors (LGICs) (Section 1.2.5), including the
nicotinic Acetylcholine receptor and later on, the glycine receptor. Since the original MWC did
not provide a good fit to some of the experimental data obtained from the single-channel study of
LGICs, multiple models have been proposed which built upon the original assumptions, nevertheless
retaining the overall features predicted by the MWC [88].
1.3.2 Kinetic models
Due to the normally low levels of expression in cells, study of proteins often involves overexpression
of the protein in question in model organisms, which is far from the in vivo environment the protein
normally operates in. This is invaluable in elucidation of the single protein structure and function
but lacks the context within which the protein operates. Kinetic modelling of systems combines
the knowledge of numerous single-protein reactions and can aid in the understanding of component
interactions within the system as a whole. Kinetic models are a type of mathematical model and
include sets of equations which describe the time evolution of events within a system composed
of multiple reactions. Often, multiple kinetic mechanistic models may be proposed for a set of
experimental observations and that which provides the best fit to the data offers an insight to the
sequence of events that take place.
The importance of studying component interactions is central to the field of systems biology, which
has strong philosophical underpinnings characterized by a holistic approach to understanding life.
This is in opposition to reductionistic approaches, which is the idea that complex phenomena can be
understood via the study of its principal components. For instance, although individual properties
of enzymes can be quantified in isolated experiments in vitro, this will not provide an understand-
ing of their action within a cell cytoplasm which contains numerous enzymes that form metabolic
pathways which operate simultaneously.
Kinetic models in biology are often composed of a set of mass balance first order differential equa-
tions (ODEs). This requires the definition of the species involved in each reaction, as well as the
appropriate kinetic rate equations which describes the speed of progress of each reaction. Which
appropriate rate equation to use is decided based upon previous experimental observations and
research by the modeller. Naturally, the model aims to represent a simplified nature of the biology
in question, thus experimental data is normally collected prior to model construction.
Consider the set of biochemical reactions in Figure 1.4, which can be described by a system of
ODEs as follows:
dA
dt = vR1 + vR3 − vR2
dB
dt = vR2 − vR3 − vR4 − vR5
dC
dt = vR4
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For convenience, it is assumed that the concentrations of external metabolites xA, xB are con-
stant thus are not changing in time. Biologically, these metabolites are those whose concentration
is high inside the cell thus changes in their concentration are considered negligible, or those which
are maintained at a constant level outside of the system. The internal metabolite concentrations
(A − C ) are non-constant and are a function of initial concentrations, time, t, and the kinetic
parameters defined in the rate equations describing the progress of reactions vR1−vR5 . The kinetic
rate equations used may be in the form of mass action statements, as in Equation 1.6, the Michaelis
Menten equation, or other. The initial conditions, at t = 0, including metabolite concentrations
and the kinetic parameters of rate equations are set by the modeller and provide a starting point for
the model simulation. The system of ODEs is integrated by a computer, where the evolution of the
dependent parameters, which are the metabolite concentrations and reaction rates are calculated
over the independent parameters, t, as well as the kinetic parameters.
Although ODE models are most common, kinetic models vary greatly in their mathematical compo-
sition. For instance, biophysical models of neurotransmitter diffusion away from the site of release
are often composed of partial differential equations (PDEs) capable of calculating species concen-
tration evolutions in time as well as space [89]. A big distinction within kinetic modelling is their
division into deterministic and stochastic models, with the ODEs systems falling in the former.
Stochastic models are more complex, and take into account random variability in the behaviour of
biological systems which is needed to be taken into account in the modelling of small scale systems.
1.3.3 Structural models
Structural modelling of metabolism represents metabolic interconversions within a system under
study, but is concerned only with the analysis of the network based on its topology rather than
reaction time evolutions. The model is composed of a set of enzyme-catalysed reactions including
their stoichiometry, but excluding the definition of rate equations and kinetic parameters that
describe their progress. The set of reactions in the system follows the fundamental laws of mass
conservation as all models describing material transfers and this, in combination with a high level
of metabolite connectivity in the network imposes a powerful set of constraints from which insight
can be gained. For instance, structural models can be used to discover those reactions in the
system which are essential for a given pathway, or those sets of reactions which must proceed at
proportionate velocities in the network. It can be argued that the analysis of the network structure
is of most importance in modelling overall, and may also provide insight into the possible rates
at which reactions proceed, even if they are not known. Furthermore, the appropriate choice of
rate equations and collection of kinetic parameters for kinetic modelling often proves difficult, and
structural modelling circumvents these issues altogether.
The set of ODEs describing the network in Figure 1.4 can be represented in matrix format:
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Figure 1.4: Representation of a reaction network in a matrix format An example of a
small biochemical reaction network can be seen in the diagram. Species with the ‘x ’ prefix are
considered external to the system, thus are not included in the stoichiometry matrix. System of
the internal reactions can be represented mathematically in a stoichiometry matrix, in which the
rows describes metabolites and columns describe reactions. Elements of the matrix are the
stoichiometric coefficients, where the negative signs mean the metabolite is a substrate and
positive sign mean the metabolite is a product. If a metabolite does not take part in a reaction,
the stoichiometric coefficient is zero.
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where the changes in the concentrations of metabolites, collected in the most left vector, can
be calculated from the stoichiometry matrix, multiplied by the vector of reaction rates. In short




where s is the vector of internal metabolite concentrations, N is the stoichiometry matrix, and
v is the vector of reaction rates. The internal stoichiometry matrix includes the set of reaction
stoichiometries which involve the transformations of metabolites considered internal to the system.
External metabolites are excluded, since their concentration is assumed to be constant. The sto-
ichiometry matrix rows correspond to metabolites, whereas columns correspond to reactions, and
the entries are filled with the stoichiometric coefficient of a metabolite taking part in a specific
reaction (Figure 1.4). For example, since one mole of A is produced in the reactions R1 and R3,
the entry in the stoichiometry matrix is positive one. One mole of A is consumed in the reaction
R2, thus the entry is minus one, and since A does not take part in reactions R4 and R5 the entries
are zero.
The stoichiometry matrix allows for the inclusion of all reactions present in the system in a single
mathematical notation. Matrix transformations, common to the field of mathematics allow for the
discovery of interesting properties belonging to the system.
Structural modelling assumes that the system is in steady state, meaning that the changes in
metabolite concentrations, s , which are a product of the concentrations of metabolites N and
reaction rates, v is equal to zero, ie.
ds
dt
= Nv = 0 (1.10)
The assumption of steady state means that the system maintains the internal concentrations con-
stant over time, such that the net consumption of external metabolites that are consumed equals the
net formation of excreted products. Fluctuations in enzyme concentrations which catalyse internal
reactions, such as degradation or synthesis happen on a much longer time scale than enzymatic
transfomations, thus are considered external to the system [90]. The steady state assumption is
very powerful, as the relationships defined by the directionality of the reactions, stoichiometric
coefficients, as well connectivities between the metabolites only can provide lots of information
regarding the interactions between these variables. The addition of reactions with known rates
further allows for the calculation of a physically meaningful rates vector v [91], as described in the
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following sections.
Analysis of the right nullspace of the stoichiometry matrix
The relationships between reaction rates contained within vector v as imposed by the steady state
constraint have useful biological interpretations [92]. Linear algebra can be applied to the matrix
in a set of transformation, from which insight into the boundaries within which the biological
system operates can be gained. The complete set of possible solutions to the Equation 1.11 forms
a subspace of the stoichiometry matrix called the null space, or the kernel of the matrix, K, thus
Equation 1.11 becomes:
NK = 0 (1.11)









The row order of the kernel is the same as the column order of N, and each column in the kernel
represents a flux distribution vector at steady state. Any steady state flux vector can be further




























From these examples, a number of important properties of the network can be understood. In
the first instance, one can identify reactions in the network which cannot carry flux under any
condition as given by those rows all elements of which are equal to zero, in this example, reaction
4. These reactions are considered dead, and are often a result of incomplete network annotation.
Secondly, the kernel identifies sets of reactions which carry proportional or identical flux at steady
state, which can be seen as proportional row vectors of K, in the above example reactions 1 and
5. These reaction sets are named enzyme subsets, and they identify reactions that are active in
unison, therefore which reactions must all be active in a solution for any to be active; removal of
any reaction from a subset renders the others dead [93]. Graphically, enzyme subset row vectors
are parallel to each other in the solution space. An extension to the idea of enzyme subsets was
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to assess the correlation between all row vectors which was described by Poolman et al. [94], who
formally defined the correlation between kernel vectors as the cosine angle between each vector in
the orthogonal kernel form. The orthogonal kernel is defined as that which satisfies the relationship















where K is the orthogonal kernel matrix with m rows, i, j ∈ 1...n and θKij is the angle between
rows i and j in K. Mathematically, the RCC is identical to the Pearson’s correlation coefficient,
and can take any value between +1 and -1 where values of +1 identify reactions which carry propor-
tional flux (identical to enzyme subsets) and 0 indicate those which are completely disconnected.
Collection of all the φij in a matrix notation forms the dissimilarity matrix, to which clustering
algorithms can be applied such as the Weighted Pair Group Method using Arithmetic Averaging
(WPGMA) algorithm in order to generate metabolic correlation trees, that can be used to visualise
the relationships between entities [94].
Another property that can be calculated from the right null space is the set of sub-pathways that
form small ‘routes’ within the network which can operate by themselves, called elementary modes.
An elementary mode is a flux distribution such that it agrees with the steady state assumption,
reversibility constraints imposed by the network, and cannot be decomposed into smaller modes
(pathways). The last requirement means that the deletion of any reaction within an elementary
mode renders all of the other reactions in that elementary mode unable to carry flux under steady
state, thus identifying small stand-alone networks within the whole system (Figure 1.5). The con-
cept was introduced by Leiser and Blum [95], later developed by Fell, D.A. [96], and the first
algorithm for the calculation of elementary modes was described by Schuster and Hilgetag [97].
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Figure 1.5: Elementary modes within a small network Reactions which form elementary
modes within the hypothetical network a are indicated in red arrows. Elementary modes b and c
are irreversible and have identical net stoichiometries, converting x A to x B.
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Analysis of the left nullspace of the stoichiometry matrix
Just as the calculation of the right null space of the stoichiometry matrix is informative of the
relationships between reaction fluxes, calculation of linear dependencies between row vectors can
be used to derive relationships between metabolites. This information is found within the left
nullspace and is defined as the complete set of vectors by which the transpose of the stoichiometry
matrix, NT , is multiplied such that the solution equals the null vector, ie.:
KLN = 0 (1.13)
and can be calculated from:
KL = K(NT)T (1.14)
where KL is the nullspace, and NT is the transpose of the stoichiometry matrix, N. The left null
space contains information about the conservation relationships between the concentrations of all
metabolites within the model which is useful both in the area of structural and kinetic modelling.
Linear dependencies allow for the reduction of the system’s dimension since the dependent species
can be calculated from the concentrations of the independent species [90]. With respect to metabolic
modelling, the left nullspace can be used to identify moieties whose total concentration is constant,
named conserved moieties, an example of which can be seen in Figure 1.6. Biologically, conserved
moieties are atom groups which remain unchanged and often are cofactors such as NAD which take
part in many reactions. Although their concentrations must vary according to initial biosynthesis
and final degradation, it is assumed the interconversions between moieties is much faster compared
to their overall turnovers [98].
Flux Balance Analysis
Methods of structural analysis can describe the relationships between model metabolites in the
network, as well as reaction rates, without the knowledge of their absolute values. For example,
analysis of the right null space can be used to address questions such as- what is the effect of
doubling rate of reaction 1 on reaction 3? However, without the knowledge of some of the reaction
fluxes these effects cannot be quantified. This is achieved by including experimentally determined
flux values via the transport reactions defining the inputs and outputs. An example of such exper-
imental data are the rates of production of bacterial biomass components which can be determined
from the culture growth curves.
A commonly used technique for analysing metabolic models which makes use of the experimentally
determined flux values is Flux Balance Analysis (FBA), which applies Linear Programming (LP)
methods of optimization to calculate flux distributions under a set of constraints. Linear program-
ming is a technique applied to a system of linear equations which finds the most ‘optimal’ solution
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Figure 1.6: Moiety conservation relationships Set of the differential equations describing the
rate of metabolite production can be derived from the left null space of the stoichiometry matrix.
It can be seen from this example that metabolites C and D are produced and consumed by the
same reactions in opposite directions, thus are conserved across the system. This means that the
concentration of one of these metabolites only is needed to determine the other, reducing the
dimensionality of the system. Although these relationships can be easily derived by hand for the
network above, this does not hold true for larger networks including hundreds of reactions, thus
providing an obvious advantage of their derivation by the transformation of the stoichiometry
matrix.
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for an objective function under a set of defined constraints. It is a widely used technique in mathe-
matics, economics, and engineering. The application of LP to metabolic modelling was first realised
by Fell and Small [99] and Watson [100], and developed by Varma and Palsson [101] which resulted
in the FBA methods now widely used in structural modelling [102, 103]. The problem definition is
set up by the modeller thus rendering the technique applicable to a plethora of models, and thus
problems. The objective function is a value defined by the modeller which can be minimized or







Nn,m · v = 0
vxB = 1
(1.15)
where the objective function is minimization of the total flux of the reaction vector, vj , subject to
the steady state assumption which states that the reaction vector v, multiplied by the stoichiometry
matrix, N containing n metabolites taking part in m reactions must equal zero, with an additional
constraint on the value of export of a metabolite, vxB measured experimentally equal to one. In
FBA, the objective function may be that of flux minimization or maximization, under any set of
constraints on reactions internal or external to the system.
1.3.4 Construction and analysis of genome scale metabolic models
Thanks to the developments in the genome-sequencing techniques which allow for rapid identifica-
tion of a set of genes, and therefore enzyme present, experimental data is readily available for model
reconstruction. This is reflected in the high number of published models describing the metabolism
of more than 6000 organisms, and applied to a variety of problems in the fields of biotechnology,
human health, and others [104].
Although structural models vary in their network coverage, genome scale metabolic models (GSM)
are most commonly developed, which are comprised of all the known metabolic reactions within
an organisms derived from a complete genome sequence. GSMs have successfully been used to
predict genomic knockout targets for the disruption of pathogenic bacterial growth [105], increase
in production yields of biotechnologically useful compounds in yeast [106], and others.
Advances in the field have enabled reconstruction of metabolic models has expanded from the de-
scription of single-celled prokaryotes, to eukaryotic cells containing compartmentalised metabolism,
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and finally models of higher eukaryotic organisms including models of human tissues. Reconstruc-
tion of models describing human metabolism differs to those of single-celled organisms because of
the high heterogeneity in protein expression across different organs and cell types. This has led to
the development of cell specific metabolic models such as the liver hepatocyte model HepatoNet1
[107] or the model of astrocyte and neuron interactions by Çakr et al. [108]. Context-specific models
can be achieved by extensive literature review or a more automated method of -omics data inte-
gration into a more generic model. In 2007, two genome-scale models (GSM) comprising collective
human cells metabolism were released - the Edinburgh Human metabolic network [109] and Recon1
[110]. Since then, the Recon model has undergone several revisions, with the most current version,
Recon3D [111], available interactively online at https://www.vmh.life/.. The availability of these
models as templates for all human metabolism has allowed for the development of numerous tai-
lored, cell- and context- specific models by the method of integration of -omics data [112–114].
As an overview, the reconstruction of metabolic models requires the collection of a set of reactions
to include, transformation of this data into a computational object and finally, development of a
computational toolset for the analysis of the model.
Databases
Model reconstruction relies heavily on the use of well annotated biochemical databases which provide
information about the association of genes with proteins, and the stoichiometries and directionality
of the reactions they catalyze, which is lacking from gene expression data only. Two commonly used
biochemical databases are BioCyc [115] and KEGG [116] with the former used in the current study.
BioCyc contains extensive biochemical annotations for hundreds of reactions further subdivided into
organisms-specific datasets which provides a great convenience during model annotation. Organism-
specific datasets can be accessed online or downloaded as raw files from biocyc.org/download.shtlm
in the .dat format, which can be explored in any user-specific environment. Models can be derived
from the set of organism-specific reactions in the database, or else provide a good resource in the
process of manual gap filling during model curation. Another resource relevant to model curation
is the BRENDA [117] database, which encapsulates information about the properties of metabolic
enzymes such as their substrates and products as well as related kinetic parameters, and others.
The generic human-tissue model reconstructions such as Recon [111] can be of use as a template
upon which more specialised tissue and cell-specific models can be built. This requires the collection
of gene and protein expression datasets which are used to constrain the network to contain those
reactions that are likely present in the system under study. Since the first mapping of the human
genome was completed in 2001 [118], an interest in defining normal and pathological states in human
has led to an explosion of datasets including genomes, transcriptomes and proteomes. As the avail-
ability of data increased, so did the need for their organisation into single resources, making them
more accessible. The Human Protein Atlas https://www.proteinatlas.org/ is a Web-based resource
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which aims to map all human proteins present at the tissue and cellular level in non- and patho-
logical states in the body, integrating data from numerous experiments. More specialized tissue
resources have also been developed, including the Allen Brain Map https://portal.brain-map.org/
which contains transcriptomic datasets for mouse and human brain across different anatomical sec-
tions of the brain and at pathological states, including glioma. These resources are available freely
online and are crucial in the generation of tissue-specific models, as levels of -omics expressions are
informative of the likely presence of enzyme and thus, active reaction to include in the model.
Integration of transcriptomics data with metabolic models
Reconstruction of context-specific models requires a template model and an expression dataset,
for instance the transcriptome or the proteome extracted from the tissue. In the first instance,
the dataset content is mapped to reactions present in the model by relating genes encoding the
enzymes which catalyze each reaction to the genes present in the dataset. In the next step, the
expression values within the dataset are applied as constraints in an FBA problem, with the overall
objective of translating a higher expression value to a higher probability of the enzyme-catalyzed
reaction appearing in the solution. The statistical analysis of the data, and the method by which
it is applied to the model are dependent on the type of data and the choice of the modeller,
thus several algorithms have been developed so far. Some of these algorithms lead to the complete
disqualification of reactions catalysed by enzymes with low expression, such as FASTCORE [119] or
INIT [120] whilst others lead to minimization of flux via reactions without their complete removal,
such as GIMME [121]. The choice of algorithm potentially results in great variation between the
models extracted from the same dataset, which has been recently evaluated by Opdam et al. [122].
Overall, the authors found that the biggest contributor to the content of a model lies in the algorithm
threshold selection which determines whether a reaction is included or not.
Transcriptomic datasets are often used for integration with GSMs since the experimental methods
of RNA sequencing from tissues are widely available, and provide a wide coverage of the genes
expressed in cells. Conventional cell culture sequencing methods pool the expression of multiple cells
grown in vitro into an averaged dataset. Alternatively, the tissue can be dissected and the expression
of different types of cells averaged. However, organs are composed of widely diverse populations
of cells as a result of differential gene expression, which cooperate to perform the organ’s function.
Gene expression is heterogenous, even amongst the same or similar cell types [123]. A better
understanding of the function of an individual cell can be achieved by the analysis of individual cell
transcriptomes. This has been allowed by the development of single-cell RNA-sequencing (scRNA-
seq) methods, pioneered by Eberwine et al. [124] who sequenced the genomes of individual neurons
from the rat hippocampus. Single cell RNA-seq requires the isolation of individual cells, followed by
parallel sequencing of the reverse-transcribed cDNA libraries, after which cells are sorted by some
specific property. One of the methods of cell isolation is fluorescence-activated cell sorting (FACS),
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which is a commonly used technique that distinguishes cells by a known extracellular protein marker
against which a fluorescently labelled antibody is raised. Tagged cells are later separated by flow
cytometry which sorts them by the fluorescent tag attached. Once separated, mRNA is reverse
transcribed at which step it may be barcoded with a unique identifier. The tagging of the genome
allows for the counting of individual mRNA molecules present and relating them back to a single
cell [125].
The application of scRNA-seq to metabolic models can have obvious uses in the building of cell-
specific metabolic models, which could be further compounded to generate models describing the
interactions of different cells. This has been so far explored in a single study by Zhang et al. [126]
who used scRNA-seq to explore NAD+ biosynthesis in mouse tissues.
Model curation
The initial reconstruction of a model from a genome annotation in combination with a publicly
available database defines the first model draft. However, the databases often contain numerous
errors which can be a result of unspecific or incomplete annotation [127]. An example of such
errors is the inconsistent naming of metabolites which take part of numerous reaction, or the
erroneous inclusion of reactions in the database. Since these sorts of errors often result in biologically
impossible reaction sets, they can be tracked down by the modeller based on known a priori physical
constraints. Once traced, they require manual correction from the modeller on the basis of thorough
literature research, which is the model curation step. As it is relatively simple to generate a first
model draft, manual curation is often the most lengthy step of the model building process but
necessary for the construction of a high-quality model which does not violate known laws of nature.
Mass conservation
In order to respect the principle of mass conservation, the total atom transfer from a set of sub-
strates to products must remain equal. These issues can be identified by the comparison of the sums
of atoms present on each side of the equation, given that the chemical formulas for the metabolites
taking part in the reaction are present in the database. Another way of discovering mass con-
servation problems developed by Gevorgyan et al. [128] utilizes mixed integer linear programming
(MILP) applied to the left nullspace of the stoichiometry matrix which contains information about
the conservation relationships amongst metabolites (Section 1.3.3). It allows for the identification
of metabolites which cannot be assigned a positive molecular mass and thus rendering the network
stoichiometrically inconsistent. For instance, consider the two reactions:
A→ B
A→ B + C
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It can be deduced from the first equation that the chemical formulas of metabolites A and B
are the same, suggesting that it describes some example of isomerization. The second equation can
only hold true if metabolite C does not have mass, which clearly cannot be the case biologically,
meaning that one out of the two statements, or both, must be false.
Presence of such inconsistencies is often a result of incorrect database annotations. Reactions may
be reported with the incorrect or no chemical formula, which is commonly a result of generically
named metabolites that are not assigned a chemical formula. For instance, BioCyc contains a data
entry for the compound ‘3-HYDROXY-ISOBUTYRATE’ which represents a compound class with
no chemical formula attached- the specific instance of this metabolite is found with the identifier
‘CPD-12174’ which needs to be replaced in the model. Another frequent cause of inconsistencies is
the definition of polymers in the database which do not have a defined length, such as the generically
named metabolite ‘Omega-3-Fatty-Acids’ which does not have a chemical formula in BioCyc.
Atomic inconsistencies are resolved manually via the replacement of metabolite for its correct
counterpart, or its specific instance.
Energy and Redox conservation
The principle of the conservation of energy mean that it remains constant over time, which also
applies for conservation of redox, therefore ATP or the reducing agents NAD(P) should not be
formed in the model in the absence of any inputs. Since ATP and reducing cofactors take part in
numerous reactions, incorrect reaction directionality often results in internal reaction cycles that
spontaneously generate these metabolites. In addition to directionality issues, a major cause of
these types of errors is the presence of two reactions with a similar stoichiometry but utilizing a
different type of cofactor.
Linear programming can be used to identity such issues by setting a demand on the production
of a metabolite in question in the absence of any inputs. It is apparent that in this case no
output should be possible thus if the LP problem is feasible, it will contain problematic reactions.
Offending reactions can also be spotted by the calculation of the enzyme subsets from the right
kernel of the stoichiometry matrix (Section 1.3.3). Given that two reactions in a subset are carrying
flux in opposite direction, no LP solution exists in which they may both carry flux, leading to an
inconsistent enzyme subset [127]
Reaction identified by these methods are manually compared against the Brenda database and their
directionality corrected. In the instance where two identical reactions utilizing different cofactors
are found, that which utilizes the cofactor with a lower affinity to the enzyme in question is removed.
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Computational tools
Application of mathematical analysis methods described in Section 1.3.3 is only feasible if the com-
putation is done, unsuprisingly, by a computer. Although the first kinetic ODE models such as
the Michaelis Menten model were integrated by hand, even models composed of a few reactions
only are generally algebraically insoluble. Technological advances have provided a solution to this
problem, and allowed for the definition of more complex models and the development of the theories
described previously. Many modern computational tools extend beyond their use only as a vehicle
for model construction by containing functions which greatly aid in their development, curation
and simulation processes.
Given the extensive use of computational modelling, various tools have been developed for different
purposes. Early computational software tools were developed to aid the simulation of biochemical
kinetic models such as BIOSSIM [129] and SCAMP [130]. With the maturation of the structural
modelling field came the development of software for structural modelling, including METATOOL
written in 1999 [93] after which others followed. More recent software packages are written as
Graphical User Interface (GUI) programs which enables users with a less developed computational
background to build models. The various software bundles available differ in their characteris-
tics such as their computational representation of the network, the database they rely on, and
tools available for the automation of reconstruction which has been summarized in recent reviews
[131, 132].
ScrumPy software which was used in the current study was derived from the SCAMP [130] and is
a collection of Python packages which can be used for the building and analysis of both kinetic,
and structural models [133]. The packages can be accessed via IDLE, Integrated Development
Environment for Python and therefore requires the user to have a knowledge of the Python pro-
gramming language. Although GUIs are available for the plotting of data generated from models,
model analysis is mostly done in the Python language and the model itself is treated as a compu-
tational object. This was a deliberate design of the software, as it allows the user to build upon
the analysis packages already available, and make changes to the packages according to the need of
the model, both of which add to the flexibility of the software. As SCAMP [130] was written in the
C programming language, the choice of Python for the software development was also deliberate
owing to the advantages Python offers described below.
1. Python is a high level programming language, meaning that its syntax in significantly ab-
stracted from the binary machine code fed to the computer. Some operations, for example
memory assignment to data are performed without the need of user input, making it easier
to code in.
2. In comparison to other programming languages such as C, its’ syntax is very simple which
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makes it easy to learn for a novice.
3. It is an open source language which makes it freely available to everyone.
4. There are a number of scientific packages already available in Python, such as the SciPy
(Scientific Programming) package which contains algorithms with ubiquitous use in all com-
putational modelling. Due to the widespread use of Python in the scientific community, the
development and support for these packages is likely to be better than that for a new package
developed by a single person with the same use.
ScrumPy models are, at the lowest level, stoichiometry matrix objects with an array of sophis-
ticated methods attached which aid in the analysis of the matrix. Methods of analysis described in
Section 1.3.3 such as the calculation of reaction control coefficients, generation of metabolic trees or
calculation of enzyme subsets are readily available in ScrumPy. In addition to model analysis, the
software offers a collection of packages which aid in the reconstruction of models from BioCyc files
as well as the following steps of model curation. It has been successfully used for model building in
several previous PhD projects as well as publications [105, 134, 135]. Both kinetic and structural
model construction and analysis in the current study were done in ScrumPy. The software was
developed by Mark Poolman and is downloadable from http://mudshark.brookes.ac.uk/ScrumPy.
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1.3.5 Kinetic modelling of neuronal transmission
Application of mathematics to study the properties of the brain is collectively termed computational
neuroscience, a name coined in 1988 by Sejnowski et al. [136], and emerged independently from
the systems biology field which includes the biochemical reaction theories described in the previous
sections [137]. It encompasses theoretical modelling of the brain at different scales, beginning with
the microscopic scale of neurotransmitter channel activation, electrical properties of whole neurons,
events happening at the scale of synapses and finally the interactions of whole networks of neurons
[138].
The description of the brain as composed of individual neurons was first given by Cajal in 1886
who studied the anatomy of the central nervous system (CNS) and lay the foundations of modern
neuroscience. The idea of a synapse was introduced in 1897 by Sherrington, and the description
of neuronal excitability in terms of Resistor-Capacitor (RC) electrical circuits was proposed by
Hermann, based on the much earlier experiments of Galvani on the effects of electricity on the con-
traction of frog muscles in the late 18th century [139], the birth of electrophysiology. This lead to
the development of models describing the electrical excitability of neuronal membranes. The first of
these models, the leaky integrate and fire (LIF) model was developed in 1907 based on experiments
by Lapique, and introduced by Stein in 1965, which models a neuronal spike with equations taken
from RC circuits theory in physics.
The action potential ODE model derived later by Hodkin and Huxley provided a more detailed
description of the change of a neuron’s membrane voltage, in terms of changes in the concentra-
tions of Na+ and K+ ions. These pioneering experiments accurately described the time courses
of macroscopic currents, ie. those resulting from the summed responses of multiple channels in a
neuronal cell.
Neher and Sakmann developed techniques to record microscopic currents through single channels,
thus proving that the macroscopic currents are a result of summed responses of many individual pro-
tein channels in operation. The translation of the single-channel currents into mechanistic models
describing the activation of a single channel by its ligand was theoretically described by Colquhoun
and Hawkes [140]. Based on these theories, the information contained within the single-channel
data is used to predict the series and speed of conformational changes that a protein undergoes
upon ligand binding, in a similar way that chemical reactions are described. A system of differential
equations is proposed, to which the single-channel current data is fitted- that which fits the data
best is chosen as the most likely mode of channel activation.
The detailed descriptions of single channels have been integrated into larger kinetic models which
may describe the interaction of different channels, changes in the concentration of ions, and others
[141].
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Modelling of electrogenic proteins
Elucidation of mechanisms behind electrogenic protein activation by a ligand usually involves the
collection of currents via the protein under different conditions, such as varying ligand and ionic
concentration, membrane voltages, and others. It is now known that ligand activation induces
conformational changes in the protein which was confirmed at the molecular level by direct imaging
via X-ray crystallography studies that capture single molecules in different states. The first of these
structures was published by Doyle et al. [142] and described the structure of bacterial Na+ channel.
Electrophysiological experiments aiming to predict these structural changes involve the collection
of data, and subsequently the fitting of a multiple state kinetic model which is capable to describe
it well. Multiple schemes are proposed, and optimization algorithms are used to calculate which
scheme can describe the data best, and is the most mechanistically probable based on previous
information.
As previously mentioned, electrophysiological techniques based themselves in the description of a
neuron and the proteins within via RC- circuit equations formalism. The aqueous solutions inside
and outside of the neuron are filled with charged particles, thus making them good conductors in
comparison to the bilipid membrane, which does not allow the movement of ions and thus can be
described as a capacitor, C. Electrical potential, V , across the membrane is a result the difference
in the concentration of ions, thus the charge, Q, on either side of the membrane, which is set up by
active transport, and the equation for membrane capacitance can be written:
C = Q/V (1.16)





The current is a result of the movement of ions via receptor pores, due to the difference in the
electrochemical potential. The Nernst equation describes the reversal potential for the ion, which








where R is the is the universal gas constant, T is the temperature in Kelvin, z is the valence of
the ion, F is the Faraday constant, and c are the concentrations of ions outside and inside the cell.
Voltage drop across the membrane, Vm, is a result of the voltage drop across the resistor, Ri as well
as the voltage drop across the ‘battery’, given by the Nernst potential for the ion, Erev, which can
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be written as:
Vm = IiRi + Erev (1.19)
and since the conductance, g, is the reciprocal of resistance, Ri, the equation can be rearranged to
give:
Ii = gi(Vm − Erev) (1.20)
Since the current is the rate of charge flow, and the voltage is proportional to the current multiplied




= gi(Vm − Erev) (1.21)
which is the ordinary differential equation for the membrane voltage change across a circuit. In
electrophysiological recordings, parameters such as the membrane voltage, concentration of ions
defining the strength of the ‘battery’, as well ligand concentrations can be manipulated by the
experimenter in order to calculate the currents via channels, and others.
Electrophysiology techniques and TEVC
Recording techniques in electrophysiology all revolve around the manipulation of the membrane
voltage of the system in question, called a voltage clamp. This is done both in the collection of
macroscopic currents from a whole cell, meaning those generated as a summed response of individual
currents via a number of channels, or microscopic currents via single-channels in the patch clamp
techniques developed by Neher and Sakmann. Two-electrode voltage clamp (TEVC) is a technique
developed by Hodgkin and Huxley for the collection of macroscopic currents from whole cells. It can
be used in neurons dissected from the organism which allows one to obtain data on the currents from
native channels expressed in the neuron. Since neurons typically express more than one receptor
protein, pharmacological blocks are often used in order to single out currents from the receptor in
question. In these experiments the level of expression of the ion channels cannot be manipulated
by the experimenter thus the currents are often low in amplitude. In addition, the small size of
cells makes the experimental set up difficult. Genetic manipulation of mammalian oocytes excised
from the African clawed frog Xenopus laevis to express heterologous proteins of interest provided
a solution to these issues and since has become a widely used technique in electrophysiological
recordings. Foreign cDNA or mRNA prepared in vitro is injected into the oocyte which translates
the genetic material into proteins which express in the cell membrane. The large size of the oocyte
- around 1mm diameter - makes oocyte handling more easy, including molecular material injections
as well as collection of electrophysiological data. In addition, the oocyte does not depend on
substrates taken up from the environment, expression of endogenous transporter proteins is low,
meaning recordings can be taken in low background noise [143].
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In TEVC, the oocyte expressing the protein of interest is placed in an aqueous solution of known
salt concentrations inside a recording chamber. The intracellular concentration of ions and charged
proteins versus the concentration of ions in the bathing solution generates a voltage across the lipid
bilayer of the oocyte. Two electrodes are used to impale the cell, one of which injects current and
the other measures the membrane voltage, Vm. This allows the experimenter to aritificially control
the membrane potential via setting of the Vm0.1cm to a chosen command potential, Vc, both of
which are connected to a clamping amplifier. The ionic flux that is carried via the protein of interest
upon simulation - for instance application of a ligand - displaces the Vm0.1cm which is compared
to the Vc applied by the experimenter. In order to counteract the deviation, the output voltage
from the amplifier forces the current electrode to pass a current directly proportional and opposite
in polarity to the ionic flux via the protein. It is this current which is measured, which changes as
a function of the macroscopic currents via the recombinant protein. A schematic diagram of the
TEVC setup can be seen in Figure 1.7.
Given the previously mentioned advatantage of TEVC recordings in X. oocytes, this system has
been widely applied in the study of the properties of electrogenic receptor and transporter proteins.
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Figure 1.7: TEVC recording arrangement Oocyte is placed in a chamber which contains an
ionic solution. The voltage-measuring amplifier receives input from the measuring electrode (A1)
and the bath electrode (A3) and determines the voltage which approximates Vm. The membrane
voltage is sent to the feedback amplifier which compares it to the command voltage (Vc) as set
manually in the TEVC instrument. The deviation of Vm from Vc is corrected by the feedback
amplifier connected to the current-injecting electrode (A2). The feedback current is the measure
equal and opposite in polarity to the ionic currents through protein upon agonist application.
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1.4 Aims and thesis structure
The various aspects of glycine metabolism and function in the CNS are in need of further clarifica-
tion, and are adressed in the current thesis. Much of what is known about the initial pathways of
glycine biosynthesis specific to the brain comes from studies performed in rats in the 1970s, and has
not been revisited in the light of new experimental findings. For instance, it is now widely accepted
that brain metabolism is compartmentalized across different cell types, as is the case in the cycling
of the major neurotransmitter, glutamate. Expression of genes encoding the proteins involved in
glycine metabolism in monocultures of astrocytes and neurons suggests the compartmentalization
of glycine biosynthesis, but has not been conclusively proven. Furthermore, glycine metabolism in
vivo takes place in the background of large demands for ATP required for neurotransmission which
should be taken into account in a holistic approach to the study of metabolism. Therefore, one of
the major aims of this project is to discover the metabolic pathways of glycine biosynthesis in the
context of the background CNS metabolism via the use of computational modelling techniques, and
integration of scRNA-seq dataset which allows for the study of glycine across different cell types.
As a metabolic intermediate of cellular biosynthetic pathways, evidence points to the role of ser-
ine/glycine in the support of cancer cell proliferation, with a potential of developing novel treatments
that disrupt these pathways. However, questions such as whether these two amino acids are equally
capable of supporting proliferation, and the possible metabolic pathways utilized are underdeter-
mined which is also addresses in the current work via the analysis of a metabolic model representing
the CNS.
With respect to glycine’s role as a neurotransmitter, it has been proposed that regulation of its con-
centration via the manipulation of its reuptake via GlyT1 in different brain regions can be used as
a treatment for numerous conditions. However, the most advanced clinical trials of GlyT1 inhibitor
bitopertin did not result in a positive outcome, and studies of alternative inhibitor compounds show
contrasting result. Increasing the understanding of the interaction between the glycinergic synapse
components could therefore be of use in the future development of neuromodulators. The direct
effect of GlyT1 inhibition on the glycinergic currents is difficult to measure in the organism in vivo,
and computational methods can aid in the understanding of the mechanism at the molecular level.
Therefore, the second major aim of this work was the development and analysis of a computational
model which integrates previous kinetic studies of single proteins which compose the glycinergic
synapse for the purpose of better understanding how glycine is modulated and its effect on the
glycinergic Cl- currents via the GlyR.
Lastly, a point mutation at position Ser 407 in the GlyT1 was identified by Alfadhel,M. et al. [80]
as a novel cause for NKH, but the effect of the mutation on currents via the GlyT1 has not yet been
characterised. Another major aim of the work presented in this thesis was to perform electrophysi-
ological experiments on the Ser 407 GlyT1 mutant in order to functionally characterise the effect of
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this mutation, and observe its effects on glycinergic currents by integrating the experimental results
into the kinetic model.
In summary, the main objectives of this thesis are:
1. To use metabolic modelling in order to better understand pathways of glycine biosynthesis in
different cell types of the CNS, in the context of brain energy demands.
2. To use metabolic modelling to discover the involvement of serine/glycine metabolic pathways
in increasing cellular ATP and biosynthetic needs.
3. To use kinetic modelling in order to better understand the interaction of proteins involved
in glycine release and reuptake across the glycinergic synapse, and how the time course of
glycine concentration increases affect the Cl- currents via the GlyR.
4. To use electrophysiological TEVC techniques in order to characterise the effect of the Ser 407
GlyT1 mutation on the resulting currents via the transporter.
5. To integrate the results from the experimental studies with the kinetic model of the glycinergic
synapse for the purpose of relating the effect of the mutation on the resulting Cl- via the GlyR.
The structure of the thesis is as follows:
Chapter 1 contains an introduction to the concepts relevant to the biology of glycine meta-
bolism in the CNS, as well as an overview of the computational and experimental methods used in
the current thesis.
Chapter 2 describes the construction of a metabolic model of the CNS, and the analysis of the
model for the estimation of energy and biosynthetic needs which are used in later sections for the
discovery of glycine biosynthetic pathways.
Chapter 3 describes the integration of a scRNA-seq dataset with the CNS model, and analysis
of the pathways of energy as well as glycine production used by the different CNS cell types. The
ability of serine and glycine to support biomass and energy production is also described in this
chapter.
Chapter 4 describes the construction and analysis of a kinetic model of a glycinergic synapse.
A detailed scheme of GlyR activation by glycine taken from Burzomato [144] is analysed, and built
upon by the addition of reactions describing glycine release and reuptake by GlyT1 and GlyT2.
The full model is used to look at the effects of changing components of the glycine synapse on the
resulting Cl- currents, including the result of the GlyT1 Ser 407 mutation which abolished currents
via the GlyT1, as described in Chapter 5.
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Chapter 5 describes the experimental results from electrophysiological study of the effect of
Ser 407 mutation in the GlyT1 on the rate of glycine transport.
Chapter 6 contains an overview of the main results presented in the thesis, as well as an overall
discussion of the results.
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Chapter 2
Metabolism of CNS glycine in the
context of energy and biomass
requirements
2.1 Introduction
This chapter describes the developement and curation of a CNS metabolic model in the ScrumPy
modelling software. The model was derived from a pre-existing GSM model of human metabolism,
Recon2.2 which encompasses reactions present in all human cells and tissues [145]. Previous models
pertinent to CNS metabolism have been published, including the astrocyte and neuron model by
Çakr et al. [108], as well as a model of the human astrocyte network by Mart́ın-Jiménez et al. [146].
Both of these models are cell-specific, thus the development of the CNS model was motivated by a
need for a more generic reconstruction in the first instance. Further contextualisation of the generic
reconstruction is applied in Chapter 3, where metabolism in different cell types is investigated via
the integration of transcriptomic data.
The purpose of the model reconstruction was to probe questions relating to glycine metabolism
in the CNS, subject to the constraints imposed by substrate availability, as well as the metabolic
context within which biosynthesis occurs. The first is determined by the rate of metabolite passage
across the blood brain barrier (BBB), thus second to model curation, constraints on model import
were added according to literature values. In the next step, uptake constraints were used to estimate
energy and biomass turnover rates within the brain. The oxygen to glucose consumption index
(OGI) is a previously well defined parameter and is between 5.5- 6.0 in human brain (Introduction,
Section 1.2.3). This value range was used to estimate the metabolic state of the cell, and variations
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in the energy and biosynthetic demands were assessed via their effect on the OGI. Estimation of
these values, as well as the uptake rates of metabolites were used later to provide a meaningful
cellular context in which to evaluate glycine biosynthesis. This was achieved by the comparison
of pathways utilized in the absence of the biosynthetic and energy demands, and later on in their
presence. Pathways utilized within each scenario were compared to elucidate the most likely routes
of glycine production in the background of cellular metabolism.
2.2 Methodology
All steps of model construction and analysis were completed ScrumPy (Chapter 2, Section 1.3.4).
The model was derived from the Recon2.2 GSM [145] under the assumption that it has under-
gone more extensive curation in comparison to the MetaCyc database of human metabolism. The
Recon2.2 model was downloaded from http://identifiers.org/biomodels.db in the systems biology
markup language (SBML) format and converted into a ScrumPy model via identification of equiv-
alent MetaCyc species.
Model metabolite names were translated in the first instance, followed by reaction names. Metabo-
lites were matched to MetaCyc counterparts by their unique identifiers (ChEBI, InChi, SMILES)
found in the annotation files or via the application of the Python Levenshtein string matching algo-
rithm. Around 43% of the Recon2.2 reactions represented unique, metabolic reactions which were
subject to translation. In the first instance an annotation of the Recon2.2 was downloaded from
http://metanetx.org which contained MetaCyc equivalents for some of the reactions in the model.
Additional reactions were matched via their enzyme EC numbers and gene associations, and the
remaining reactions were matched by their metabolite stoichiometry. In result, the model Recon2.2
derivation covered 41% of metabolites and 63.6% of reactions present in the original model.
2.2.1 Model curation
Derivation of a reaction set allowed for the generation of a first model draft which required further
revision in order to ensure it becomes a faithful representation of CNS metabolism. More specifically,
that it contains a set of reactions relevant to the system in question and thus reactions known to
be inactive in the brain were manually removed. Enzyme ‘inactivity’ was determined as zero mean
expression of enzyme RNA across various regions of the human cortex, as identified from the Allen
Brain Map. Secondly, the model must obey the laws of nature known a priori (Introduction,




Reactions which violated mass conservation were identified via comparison of the sums of molecular
masses on each side of the equation, as well via the analysis of the left null space of the stoichiometry
matrix (Introduction, Section 1.3.3). Atomic inconsistencies resulting from C, N, S, O, P imbalances
were resolved manually via the replacement of metabolite for its correct counterpart, or its specific
instance. Since H imbalances are mostly caused by the incorrect protonation state of the metabolite
which may be missing from the database, they were resolved automatically via the addition of a H
atom on either side of the equation.
Energy and Redox conservation
Flux Balance Analysis was used in order to identify reactions which lead to spontaneous energy
formation. In the LP formulation, a positive value was set as the flux constraint on a hypothetical
ATPase reaction which catalyses the breakdown of ATP into ADP and Pi, in the presence of
zero constraint values on all the import reactions. A similar approach was used to ensure redox
conservation, where flux via a NAD(P) oxidation reaction was chosen as the objective function.
If the problem was feasible, the flux distributions returned contained offending reactions which
required curation. In a different approach, offending reactions were identified by the analysis of the
right null space of the stoichiometry matrix (Chapter 2, Section 1.3.4)
Reaction identified by these methods were manually compared against the Brenda database and
directionality corrected. A second major cause of imbalance was the presence of reactions with very
similar stoichiometries, differing only by the cofactors involved. This was solved via removal of the
reaction which utilized the cofactor with a lower affinity to the enzyme in question, as defined in
Brenda.
2.2.2 General model properties
The final version of the curated model is composed of a top level file which includes 11 subfiles
(Figure 2.1) that represent :
 six internal compartments of a cell, including:
– Cytoplasm (907 reactions)
– Mitochondrium (395 reactions)
– Peroxisome (156 reactions)
– Endoplasmic Reticulum (125 reactions)
– Nucleus (66 reactions)
– Lysosome (22 reactions)
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 three metabolite transport reaction files split into extracellular transporters (44 reactions),
intercompartmental transporters (402 reactions) and biomass exporters (36 reactions)
 a representation of the electron transport chain (ETC)
 internal ‘extra reactions’ file added during model curation
Out of the total of 2193 model reactions, 674 are ‘dead’ reactions which cannot carry flux at
steady state.
Internal compartments
Assignment of reactions to compartments was kept consistent with Recon2.2. However, three
compartments were removed in the curation process. The golgi apparatus was removed due to a
low number of identified reactions (7) which were moved to the cytoplasm. The ‘boundary’ com-
partment, which in the original model represents extracellular fluids did not contain any metabolic
reactions thus was also removed. Lastly, the mitochondrial intermembrane space compartment con-
tained five reactions describing the accumulation of H+ in the intermembrane space, ATP synthase
reaction, an aspartate-glutamate shuttle, and the heat-producing uncoupling protein catalyzed re-
action. This compartment was removed and the ETC added as a separate module.
Transport reactions
The movement of metabolites in the system was split into three logical components, more specifi-
cally;
 Extracellular uptake and release
Import and export of metabolites in the model was added manually based on studies of
metabolite transport across BBB membranes. Substrates are composed of glucose, amino
acids, ketone bodies and fatty acids known to be essential for the compositions of mem-
brane lipids. Pantothenate used for the formation of vitamin B, and choline used in the
biosynthesis of phosphatidylcholine are obtained from diet [147] thus also comprise cellular
import. Lastly, transport of inorganic phosphate (Pi, PPi) and ions was added. A list of all
transport reactions can be seen in Table 2.1, including both uptaken and released metabolites.
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 Biomass exporters
Most structural models of metabolism utilize cellular growth as a metabolic objective. As
this condition applies to model describing bacterial cultures or plant metabolism, it does not
apply to mature, differentiated neuronal cells which do not divide [148]. Nevertheless, under
steady state these cells require the replacement of their contents including metabolic enzymes,
phosholipids and neurotransmitter receptors. This demand on cell metabolism was added in
the form of a set of export reactions for micromolecules making up cellular components. The
latest revision of the human GSM, Recon3D [111] contains a biomass turnover equation which
was used in the CNS model. The complete list of biomass components can be seen in Ta-
ble 2.1. Manual gap filling was performed to ensure that the model is capable of exporting
each compound from uptake metabolites, and a separate model file was designated that de-
scribes their export. Apart from formation, turnover processes also include degradation of
cell components however this was not taken into account in the CNS model.
 Inter-compartmental exchange
This module contains reactions which transport metabolites between the internal compart-
ments of the cell, as originally defined in the Recon2.2 model.
Electron Transport Chain
Production of ATP via oxidative phosphorylation in the mitochondria is driven by the electro-
chemical gradients established by H+ accumulation in the mitochondrial intermembrane space. H+
accumulation is achieved by mitochondrial complexes complexes I ,III and IV which take part in re-
dox reactions that harness the energy produced by the movement of electrons for H+ translocation.
The ETC model file is a representation of this process. It includes reactions catalyzed by complexes
I - IV, with the net transfer of 10 mitochondrial H+ to a H+int species, representing H
+ located in
the mitochondrial intermembrane space. The last reaction is a representation of the ATP synthase
reaction, fixed in the direction of ATP formation where one ATP molecule requires the transport
of four H+int back into the matrix, of the form;
1.0 ADP + 4.0 H+int + 1.0 Pi → 1.0 ATP + 3.0 H+ + 1.0 H2O
The resulting model P/O ratio is 2.5, assuming two electrons used in the process enter via
complex I and pass via all three complexes I,II, III and IV, which is in line with previously reported
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Table 2.1: Complete set of model transport reactions
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Figure 2.1: Composition of the final model. Internal compartments include (a) cytoplasm,
(b) mitochondria, (c) peroxisome, (d) endoplasmic reticulum ,(e) nucleus, (f) lysosome, as well as
the ETC and the inter- compartmental transport reactions. Cell substrates can be divided into
several subclasses, C and N sources (glucose, amino acids), long and short chain fatty acids,
metabolites obtained from diet and small molecules and ions. Export of metabolites includes the
general by-products lactate and CO2, amino acids and biomass components. Biomass export can
be further subdivided into amino acids, phospholipids, nucleotides and cholesterol. All transport
reactions are summarised in Table 2.1
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values in human [149].
ATP production via the ETC relies on the availability of reducing agents in the mitochondria, mostly
in the form of NADH produced in glycolysis via the oxidation of glyceraldehyde-3-phosphate. Since
the mitochondrial membrane is impermeable to NAD it its oxidised and reduced form, electrons
from NADH are carried across the membrane mostly via two mechanisms, the malate-aspartate
shuttle and the glycerol-phosphate shuttle with the former constituting the primary mechanisms
for NADH generation in the brain [150]. Apart from their role in providing electrons for the ETC,
these shuttles are important for the regeneration of NAD required for the operation of glycolysis.
Increasing evidence also points to the importance of lactate-pyruvate cycling in the regulation of
cytosolic NAD levels via the enzyme lactate dehydrogenase (LDH) [151] which interconverts these
monocarboxylates in the following reaction:
1.0 Pyruvate + 1.0 NADH + 1.0 H+↔ 1.0 Lactate + 1.0 NAD
Lactate dehydrogenase is present both in the cytosol as well as in the mitochondrial intermem-
brane space (mLDH) and the direction of the reaction is dependant on the specific isoform of the
enzyme as well as the concentrations of each compound [151]. Cycling of these compounds is also
dependant on the presence of monocarboxylate transporters (MCT) in the intermembrane space
which may co-transport each metabolite with a proton, or act as exchangers where the uptake of
one of the metabolites is accompanied by the release of the other on the other side of the membrane
[152].
The above named processes, including the malate-aspartate shuttle, the glycerol phosphate shuttle,
as well as the LDH, mLDH and MCT-catalysed reactions were included in the model. Since the
model is a simplification of the biological entity, reactions taking place in the intermembrane space
such as the mLDH were included in mitochondrial compartment.
The last file, ’Extra Reactions’ contains internal metabolic reactions that were manually added
during model curation such as those used to gap-fill pathways of biomass components production.
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2.3 Results
Formulation of LP problems
The following results sections describe the output of FBA-type problems which utilizes LP to impose
a set of constraints on the flux distributions of model reactions. Across all solutions, the objective
function was minimization of the sum of all reactions fluxes, subject to the steady state condition.
Additional constraints were added according to the problem, including a specific cellular objective
subject to constraints on the upper limits of fluxes in the transport reactions and/or a fixed flux
value of biomass export reactions. The LP can be expressed as follows:
minimise :
∑m
i=1 |v| · ji
subject to

Nn,m · v = 0
vbj = bj
0 ≤ vtj ≤ tj
vATPase = 1
(2.1)
where |v| represents the vector of all reactions fluxes weighed by an objective coefficient vector, ji
, values of which are all set to 1 in the current chapter. Steady state condition is imposed where the
stoichiomentry matrix, N of n metabolites and m reactions multiplied by the reaction flux vector
|v| must equal zero. The vector of biomass transporter fluxes, vbj is constrained to single values for
each component in a flux vector, bj . Vector of transport reaction fluxes, vtj , is constrained only by
the upper limit of flux for each reaction defined in vector tj . In this LP formulation, the specific
objective function is breakdown of ATP via the ATPase reaction which is applied by setting the
flux via the ATPase, vATPase, to a value of one. Apart from the steady state condition, constraints
are varied according to the problem in order to probe the specific metabolic objective in question.
Metabolite uptake constraints
The rate of uptake of import metabolites was constrained to physiologically relevant values, as sum-
marised in Table 2.2. Since the concentrations of compounds in the blood vary according to the
dietary intake and physiological state, the constraints were formulated such that the upper limit
is constrained only, as in Equation 3.1. This should result in physiologically relevant solutions,
without over-constriction of the model to produce the desired result. Amino acids include all of the
import amino acids, as specified in Table 2.1.
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Table 2.2: Upper limits on the rate of metabolite uptake in the model
Metabolite Uptake limit( µmolg−1min−1 ) Reference
Glucose 0.6 [154–158]
Amino acids 0.01 [159–163]
Palmitate 0.0015 [164]
Linolenic acid 0.0001 [165]
Linoleic acid 0.0001 [165]
Decosahexanoate 0.0001 [164]
Although intracellular levels of brain glutamate is high, passage of this amino acid across the BBB
is highly restricted thus majority of its synthesis takes place inside the organ from anaplerosis of
glutamine as well as the TCA intermediate, alpha-keto-glutarate [153]. There is a net uptake of
amino acids into the brain which serve as amino donors for these reaction in the first instance.
Since in this chapter metabolism of the brain as an organ is considered, substrates available are
constrained to those amino acids which pass the BBB, excluding glutamine and glutamate. In
Chapter 3, where metabolism of different CNS cell types is assessed, large intracellular concen-
trations of glutamine and glutamate are taken into account and these amino acids are allowed as
uptake metabolites during model analysis.
Biomass export constraints
The sum of fluxes for biomass exporter reactions in Recon3D representing cell maintenance without
the production of replication precursors is 113.7 µmolg−1min−1 . It can be seen that there is a large
discrepancy between the magnitude of the total biomass output and the biological upper limits in
the uptake of glucose and nitrogen sources as in Table 2.2. The origin of the absolute flux values
provided in Recon3D is not well documented in the original publication thus the reason for such a
discrepancy is unknown. Since the total biomass output was infeasible according to the uptake rates
gathered from literature, it was adjusted in the current model. In addition, the ratio of compounds
in the original equation were changed to better represent CNS cell metabolism.
The flux value for each individual biomass transporter as in Recon3D represents a percentage of
the total biomass output,
∑
bj . Similarly, components of the biomass transport can be grouped
into classes such as ‘amino acids’, which can also be represented as a percentage of
∑
bj . Since
neuronal cells have a high lipid composition, the percentage of ‘lipids’ class, including phospholipids
and lipids (Table 2.1) was adjusted to 24% [166] of
∑
bj with the remaining percent demand on the
other compound classes adjusted accordingly. Within each class, the percent of a specific compound
out of the class total was kept the same as in the original publication. For example, if cholesterol
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composes 7% of the total lipids class then although the flux demand on its export increases by
adjustment of lipids to 24% of biomass sum, its percent composition of lipids class remains the
same at 7%. In each LP problem, the ratio of each biomass component was used to calculate the
bj from the specified
∑
bj .
2.3.1 Pathways of ATP production in the model
The brain has large requirements for ATP synthesis with the majority of energy used to re-establish
ionic concentration gradients necessary for signal transmission (Introduction, Section 1.2.3). This
requirement will be referred to as the ATP demand (ATPd ) in the following sections and is ab-
stracted in the model by setting a constraint on the rate of ATP hydrolysis by the ATPase-catalyzed
reaction, vATPase, of the form:
1.0 ATP + 1.0 H2O→ 1.0 ADP + 1.0 H+ + 1.0 Pi
In order to establish the pathways of energy production from glucose, as well as to estimate the
upper limit on ATP synthesis in the presence of physiological uptake constraints (Table 2.2) and
constraints on the uptake of ketone bodies 3-hydroxybutyrate (HB) and 3-ketobutyrate (KB), an
increasing demand on the ATPase reaction was formulated in an LP :
minimise :
∑m
i=1 |v| · ji
subject to

Nn,m · v = 0





In each FBA problem the changing variable was the aj , which was incremented from 0.2
to 21 µmolg−1min−1 . The maximal feasible rate of ATP production in the model was 16.7
µmolg−1min−1 , shortly after glucose uptake saturation at 15.6 µmolg−1min−1 . Within the range
of ATPd = 0.2-16.7 µmolg
−1min−1 the solutions remained the same. There is a consumption of
glucose which is processed via the pathways of glycolysis and subsequently complete oxidation via
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the TCA cycle and oxidative phosphorylation in the mitochondria (Figure 2.2). The OGI index
remains at six across all solutions up to glucose saturation. Pyruvate formed in the cytosol is
converted to lactate via lactate dehydrogenase (LDH), oxidizing NADH to NAD. Subsequently,
lactate is co-transported with a H+ via the mitochondrial membrane where it is oxidized back to
pyruvate by the reverse reaction of mitochondrial LDH (mLDH), releasing a H+ and reducing NAD
to NADH. No lactate export is present, and the uptake of oxygen is unlimited thus lactate acts an
intermediate of oxidative phosphorylation under normal oxygen tension.
ATP demand increase in the background of biomass turnover
The OGI index provides a good overview of the degree of coupling between glucose and O2 con-
sumption and therefore the fate of glucose. In addition, the values for the human brain OGI have
been previously well established to range from 5-6 under ‘normal’ physiological conditions [17].
Therefore in the next set of analysis the effect of ranging demands for biomass turnover and energy
production on the resulting OGI index are measured. It is anticipated that an increase in ATPd on
its own will increase the coupling between O2 and glucose consumption and therefore OGI, as an
increasingly higher proportion of ATP is produced via mitochondrial oxidative phosphorylation.
On the other hand, an increase in biomass demand is expected to lower OGI because glucose is
being used in biosynthetic reactions, such as the NADPH-generating PPP and reactions diverting
glycolytic intermediates to amino acids and lipid production.
In order to confirm these predictions, OGI was determined as a function of changing ATPd at
a bmd of 0.09 µmolg
−1min−1 . The demand for increased ATPd was formulated in a LP as in
Equation 3.1 with the added constraint on the sum of biomass export. Upon each sequential LP
formulation the value of the vATPase was incremented from 0.2- 21 µmolg
−1min−1 .
As the ATPd increases between 0.2-16.6 µmolg
−1min−1 , there is an hyperbolic rise in the OGI
from 0.8 to 5.4 which is coupled to increased glucose and oxygen uptake. Conversion of cyto-
plasmic pyruvate to lactate and its subsequent transport across the mitochondrial membrane and
conversion back to pyruvate remains as in the previous scan with no additional bmd (Section 2.3.1).
Reactions of lactate to pyruvate conversions, as well as those composing the TCA cycle and ETC
components increase linearly across the scan until ATPd = 16.6 µmolg
−1min−1 at which they hit
a plateau. Although there is a stable linear increase in the TCA cycle reactions, there is a change
in the diversion of glucose which at lower biomass demands is shunted to the PPP pathways.
From 0.2- 6.7 µmolg−1min−1 all of the glucose imported is phosphorylated to glucose-6-phosphate,
which subsequently enters the oxidative PPP via conversion to 6-phospho D-glucono-1,5-lactone by
glucose-6-phosphate dehydrogenase. Until bmd = 6.7 µmolg
−1min−1 , the second step of glycolysis
is active in the direction of fructose-6-phosphate to glucose-6-phosphate conversion. Reactions of


















Figure 2.2: Pathway of ATP production in the model Glycolytic product pyruvate is used
to make lactate under normal oxygen tension. Next, lactate is co-transported with a H+ and
re-converted back to pyruvate via mLDH. Dashed arrows represent a condensed pathway, where
intermediate reaction are not shown.
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6-phosphate and glyceraldehyde-3-phosphate to the subsequent pathways of glycolysis thus allowing
for linear increase in the downstream glycolytic pathways feeding the TCA cycle.
At all biomass demands there is an uptake of ketobutyrate which is converted to acetoacetyl-CoA in
the cytoplasm, further converted to acetyl-CoA. Acetyl-CoA is next used to feed the TCA cycle via
conversion to citrate in the mitochondria, or for the formation of malonyl-CoA used in lipid biosyn-
thesis. The contribution of ketobutyrate to the total acetyl-CoA pool decreases in comparison to its
derivation from pyruvate, reflecting the relatively stable uptake (range 0.14-0.15 µmolg−1min−1 )
of ketobutyrate and large increase in the rate of glucose uptake.
At the point of the metabolic switch, ATPd = 16.6 µmolg
−1min−1 , glucose uptake is saturated
and 3-hydroxybutyrate uptake switches on. Reactions present in the subsequent solutions but ab-
sent from the previous are the pathways of hydroxybutyrate breakdown into acetoacetyl-CoA, and
subsequently acetyl-coA in the mitochondria. Thus, the metabolic switch occurs when the cell
has run out of glucose and begins to use ketone bodies for acetyl-CoA production, explaining the
rapid rise in oxygen consumption. This is reflected in the rate of OGI increase which switched
from exponential to linear rise. Across the dataset, there is a stable uptake of nitrogen sources
including Threonine, Tyrosine, Isoleucine, Leucine , Histidine, Phenylalanine, Lysine, Methionine,
Tryptophan, Arginine and Cysteine. Finally, fatty acids palmitate and linoleate uptake is saturated
at 0.0015 µmolg−1min−1 and 0.0001 µmolg−1min−1 , respectively across the whole dataset. Coen-
zyme A is attached to palmitate to form palmityl-CoA, which takes part in subsequent reactions of
lipid production. Linoleate is used to form steraoyl- CoA which also takes part in lipid biosynthetic
pathways.
Estimation of physiologically relevant energy and biomass demands
In order to estimate a range in which the combination of ATPd and bmd produce an OGI in the
5-6 range, in the next set of analyses the effect of increasing the bmd on OGI at various ATPd was
measured. Each subsequent LP formulation was defined as in Equation 3.1), where the bmd was
increased from 0 to 0.9 µmolg−1min−1 at a constant value of ATPd . This was repeated over a
series of ATPd ranging from 1- 20.8 µmolg
−1min−1 .
At the lower range of ATP demands, OGI decreases rapidly as a function of biomass demand in-
crease (Figure 2.5) quickly approaching non-physiological brain OGI index values below 5. At a
higher range of ATPd = ≥ 18.6 µmolg−1min−1 the OGI ≥ 6 even at the lowest biomass demands
and increases linearly (Figure 2.5). As seen in Section 2.3.1, the increase in OGI is a reflection
of glucose saturation and uptake of ketone bodies for energy production. Since the model repre-
sents the brain under ‘normal’, fully-fed conditions when the main substrate for energy production
is glucose (Section 1.2.3), the higher ATPd values can be excluded. Within the middle region of
the graph (ATPd = 7.6 -16.4 µmolg
−1min−1 ) there is a stable decrease in the OGI as the bmd
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Figure 2.3: Effect of increasing the ATP demand in the presence of a biomass demand
Glucose is able to support an ATP demand increase only up to ≈16 µmolg−1min−1 , after which
the uptake of ketone bodies begins. The complete list of precursors required for biomass
production can be seen in the legend.
physiologically relevant OGI.
However, this result does not constrain the ATPd and bmd to any specific value because any combi-
nation of ATPd 7.6 -16.4 µmolg
−1min−1 and bmd 0- 0.09 µmolg
−1min−1 will produce an OGI that
falls between 5-6. Since glucose uptake of 0.6 µmolg−1min−1 defines the most extreme limit of glu-
cose consumption which at resting state is closer to 0.2-0.4 µmolg−1min−1 , an additional constraint
on these values can be applied by specifying a limit on glucose consumption. Under the assumption
that neurons have a relatively low biomass turnover but maximise their ATP production, specific
values for ATPd and bmd were obtained by running the same analysis over a larger number of
data points, ranging ATPd from 0.001- 17 µmolg
−1min−1 and bmd from 0.11- 0.10 µmolg
−1min−1 .
Maximum feasible ATPd and bmd were searched for such that they satisfy the following criteria;
 OGI ≥ 5.4
 glucose uptake rate ≤ 0.35 µmolg−1min−1
The final estimations which satisfy the above are ATPd = 9.6 µmolg
−1min−1 and bmd = 0.027
µmolg−1min−1 which are the constraints used in the following model analysis sections. The ATP
demand is in line with the value of 9.5 µmolg−1min−1 for the forward rate of the ATPase reac-
tion in the grey matter of the human brain [167]. Solving an LP formulation using the demands
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Figure 2.4: OGI increase across the ATP demand scan The trend of OGI increase is
hyperbolic when glucose is the only used substrate as more glucose is processed via oxidative
phosphorylation. The linear trend begins upon glucose transport saturation, when ketone body
uptake switches on.
set to the calculated values results in the rate of malate dehydrogenase reaction which catalyses
malate to oxaloacetate conversion equal to 0.63 µmolg−1min−1 . Using this reaction as a proxy
to the rate of the overall TCA cycle, this value is similar to the rate of the TCA cycle estimates
from kinetic modelling of NMR data in human brain, ranging from 0.6 µmolg−1min−1 to 0.77
µmolg−1min−1 [168–170].
It is worth to note that the these values are only an approximation for use in the subsequent anal-
ysis, and the true values will be a reflection of the substrate availability and physiological state of
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Figure 2.5: Effect of changing the ATP and biomass demands on the OGI values
Biomass was increased at various ATPd ranging from 1.0 - 20.8 µmolg
−1min−1 . At the lower
ATPd (1.0 - 5.4 µmolg
−1min−1 ) there is an unstable and rapid decrease in the OGI which is not
as dramatic in the regions of ATPd 7.6 -16.4 µmolg
−1min−1 . Above the values of ATPd 18.6
µmolg−1min−1 there is an increase in the OGI, likely reflecting fast glucose uptake saturation and
use of ketone bodies for energy production.
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2.3.2 Pathways of glycine production in the model
It has previously been established that CNS glycine is primarly synthesized from glucose-derived
serine by the enzyme serine hydroxymethyltransferase 2 (SHMT2) in the mitochondria [39]. Given
the slow uptake of serine by the BBB transporters [161] and alternative fates of glucose, questions
pertinent to serine metabolism in the first instance remain. In this section the model is used
to identify potential pathways of serine/glycine biosynthesis. The relationships between glycine
biosynthesis and overall cell metabolic function of energy and biomass production using the rates
established in Section 2.3.1 are also explored.
In the first instance, an estimate for the glycine synthesis rate was required. Although the most
accurate rates of neurotransmitter formation are determined via MRS, to my knowledge, the rate
of glycine synthesis via these methods is not available in the literature. Therefore it was taken
from pioneering studies on glycine metabolism by Shank and Aprison [171] performed in rats in
which synthesis rates were calculated for white (WM) and grey matter(GM) of different brain
areas. In the grey matter of the spinal cord, the rate of glycine synthesis from serine equalled 0.035
µmolg−1min−1 . Although glycine synthesis rate is not equal to its export, due to lack of alternative
data, this rate was chosen as the demand for glycine export in the subsequent analysis sections.
Glycine biosynthesis in the presence of uptake constraints
Firstly the pathways of glycine biosynthesis without the need for energy production were assessed.
The FBA problem was formulated in an LP as follows:
minimise :
∑m
i=1 |v| · ji
subject to

Nn,m · v = 0
0 ≤ vtj ≤ tj
vglytx = aj
(2.3)
given constraints and a demand for glycine export, aj = 0.035 µmolg
−1min−1 . Solving the
LP produces the solution as in Figure 2.6. Histidine is the most highly consumed metabolite the
uptake of which is saturated at 0.1 µmolg−1min−1 . There is a small uptake of threonine at 0.005
µmolg−1min−1 , and a net efflux of glycine, lactate and CO2 (both at 0.0025 µmolg
−1min−1 ).
Glycine biosynthesis takes place in the mitochondria via the forward reaction of SHMT2, as well as
the reverse action of the glycine cleavage system (GCS) which balances all of the methylene-THF
produced in the former. Thus, the carbon released during serine breakdown is not ‘wasted’, rather
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used for the formation of the desired product which is further exported into the cytoplasm. Twenty
percent of glycine formed is used to synthesize serine via the reverse reaction of the cytoplasmic
SHMT1, and the remainder released extracellularly.
The majority of serine is formed from glutamate released in the histidine degradation pathways
and 3-phosphopyruvate that is generated from the reverse reactions of glycolysis, via the glycolytic
intermediate 3-phospho-glycerate. The pathway of threonine degradation leads to the formation of
2-oxobutanoate via threonine deaminase which is transported into the mitochondria and degraded
into succinate, with the production of NADH available to the TCA cycle. In the next step, succinate
oxidation to fumarate takes place leading to reduction of ubiquinone to ubiquinol, the transport of
2 H+int via complex III and subsequently ATP formation via the ATP synthase. Fumarate is used
to produce phospho-enol-pyruvate which is transported into the mitochondria for the formation of
3-hydroxypyruvate required for serine synthesis.
Histidine is the major source of N in the solution, contributing 80% of the total as well as 100%
of the total glutamate production. The net release of lactate results from the conversion of malate
to pyruvate in the cytoplasm via the malic NADP enzyme, with a reduction of NADP to NADPH
and the release of CO2. This is the only reaction providing reduced NADPH, which is necessary
for the conversions of 5,10-methenyl-THF to methylene-THF in the cytoplasm and mitochondria.
Glycine biosynthesis in the presence of an ATP demand
In this section the effect of adding an ATP demand on glycine biosynthesis is described. The LP
formulation is the same as in Equation 2.3 with an additional constraint on flux via the ATPase
reaction set at 9.6 µmolg−1min−1 .
Addition of glycine synthesis in the background of ATP production increases the OGI from 6 (Sec-
tion 2.3.1) to 6.1 . This is expected, as additional O2 is utilised for the oxidation of amino acids
used for glycine production. Overall, TCA cycle reactions comprise 18.15% of the total solution
flux, glycolytic reactions carry 5.6% of total flux and PPP is not active.
The majority (85%) of ATP synthesis occurs via oxidative phosphorylation in the mitochondria.
As seen in Section 2.3.1, LDH-catalyzed pyruvate to lactate cycling takes place.
Apart from glucose and oxygen, the amino acids isoleucine, histidine and threonine are used as
substrates (Figure 2.7). Comparison of results for the demand of an equal amount of ATP (Section
2.3.1) shows there is a slight decrease in the rate of glucose uptake as well as the rate of conver-
sion of pyruvate to lactate. On the other hand, the rate of mitochondrial ATP synthase is slightly
increased. Thus, the addition of a demand for glycine synthesis lowers the dependancy of mitochon-
drial ATP generation on glucose uptake which is fuelled by the C skeletons cleaved from threonine
and isoleucine breakdown, which lead to the formation of TCA cycle intermediates succinyl-CoA
and acetyl-CoA, respectively. In addition, pathways of isoleucine and threonine degradation pro-
duce NADH for use by the ETC. Nitrogen used for the formation of serine phosphate is derived











































Figure 2.6: Pathway of glycine biosynthesis in the model In the absence of other biological
objectives, glycine is made mostly from histidine and threonine. This pathway is linked to
glycolysis, since hydroxypyruvate is required for serine biosynthesis in the first instance. In









































Figure 2.7: Glycine biosynthesis in the presence of an ATP demand Addition of ATP
production to the metabolic objective induces the uptake of isoleucine, which provides glutamate
and 2-keto-methyl-valerate, and the latter is degraded to acetyl-CoA. Folate groups are no longer
cycled across the two compartments, as in the previous results.
from glutamate, which in turn comes from pathways of isoleucine (54%) and histidine (34%) degra-
dation. In comparison to the previous result, histidine remains the primary source of NH3 in the
solution (58%) however isoleucine is the major source of glutamate used for the phosphorylation of
glycolytic intermediate 3-hydroxypyruvate to form serine. Cytosolic serine is transported into the
mitochondria, where 100% is used for glycine biosynthesis via SHMT2. As seen previously in Section
2.3.2, the contribution of SHMT2 to total glycine synthesis is approximately 50% with the other
half produced via the reverse action of the GCS. Eighty-five percent of glycine is released extracel-
lularly and the remaining 15% used to fuel the production of cytoplasmic serine via reverse SHMT1.
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Response of serine/glycine biosynthetic pathways to an increase in biomass turnover
Pathways of serine/glycine production are coupled to biomass increase in human cells due to the in-
volvement of these metabolites in one carbon metabolism as well as lipid biosynthesis (Introduction,
Section 1.2.4). In order to explore the possible changes in the serine/glycine biosynthetic pathways
the sum of the biomass flux was increased in the background of an ATP demand, with no forced
glycine export. This was formulated in an LP as in Equation 3.1, where the sum of biomass flux
was increased from 0 to 0.1 µmolg−1min−1 at a constant value of ATPd = 9.617 µmolg
−1min−1 .
There is an overall increase in glucose consumption but it does not reach transport saturation. Anal-
ysis of individual reaction fluxes of glycolysis shows that the pathways leading to the formation of
glyceraldehyde 3-phosphate from glucose decrease, however there is an increased flux in the down-
stream reactions leading to pyruvate synthesis. This is because glucose-6-phosphate conversion to
6-phospho D-glucono-1,5-lactone increases linearly, as well as the subsequent reactions of the PPP
which contribute to over 90% of NADPH production from bmd = 0.011 µmolg
−1min−1 onwards.
Consequently, there is a linear drop in the OGI value which equals 6.0 when there is no biomass
demand and reaches 4.1 at maximal demand.
Across all solutions, there is a glycine and serine turnover since, apart from their role in phos-
pholipids (serine) and purine (glycine) biosynthesis, they are themselves components of biomass
precursors. In the range of biomass demands 0- 0.09 µmolg−1min−1 total serine is synthesized from
glucose and glutamate in the cytoplasm (Figure 2.8,a). Serine that is not used in biosynthetic path-
ways is transported into the mitochondria for glycine biosynthesis via SHMT2 and reverse GCS.
Up to 0.05 µmolg−1min−1 , around 15% of glycine is synthesized from serine in the cytoplasm via
SHMT1 which is the main source of methylene-THF used in inosine monophosphate biosynthesis.
This reaction becomes inactive from 0.07 µmolg−1min−1 onwards which correlates with a large
increase in the uptake of histidine. At this point, the rate of glycolytic reactions downstream of
glyceraldehyde-3-phosphate, including the conversion of pyruvate to lactate, increases and the rate
of serine transport into the mitochondria decreases. Consequently, there is a decrease in the per-
cent glycine production via SHMT2 and an increase in its biosynthesis from the reverse GCS. At
the higher biomass demands (≥0.09 µmolg−1min−1 ) reverse reaction of SHMT1 switches on and
cytoplasmic glycine begins to be used for serine formation as seen in Section 2.3.2.
The reactions of histidine degradation (Figure 2.8,c) form an enzyme subset which leads to the
formation of 5,10-methenyl-THF. Therefore, if the cell acquires its C and N atoms via this pathway
there is an obligatory production of methylated THF. Due to the steady state condition, this is
balanced by a net decrease in methylene-THF formation from serine as well as reverse SHMT1-
catalysed reaction which acts both to replenish the cells tetrahydrofolate and as a sink for surplus










































































Figure 2.8: Pathways of serine/glycine metabolism at different biomass demands At
lower biomass demands ranging up to 0.07 µmolg−1min−1 (a) cytoplasmic SHMT1 operates in the
glycine- forming direction, providing methylene-THF groups required for pathways of IMP
synthesis. Carbon atoms enter the folate pool from serine, as well as formate in the mitochondria.
Serine is used for glycine formation, as well as in the pathways of phospholipids biosynthesis
(inluding phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine). Glycine is
used in the formation of purine nucleotides. Tetrahydrofolate crosses the compartments and is
regenerated in the cytoplasm from AICAR and 10-formylTHF in the intermediate pathways of
IMP biosynthesis. At higher biomass demands, histidine uptake and degradation pathways switch
on. In the range of bmd 0.07-0.09 µmolg
−1min−1 , cytoplasmic SHMT1 becomes inactive. It
begins to carry flux again at bmd ≥0.09 µmolg−1min−1 , where SHMT1 uses methylene-THF and
glycine for serine formation, regenerating tetrahydrofolate in the process (b). Since pathways of
histidine degradation form an enzyme subset (c) by necessity they must carry equal flux, leading
to consumption of tetrahydrofolate and production of 5,10-methyleneTHF, adding an additional
entry of carbons into the folate pool. Conversion of glycine to serine may therefore be active to
consume the additional C atoms.
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2.4 Discussion
ATP production in the model
The model was used to establish the likely pathways of ATP production in an ATP scan. At all
energy demands, glucose is processed via glycolysis for pyruvate formation in the cytosol. Next,
pyruvate is converted to lactate via LDH leading to the regeneration of cytosolic NAD. Lactate
is co-transported with a H+ into the mitochondria where it is re-converted to pyruvate via the
mLDH, leading to the formation of NADH for use in the TCA cycle. Given there was no constraint
applied on the uptake rate of oxygen, these results are not representative of the typical description
of lactate production under low oxygen tension occurring due to a mismatch between the rate of
glycolysis and the TCA cycle [172].
Contrary to the classical hypothesis, it has previously been proposed that in all tissues lactate is
constantly being produced under aerobic conditions and is the natural end-product of glycolysis
[173]. The ability of the brain to use lactate as an energy substrate has been established in neu-
ronal cells in vitro [174] as well as in human brains in vivo. Whole-brain glucose uptake rates in
human are decreased in the presence of circulating plasma lactate [175], showing that it can be
used as an energy substrate. The ability of mitochondria to oxidise lactate relies on the presence of
transporters across the mitochondrial membrane. Both lactate and pyruvate are transported across
biological membranes by a family of the monocarboxylic acid transporters (MCTs) the expression
of which is widespread across the brain and has been shown in the mitochondrial membranes of
rat neurons [176]. Following import, the expression of mLDH is required and was demonstrated
in mitochondrial extracts from isolated human astrocytes, capable of generating ATP from lactate
[177].
Oxidative phosphorylation in the mitochondria is dependant on the availability of reducing equiv-
alents, mainly NADH. In a similar manner, the rate of glycolysis will be determined by the re-
generation of NAD in the cytosol. In the model, both of these requirements are met by the inter-
compartmental conversions between pyruvate and lactate where the conversion of mitochondrial
lactate to pyruvate provides NADH needed for oxidative phosphorylation without the activity of
the malate-aspartate shuttle. Since the model is a simplification of the system, it does not contain
the intermembrane space compartment, which is the location of mLDH. Biologically, the system
would still require the operation of the malate-aspartate shuttle, which generates NADH in the
mitochondrial matrix, as required for ETC activity- thus the absence of the malate-aspartate shut-
tle reactions is likely an artefact of the model definition. Nevertheless, it has been proposed that
the inter-compartmental conversions of pyruvate and lactate is important in the homeostasis of
NAD/NADH levels in the cytosol. Secondly, proton release which accompanies lactate oxidation
in the intermembrane space contributes to the proton gradient forming the proton motive force for
use by the ETC, or may also be used indirectly by the malate-aspartate shuttle for transport into
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the matrix [151].
The model predicts the maximal rate of ATP production from glucose at 16.7 µmolg−1min−1 which
is lower in comparison to the estimated values of 30-45 µmolg−1min−1 for the rat brain grey matter,
or 20 µmolg−1min−1 for rat brain as a whole [19]. This could be due to a difference in the rates
of glucose consumption in a rat versus human. In addition, import of lactate or other possible
energy substrates was not allowed in the simulation, thus the rate is representative of ATP pro-
duction from glucose only. Brain energy production also relies on the catabolism of amino acids,
most notably glutamate which is widely used across the brain. It has been previously shown that
astrocytes catabolize some of the uptaken glutamate to CO2 in vitro [178]. Thus, the slightly lower
estimation of 16.7 µmolg−1min−1 for the rate of ATP biosynthesis is possibly a result of incomplete
representation of substrate availability in the brain. In addition, the model does not depict all of
the processes active within the brain at any moment, such as the energy-consuming pathways of
vesicle recycling across chemical synapses, and others.
In the next step, the effect of adding a biomass demand on energy production was assessed in the
presence of ketone body uptake. In comparison to the previous results where the OGI ratio is six
across all solutions, showing complete glucose oxidation, the OGI increases as the ATP demand
goes up. This is because at lower biomass demands majority of glucose is shunted to the oxPPP
pathways, generating NADPH used mostly in lipid biosynthesis. Increasing the demand for ATP
causes a large increase in the uptake of oxygen used in oxidative phosphorylation, explaining the
higher coupling between the consumption of the two. Upon glucose exhaustion, there is an increase
in the uptake of hydroxybutyrate. The trend of OGI increase is hyperbolic as glucose is used as the
primary energy source and switches to linear upon the increase of hydroxybutyrate uptake thus,
the trend of OGI increase is informative of the type of substrate used.
It has been shown that ketone bodies can protect the viability of rat hippocampal neurons from
glucose deprivation in vitro [179]. However, this scenario is applicable under glucose deprivation,
causing a high concentrations of circulating ketone bodies produced by the liver and is not relevant
in fully-fed conditions. Lastly, the physiological range for brain OGI subject to glucose uptake rates
were used in order to estimate the ATP and biomass turnover demands. The resulting forward rate
of the ATPase reaction was estimated at 9.6 µmolg−1min−1 , which is in line with the previously
published estimations at 9.5 µmolg−1min−1 in the grey matter of human brain [167]. At this value
of ATP demand and a biomass turnover demand of 0.03 µmolg−1min−1 , the rate of malate dehy-
drogenase reaction of the TCA cycle is 0.6 µmolg−1min−1 . If this reaction is used as a proxy for the
overall rate of the TCA, the value of 0.6 µmolg−1min−1 is in line with previously published results
for the rate of the TCA cycle ranging from 0.6- 0.77 µmolg−1min−1 [168–170]. Thus, the OGI ratio
can be meaningfully used for the predictions of the rate at which oxidative phosphorylation in the
mitochondria occurs. These values provided an estimate for use in the following model analysis
sections.
72 CHAPTER 2. GLYCINE METABOLISM IN THE CNS
Glycine biosynthesis in the model
In the first instance, pathways of glycine synthesis in the model were assessed in the absence of an
energy demand. Under equal constraints on the rate of uptake of imported amino acids, the pre-
ferred substrates were histidine and threonine. The involvement of histidine breakdown pathways
in the supply of methylated THF is known although its’ role in serine/glycine metabolism has not
been described. Reactions of histidine breakdown produce two molecules of NH3 as well as gluta-
mate, thus providing a rich source of nitrogen for glycine metabolism, meanwhile taking part in the
reactions of tetrahydrofolate -mediated methyl transfers the metabolism of which is tightly coupled
to serine/glycine biosynthetic pathways. Given that regeneration of tetrahydrofolate is required by
the mitochondrial glycine production, histidine degradation provides a pathway that can balance
the tetrahydrofolate transfers in glycine metabolism without the involvement of purine, methionine
or choline metabolism. Although the majority of glycine is formed via the mitochondrial pathways,
a proportion of glycine is used to regenerate serine in the cytoplasm.
Previous studies imply that the roles of cytoplasmic and mitochondrial SHMT differ. Mitochon-
drial SHMT2 has been found to be overexpressed in different cancer cells [180] where SHMT1 is
not. Growth of Chinese Hamster ovary (CHO) cell lines mutant for the mitochondrial SHMT2
are dependant on glycine addition to the media [181], and later studies tracking the incorporation
of isotopically labelled serine show that majority of methyl groups incorporated into downstream
methionine in the cytoplasm are derived from the mitochondrial SHMT2 reaction [182]. On the
other hand, studies on cytoplasmic SHMT1-knockout mice show that although the deficiency affects
one carbon metabolism in the organism, the mice are viable thus the gene is not essential [43]. In
line with these findings, mitochondrial SHMT2 is the main glycine producer in the model, and the
backflux of glycine into serine seems only to function as a sink for 25% of methylene-THF groups
formed in the pathways of histidine breakdown. The remainining 75% of methylene-THF is sunk
into glycine production via reverse GCS. In the model, glycine is produced in nearly equal amounts
by the forward conversion of serine to glycine via SHMT2 and the reverse reaction of GCS, which
balances the methylene-THF produced in the former. Yet, the primary role attributed to GCS is
glycine degradation, as opposed to its synthesis (Introduction, Section 1.2.4). In the pathway of
serine production of glucose, carbons at positions 3 and 4 constitute the carboxyl α carbon of ser-
ine, and carbon at position 1 constitutes the β carbon of serine. Via the SHMT-catalyzed reaction,
the α carbon of serine is incorporated into glycine and the latter released as methylene-THF [39].
Although the reversibility of GCS, producing glycine from methylene-THF was doubted to occur
in vivo due to thermodynamic constraints [46], formation of two molecules of glycine from serine
has been shown by Motokawa and KIKUCHI [45], and later the direct incorporation of the β car-
bon of serine into glycine via methylene-THF confirmed by the same group in liver mitochondrial
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extracts. In the spinal cord of rats, Shank et al. [39] showed that although glycine formation from
radiolabelled [3,4-14C]glucose is higher than that from [1-14C]glucose, the latter produces glycine
suggesting its biosynthesis from the β carbon of serine and methylene-THF . The pathway of glycine
production seen in the model is based on the assumption that the reaction can proceed in the re-
verse direction under physiological conditions, as suggested by previous experimental results.
The breakdown of threonine produces N atoms required for reverse GCS, and leads to the produc-
tion of oxobutanoate which is next transported into the mitochondria, where it is converted into
succinate. The next step of TCA cycle, oxidation of succinate to fumarate, also leads to the reduc-
tion of ubiquinone to ubiquinol which results in the transport of two H+ across the mitochondrial
intermembrane space. In addition, the conversion of phosphopyruvate to 3-phosphoserine leads to
the formation of 2-oxoglutarate which additionally feeds the TCA cycle pathways. In sum, the
biosynthetic pathways of glycine/serine metabolism induce ATP formation by oxidative phospho-
rylation in the mitochondria due to the requirement for sinking the C skeletons of amino acids used.
In the last step, the increase of biomass production was addressed in a biomass turnover scan, in
the background of an ATP demand. As expected, as the demand for lipid production goes up there
is a decrease in the OGI index. This is a result of disproportionate oxygen consumption to glucose,
as more glucose is converted to D-glucono-1,5-lactone by D-glucopyranose-6-phosphate enzyme and
subsequent pathways of NADPH generation by the PPP.
Serine to glycine conversion is the major producer of methylated THF groups [183] which is the
case in the model simulations. At lower biomass demands, there is no uptake of histidine and both
mitochondrial and cytoplasmic SHMT operate in the glycine-forming direction. Given the low per-
cent turnover of glycine via SHMT1, the primary role of this reaction is likely the production of
methylene-THF in the cytoplasm. As the uptake of histidine switches on, cytoplasmic SHMT1 is no
longer active until it switches on again at very high biomass demands of 0.09 µmolg−1min−1 , where
SHMT1 begins to operate in the opposite direction. It has previously been proposed that serine
formation from glycine can be used as a sink for additional methyl groups produced in histidine
degradation, meanwhile regenerating tetrahydrofolate [184]. As the SHMT2-catalyzed reaction
in the mitochondria proceeds forward at all biomass demands, the change in the directionality of
SHMT1 across the solutions suggests further that the function of this pathways is to balance the
folate derivatives which take part in biosynthetic reactions. The compartmentalization of serine/g-
lycine thus provides metabolic flexibility to requirements imposed by the steady-state on one carbon
metabolism.
It is surmised that in the presence of a low demand of biomass turnover, serine/glycine metabolism
is unlikely to occur from histidine. Increase in serine and glycine is stoichiometrically linked to the
increase in methylene-THF . The folate pool is supplied with C atoms mainly from serine to glycine
conversions, as well as formate in the mitochondria. Utilization of histidine introduces a novel pool
of methylene-THF which requires to be balanced by the system. This has the effect of slowing down
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the rate of serine biosynthesis from glucose, and glycine biosynthesis in the mitochondria via the
forward reaction of SHMT2 which is the most likely mode of glycine biosynthesis [39]. Production
of serine from alternative amino acids, likely threonine and isoleucine as well as glucose does not
impose the additional strain on the system. One interpretation of the co-dependencies between the
metabolism of histidine, serine and glycine and reactions reliant on the folate intermediates is that
overall, this would provide a disadvantage to the cell. It can be imagined that maintaining cell
homeostasis is far more simple in a system with a higher number of control points, as opposed to a
highly intertwined set of entities. More dependencies would lead to a decrease in both the external
and internal entries of regulation. Following the logic, if a cell acquires its N atoms from amino
acids other than histidine, there is no additional demand on the system to regulate levels of folate
cofactors.
2.4.1 Conclusion
In summary, the major insights of this chapter can be split into those pertinent to energy and
biomass generating pathways, and those specific to glycine production under normal physiological
conditions. Simulations of energy production constrained by literature-defined upper limits of sub-
strate uptake across the BBB showed an emergence of the lactate-pyruvate shuttling under normal
physiological conditions. Although several studies suggest this phenomenon may be a common oc-
curance in the brain (Section 2.4), the model is an incomplete representation of the cell exemplified
by the absence of the intermembrane space compartment which highlights the limitations resulting
from the simplification of metabolic processes in computational modelling overall.
Nevertheless, the maximal rates of ATP production predicted by the model were not too far from
experimental findings (Section 2.4). It should be noted that the estimations were taken from rat
brain ATP estimations as available in the literature. The differences in the values are likely due
to an incomplete representation of all substrates available in the brain at a given moment, such as
recycled amino acids. Furthermore, not all ATP-consuming pathways that fall outside of strictly
metabolic processes are represented in the model, such as neurotransmitter vesicle recycling.
Another major insight is the establishment of a method to visualise and quantify changes in the
metabolic pathway utilizaton in parallel to variations in the OGI values, as energy and biomass
needs of the system are changed. Measurement of the OGI changes is also reflected in the type of
substrate used to support these processes, such as a switch to ketone body catabolism as seen in
Section 2.3.1.
Related to glycine metabolism, the contribution of amino acid metabolism to ATP generation in
the mitochondria and following, the rates of glucose uptake were highlighted (Section 2.3.2). In
addition, the possible importance of the reverse action of the GCS in glycine production from serine
was shown which is supportedby some experimental findings, although previously debated in the
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literature (Section 2.4).
Furthermore, contribution of different amino acids to glycine metabolism was assessed in relation-
ship to tetrahydrofolate cycling in the cell. A major limitation of these findings is that glutamate,
which is a major amino acid that relays N balancing in the brain, was not present in the simulations.
This is taken into account in Chapter 3, where metabolism of glycine across different CNS cell types
is assessed, as opposed to the whole brain metabolism.
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Chapter 3
Integration of single-cell RNA-seq
data
3.1 Introduction
In the previous Chapter, the CNS model was contextualized via manual removal of reactions likely
inactive in the brain, application of constraints on substrate uptake rates across the BBB and fine-
tuning energy and biosynthetic demands to the brain OGI. Nevertheless, this represents metabolism
of the whole organ which is made up of heterogenous cell types, that at the highest glance split into
neuronal and glial cells (Introduction, Section1.2.1). Classification of brain cell types has proven
complex, partially due to different criteria for specifying subgroups [185]. For instance, some neu-
rons have previously been named according to the brain region they populate rather than function,
as is the case for the GABA-ergenic Purkinje neurons present in the cerebellar cortex.
Naturally, these various cell types differ in their function and thus they show a varied signature of
structural and metabolic protein content. Efforts towards the improvement of brain cell type clas-
sification have come from the advances in the single-cell RNA sequencing (scRNA-seq) technologies
which classify and group single cells based on their mRNA expression (Introduction, Section 1.3.4).
Computational methods are used to cluster cells based on their transcriptome which are identified
by their known molecular markers and in reverse, can help to identify novel molecular markers
unique to a cell type.
Apart from classification, these studies can aid in our understanding of the function of these cells-
the individual transcriptomes can provide clues on the metabolic pathways the cell uses for energy
production and peripheral functions. One of the theories pertinent to the differences in brain cell
bioenergetics implies the differential glucose utilization and cycling between excitatory glutamateric
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cells and astrocytes, as described by Pellerin and Magistretti [24] in the astrocyte-neuron lactate-
shuttle (ANLS) hypothesis (Introduction, Section 1.2.3). Although evidence supporting the ANLS
theory exists in the form of experimental observations of substrate uptake in cultured cells in vitro
and differential gene expression, direct evidence is still lacking.
In the following chapter, the CNS model is contextualized further via the integration of a scRNA-
seq dataset from Zeisel et al. [186]. As described in the Introduction, Section 1.3.4, transcriptomics
datasets used for integration with metabolic models are usually the expression patterns of a bulk
of tissue. Indeed, majority of the conclusions reached regading the natural world are based on the
mean representation of a system which allows one to describe the patterns of behaviour for greater
predictability. However, can looking at the pattern of gene expression of a single cell reveal the
possible states of a cell and its function? Moreover, randomness of gene expression can provide
benefits to a cell. The advantage of stochasticity in cellular transcription and translation seen in
bacteria is the emergence of sub-populations resistant to its external environments, increasing sur-
vival. In eukaryotes, the random gene-protein expression may lead to the differentiation of cellular
sub-types from a homogenous population with a unique, specialised function [187]. The possible
gains of studying cell heterogeneity in human is apparent in tumour research, where the knowledge
of the various mutations within a population can aid in the design of combinatorial treatments
[188]. It may be also possible that the study of single-cell expressions in non-cancerous tissue may
lead to the discovery of novel, albeit rare cell phenotypes, which was the reason for the choice of
the scRNA-seq dataset used in the current study.
In Chapter 2, Section 2.3.1, the brain ATP demand was estimated by fixing the value to the overall
brain OGI index. The assumption that follows from this is that glucose is used as the main energy
substrate, and energy production occurs mostly via oxidative phosphorylation in the mitochondria.
Further to the ANLS hypothesis, this may not hold true for different cell types of the CNS. In order
to test the possible differences in energy production across brain cell types, scRNA-seq was applied
to the CNS model and the pathways of ATP production across different cell types analysed. In
the original publication by Zeisel et al. [186] cells were clustered into cell classes by their genetic
expression. In order to test whether the heterogeneity based on the genetic signature overlays with
clustering based on the metabolic pathways utilized by cells, pathways of ATP production were
used to cluster cells within the dataset.
In the next section, the scRNA-seq dataset was used to analyse possible differences in glycine pro-
duction in each cell type. Results from Chapter 2, Section 2.3.2 show that serine/glycine metabolic
pathways depend on the overall balance of folate derivatives. This may explain the reason for
serine hydroxymethyltransferase (SHMT) compartmentalization in the cell. The purpose for the
compartmentalization, as well as the implication of an irreversibility constrain on the GCS were
assessed in the model weighed by the median enzyme expression of the interneuron cell cluster.
In the last section, the ability of different amino acids to support cellular growth was analysed. As
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described in the Introduction, Section 1.2.4 expression of genes related to serine/glycine metabolic
pathways has been found in a subset of human cancer cells, including gliomas [6–10, 53]. In ad-
dition, serine has previously been found to support human cancer cell line proliferation in vitro
[54]. Further to the interest in the development of novel molecular inhibitors of enzymes involved
in serine/glycine biosynthesic pathways for the treatment of cancer [189–191], the model was used
to assess the potential of these substrates to support cellular growth.
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3.2 Methodology
The dataset was downloaded from http://linnarssonlab.org/cortex/ in a .txt format and organised
into a matrix, columns of which were populated with cell IDs and rows with gene names. The en-
tries contained the absolute mRNA counts for 19,972 genes across 3005 individuals cells separated
from the rat somatosensory (SS) cortex and CAI region of the hippocampus [186]. It is impor-
tant to note that expression of mRNA does not always correlate with protein levels thus the use
of a quantitative cell proteome would provide more insightful, were it available. Upon inspection
of several proteomic datasets [192] it became clear that they usually do not identify more than
≈ 300 proteins, which is likely due to difficulties arising from the experimental methods used to
obtain proteomic data. Moreover, single cell proteomic datasets are not yet in existence [193]. The
scRNA-seq dataset used in this study was chosen as it contains a high coverage or genes in cells
separated from two distinct brain regions.
Statistical analysis of the dataset
The majority of data counts (81.2%) equalled zero, which could be an artefact of considerable RNA
loss during processing which particularly affects transcripts present in low count numbers [125].
Distribution of the remaining 19% of the data is highly skewed showing a large variability in the
numbers of counts with a Std.dev. = 19.6 and normality test p-value = 0.0 (Figure 3.1). Overall,
out of the positive mRNA counts, 90% are between 1 and 6 with a median value of 2 .
Clustering of the data in the original publication split the cells into six different “level 1” classes
and a further 47 sub-classes. Level 1 classification includes glial cells (astrocytes, oligodendrocytes
and microglia), neuronal cells (pyramidal CA1, pyramidal SS, interneurons) and endothelial cells.
There is an unequal representation of each cell class, with a much larger population of pyramidal
CA1 and oligodendrocytes as compared to the other cell types (Table 3.1). As stated in the original
publication, there is a difference in the mRNA content between glial and neuronal cells with the
former containing fewer total transcripts overall.
In order to assess gene up- or down-regulation across the different level 1 cell classes, the
proportion of a specific cell class positive for a gene in question out of all cells positive for that
gene was compared to the overall proportion of the cell class in the whole dataset by the χ2 test.
This did not take into account the overall cell numbers, nor the absolute number of mRNA counts,
which may affect the results.
Application of the dataset to the CNS model
Genes that do not encode metabolic enzymes which catalyse reactions present in the model were
reduntant for the next steps, and thus removed from the dataset. Out of 1747 metabolic reac-
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Figure 3.1: Distribution of gene counts in the scRNA-seq dataset Data is highly skewed
towards the right tail, thus a vast majority of counts are in the lower count numbers, with
exceptions of single transcripts present in extremely large counts.
tions in the model, 75% were assigned to one or more gene associations across 860 unique genes.
Gene-reaction relationships were identified from the original Recon2.2 model annotations or the
HumanCyc database. Out of the 860 genes in the model 86% (740) were present in the transcrip-
tome, which was reduced to include the entries for only these genes across all 3005 cells.
Distribution of the ‘trimmed’ dataset shows that the percentage of zero counts was slightly lower, at
75.3%. Similarly to the original dataset, after the removal of zero counts the distribution is highly
skewed, with few genes present in very high copy numbers.
Given the high proportion of zero counts in the dataset disqualification of reactions based on an
expression threshold was not a viable option. Instead, for the purpose of correction for the false-
negative bias a zero entry for any gene was replaced by its median value across the whole dataset.
Corrections were not cell-specific because of the differences in the numbers of zero counts for each
level 1 class. The overall mRNA content is higher for neuronal cell types in comparison to glial cell
types (Table 3.1). In effect, the higher number of overall positive counts brings the median value
down in comparison to cells with less overall positive hits.
Since the original model annotations did not contain information about the genes associated
with the model transport reactions, these reactions were weighed by a coefficient equal to the
median of the dataset.
A number of reactions had more than one gene association defined by AND/OR relationships. In
order to maximise the feasibility of the objective function, these relationships were not taken into
account and the maximum mRNA count for any of the genes associated with the reaction was
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Table 3.1: Number of cells in the dataset versus zero counts present for each cell type
Level 1 class Cell number Zero counts (/740 genes) Zero counts (/19972 genes)
Pyramidal CA1 939 556 15726
Pyramidal SS 399 580 16412
Interneurons 290 545 15967
Oligodendrocytes 820 630 18365
Astrocytes-ependymal 224 664 19179
Microglia 98 710 19273
Endothelial-mural 236 714 19315
The total number of genes in the original dataset from Zeisel et al. [186] was 19972, out of which
740 genes were associated with one or more reactions in the model.
set as the single expression value. These values were applied in the LP formulation as objective
coefficient weights for individual reaction fluxes. Since all the FBA calculations used minimization
of the sum of flux as the primary objective function, the weight was defined as the reciprocal
of the mRNA count. During minimization, the higher weighting factor makes it less likely for the
reaction to appear in a solution. Zero count values were constrained by an arbitrarily large objective
coefficient weight of 10, meaning that reactions were not completely disqualified from the solution.
The LP formulation can be expressed as follows:
minimise :
∑m
i=1 |v| · ji
subject to

Nn,m · v = 0
vbj = bj
0 ≤ vtj ≤ tj
vATPase = 1
(3.1)
Where the variables have an equal definition to those described in Chapter 2, Equation 2.3. The
specific objective function varied according to the problem. The values for the objective coefficient
weights from scRNA-seq dataset were collected in the vector ji and applied in the LP formula-
tion. In all results sections apart from Section 3.3.2, the weights dictionary was calculated from
the median expression values of a given cell class. Responses of microglia were not analysed in the
following sections because of the small representation of these cells in the dataset, at 98 individual
cells only. Endothelial cells were also not taken into account because they are not considered glial
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or neuronal cells.
Clustering of cells based on FBA solutions
In Section 3.3.2, the scRNA-seq was clustered based on the solutions returned from FBA problems
weighted by the gene expression values for each individual cell. The solutions were organised in a
matrix as follows:
Ci,j =
v11 v11 . . . v1j





vi1 vi2 . . . vij
(3.2)
where matrix rows, i, represent reaction names and columns, j, represent individual cell IDs.
Matrix element vij contains the flux carried by ith reaction in the solution of jth cell, thus each
column vector contains an individual solution. The transpose of this matrix was used to calculate
a dissimilarity matrix (Introduction, Section 1.3.3) containing Pearson’s correlation coefficients
between the solution vectors. The resulting matrix was visualized as a hierarchical tree via the
application of a Weighted Pair Group Method using Arithmetic Averaging (WPGMA) clustering
algorithm.
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3.3 Results
3.3.1 Pathways of energy metabolism in different CNS cell types
In order to establish the possible differences in the ATP production pathways across different cell
types, expression of genes related to ATP production was analysed directly by comparison of the
expression levels, and later via FBA simulation of the model weighted by the scRNA-seq values
with the objective function of ATP production in the presence of glucose and lactate.
Expression pattern of genes related to central carbon metabolism
The trends in the expression pattern of genes related to central metabolism are summarised in
Table 3.2 as follows:
1. Pyruvate dehydrogenase kinase (PDK) catalyzes the phosphorylation of pyruvate dehydroge-
nase (PDH) thus lowering its activity and flux of pyruvate to acetyl-CoA in the mitochondria.
The expression of the pyruvate dehydrogenase kinase isozyme 4 (PDK4) is more frequent
in astrocytes in comparison to the other cell types, slightly lower in pyramidal CA1 cells
and considered ‘normal’ for all other cell types. However, PDK can be transcribed into four
isoenzymes and PDK4 is the least expressed type, with a significantly higher number of cells
positive for the remaining three (PDK1, PDK2, PDK3). As opposed to PDK4 expression,
PDK1-3 are more frequently expressed in pyramidal CA1 cells and below the expected num-
bers in oligodendrocytes and astrocytes.
2. The overall expression of the PKM gene, which encodes pyruvate kinase that catalyses the
dephosphorylation of phosphoenolpyruvate to pyruvate is widespread across all the cell types
(2427 cells positive). It is expressed in higher proportion in pyramidal CA1 cells, pyramidal
SS and interneurons. On the contrary, less than expected numbers of oligodendrocytes express
the gene and it is present at normal levels in astrocytes. Thus, neuronal cell types have a
higher PKM expression overall.
3. GLO1 encodes the components of the glyoxylate system, lactoylglutathione lyase and hydrox-
yacylglutathione hydrolase which are important in detoxification of methylglyoxal produced
in glycolysis. Expression of the GLO1 gene is widespread and normally distributed across all
cell types.
4. Genes encoding the subunits of lactate dehydrogenase (LDHA-D) which interconverts pyru-
vate to lactate are slightly higher in all neuronal cell types and normal in astrocytes and
oligodendrocytes. This could be suggestive of high rates of pyruvate to lactate conversion,
although the opposite also applies given that the reaction is reversible.
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5. Differences in the distribution of the expression of genes encoding glycolytic enzymes can be
seen in Figure 3.2. A cell was counted as positive for expression if any of the genes encoding
the subunits of enzyme in question were present. The expression of nearly all glycolytic
enzymes is higher in neuronal cell types and slightly low in astrocytes and oligodendrocytes.
6. In comparison, expression of genes encoding the PPP enzymes shows a split between the
oxidative and non-oxidative PPP (Figure 3.3). In general, a smaller number of cells express
enzymes of the oxPPP (maximum 712 cells) which are slightly upregulated in neuronal cells
and downregulated in oligodendrocytes and astrocytes. Genes relevant to the non-oxidative
PPP are more prevalent, with normal expression distribution in both types of pyramidal cells
and astrocytes, and slighly higher levels in oligodendrocytes and interneurons. Although the
genes of oxPPP are overexpressed in neuronal cell types, glycolytic genes are overall more
widespread and significantly overexpressed in pyramidal cells.
Cell type specific ATP production in the presence of glucose only
In this step a systems-level approach was applied and substrate preference for ATP production in
each cell type was investigated in a set of FBA problems. In the first instance, the demand for
ATP synthesis, vATPase was increased from 1 to 20 µmolg
−1min−1 in the background of uptake
restrictions (Section 2.3, Table 2.2) which can be expressed in the LP formulation below:
minimise :
∑m
i=1 |v| · ji
subject to

Nn,m · v = 0
0 ≤ vtj ≤ tj
vATPase = aj
(3.3)
Overall, the metabolic pathways used by interneurons, pyramidal CA1 and pyramidal SS cells
were the same, thus they were grouped together into neuronal cell responses. Similarly, the same
solutions appeared for oligodendrocytes and astrocytes, which were grouped into glial cell responses.
Both cells utilised pathways of glucose uptake and processing via glycolysis and subsequently ox-
idative phosphorylation in the mitochondria. As seen in the previously described results (Chapter
2, Section 2.3.1), cytoplasmic pyruvate is converted to lactate which is further transported across
the mitochondrial membrane and converted back to pyruvate, generating NADH. The single differ-
ence between the solutions for each cell type is that glial cells consume less glucose and oxidise it
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Figure 3.2: Distribution of cell types amongst cells positive for genes encoding
glycolytic enzymes Overall there is a high expression of glycolytic gene across the whole
dataset. Neuronal cell types compose a higher proportion of these cells, with a slightly lower
representation of oligodendrocytes and astrocytes. The plus and minus signs represent up- or
down- regulation of genes, where + +/- - p= ≤ 1× 10−09, +/- p= ≥ 1× 10−09, and N shows a
‘normal’ distribution, ie. p= ≥ 0.005.
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Figure 3.3: Distribution of cell types amongst cells positive for genes encoding the
Pentose Phosphate Pathway There is an unequal expression of genes of the PPP, with genes
encoding enzymes of the oxidative PPP present in fewer cells than the pathways of non-oxidative
PPP. Distribution of cell types is more equal than the distribution of genes encoding glycolysis
and less homogenous overall, where only the non-oxidative PPP pathways are consistently
overexpressed in oligodendrocytes. The plus and minus signs represent up- or down- regulation of
genes, where + +/- - p= ≤ 1× 10−09, +/- p= ≥ 1× 10−09, and N shows a ‘normal’ distribution,
ie. p= ≥ 0.005.
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completely, whereas neuronal cells saturate the uptake of glucose even at the lower energy demands
and release the surplus as lactate (Figure 3.4). It follows that the OGI index for glial cells is a
perfect ratio of six across all solution up to 18 µmolg−1min−1 , whereas there is a linear increase in
the OGI for neuronal cell types (Figure 3.4, b), where the increasing ATPd causes the cell to use
more glucose directly for energy production and not ‘wasting’.
The values of ATPd at which the OGI falls into the previously recorded range for the whole brain
(5.4-6.0) are between ≈17-19 µmolg−1min−1 for neuronal cells. At an ATPd of 17.5 µmolg−1min−1 ,
neuronal OGI = 5.44 and lactate efflux is 18% of glucose uptake, in line with the range previously
reported in isotopic label incorporation studies [108]. Thus, this value for ATPd will be used to
constrain the background ATPd in neuronal cells in the subsequent problems. Since the glial cell
OGI index remained consistent across the range at six, to allow for direct comparison of solutions
the same value for ATPd will be used to constrain glial energy demands. This assumption may
not hold true, as it is thought that neuronal cells have a higher energy demand than glial cells
(Introduction, Section 1.2.3) meaning that energy consumption of a glial cell should be adjusted to
a lower value. However, reactions utilized by glial cells remain constant across all energy demands
thus the absolute value of energy production is irrelevant.
Cell type ATP production in the presence of glucose and lactate
In this section, the substrate preference of each cell type was assessed. The ATPd was increased
from 1-30 µmolg−1min−1 in the background of an equal uptake constraint on glucose as in Section
3.3, with the addition of a bi-directional lactate transporter reaction which was left unconstrained.
Neuronal cell types utilized the same metabolic pathways across all ATPd as in the presence of
glucose only. Up to ATPd ≈ 20 µmolg−1min−1 , glucose consumption is saturated and there is a
net release of lactate, which begins to be imported at higher demands. On the contrary, the response
of the two glial cell types differs- oligodendrocytes show a preference for glucose uptake with no
net lactate release. Similarly to neurons, lactate begins to be consumed upon glucose saturation at
ATPd ≈ 20 µmolg−1min−1 . On the other hand, astrocytes show a preferential lactate consumption
at all ATPd . It is imported into the mitochondria for pyruvate production and full oxidation in
the TCA cycle, and glycolysis is inactive altogether (Figure 3.5).
To sum up, in the absence of lactate uptake, neuronal cell types do not optimize their glucose
consumption at low energy demands and release lactate as a byproduct whereas glial cell types
oxidise glucose fully at all energy demands. When lactate is available, ATP production pathways
remain the same for neuronal cell types and oligodendrocytes, which begin to use lactate as a sub-
strate only upon glucose saturation. However, astrocytes show a preference for lactate at all energy
demands which is the sole substrate imported and is directly shunted into the mitochondria for
complete oxidation.
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Figure 3.4: Uptake of glucose versus lactate export across a range of ATP demands in
different cell types Neuronal cells saturate their glucose uptake at all ATPd and release lactate
up to ≈ 18 µmolg−1min−1 , when lactate release stops. In effect, OGI increases linearly as more
O2 is consumed by the mitochondria to oxidise glucose. On the contrary, glial cells do not release
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Figure 3.5: Uptake of glucose and lactate across an increasing ATP demand in
different cell types Neuronal cells and oligodendrocytes prefer to use glucose and only begin to
import lactate only at ATPd ≈ 20 µmolg−1min−1 and onwards. Astrocytes do not import glucose
and have a preference for lactate at all ATPd .
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3.3.2 Clustering of cells based on their metabolic response to an ATP
demand
Previous solutions represent the generalised responses of each cell class, without taking into account
the stochasticity of gene expression in individual cells. In order to test whether clustering based
on a metabolic objective function will produce similar result as in the original publication, as well
as to identify whether it can lead to the discovery of novel phenotypes, cells were clustered by
their response to an ATP demand. In each LP formulation the objective coefficient weights vector
was weighted by the expression values of an individual cell, in the background of an ATPd at 17.5
µmolg−1min−1 under constraints as in Equation 3.3.
The metabolic tree generated from the solutions can be seen in Figure 3.6 and is discussed below.
Due to a large number of individual tree leaves the nodes were condensed, with each node repre-
senting a group of cells that produced the same solution. Overall, 95% of all cells utilize one of the
two pathways of ATP synthesis described in the previous Section 3.3.1.
Node L13 contains cells that completely oxidise glucose for energy production, with no lactate re-
lease and a perfect OGI of six. As expected, the majority of the cells belonging to this group are glial
cells: oligodendrocytes (45%) and astrocytes (13%), although there is a significant representation
of neuronal cells in this node, with 15% pyramidal CA1, 7% pyramidal SS and 3% interneurons.
The other major group, node L14, contains cells that release lactate and thus do not use all the
glucose for ATP production, with an OGI of 5.4. It follows that an overwhelming majority of cells
in this group are neuronal, with 55% pyramidal CA1, 24% pyramidal SS and 19% interneurons.
There is a small representation of glial cell types, with 2% oligodendrocytes and 0.16% astrocytes.
Out of the remaining nodes, only L2 and L7 contained more than 60 cells. Node L2 is a cluster of
65 cells made up largely of microglial cells (88%) which, apart from glucose, uptake ketobutyrate
which is transported into the mitochondria and convert it to acetoacetyl-CoA and subsequently
acetyl-CoA. Node L7 is a cluster of 65 cells made up of a large population of oligodendrocytes at
75% which completely oxidise glucose to ATP. The single difference between the solution of L13 and
L7 is the succinate-CoA synthetase-catalysed reaction, which cleaves Coenzyme A from succinyl-
CoA in the formation of succinate and a nucleoside triphosphate. In the solution of L7 cells, this
reaction phosphorylates GDP to form GTP, instead of ATP.
Clustering based on the metabolic objective of ATP production does not result in the differentiation
of cells to the same extent as genetic expression does- cells split roughly into two groups of neuronal
and glial types without further subdivisions. The small population of microglial cells (98) were the
only cell class well differentiated from others as 65/98 belonged to a distant node L2 which, apart





























Figure 3.6: Clustering of cells based on the pathways used for ATP production Majority
of cells produce ATP via one of the two pathways described in Section 3.3.1, belonging to nodes
L13 and L14. Out of the remaining nodes, only L2 and L7 having a significant representation of
60 cells or more. Branch length does not represent the distance between nodes.
94 CHAPTER 3. INTEGRATION OF SINGLE-CELL RNA-SEQ DATA
3.3.3 Pathways of glycine metabolism across different CNS cell types
For the purpose of comparing pathways of glycine production in neuronal versus glial cells, in the
following section the median mRNA expression for each cell type was applied to the model. In the
second step, the model was contextualized further and the expression data for a median interneuron
was applied to assess glycine biosynthesis under different scenarios.
Constraints applied on glucose and amino acid uptake
The availability of substrate within the brain is not constrained by the BBB, and it is accepted that
metabolites are exchanged between different cell types as is the case in the glutamate-glutamine
cycle [194]. Quantification of amino acid levels in post-mortem human brain and spinal cord reveals
a relatively high concentration of these amino acids in their free form across all regions of the grey
and white matter. Similarly, glycine and serine are concentrated in the white matter of the spinal
cord, correlating with their function in this region [195]. Consequently, the uptake of glutamine,
glutamate and serine were left unbounded in the following LP formulations. The upper bounds on
the remaining metabolites introduced in Chapter 2, Section 2.3, Table 2.2 remained constant.
Results from Section 3.3.1 support the notion that in the presence of glucose and lactate, neuronal
cells have a preference for glucose and a high rate of oxidative phosphorylation. Based on this
assumption, the ATP demand of the cell was fixed to 17.5 µmolg−1min−1 in the subsequent FBA
problems.
Expression of genes related to glycine metabolism and transport
Gene expression of enzymes related to the biosynthesis and transport of serine and glycine are
summarised in Table 3.3.
1. Genes encoding the enzymes catalysing serine biosynthesis from glucose, PHGDH (phospho-
glycerate dehydrogenase), PSAT1 (phosphoserine aminotransferase), PSPH (phosphoserine
phosphatase), are widely expressed in the dataset and are significantly overexpressed in oligo-
dendrocytes. The gene PHGDH, encoding phosphoglycerate dehydrogenase which catalyzes
the first step of the pathway converting 3-phospho-glycerate to 3-hydroxypyruvate is also sig-
nificantly overexpressed in astrocytes. The expression of PHGDH and PSAT1 which encodes
phosphoserine aminotransferase is significantly lower in all three types of neuronal cells.
2. The distribution of SHMT genes encoding the two isoenzymes of serine hydroxymethyl trans-
ferase is normal across all cell types. The expression of mitochondrial enzyme, SHMT2 is
higher overall than that of cytoplasmic SHMT1.
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3. The expression of GCSH, which encodes the GCS component protein H is high across the
dataset with no significant up- or down-regulation in any cell type.
4. Genes PEPD and CNDP2 encode dipeptidase enzymes, prolidase and carnosinase which cat-
alyze the hydrolysis of amino acid pairs. The expression of these genes is widespread across
the dataset, and significantly higher in pyramidal CA I cells. The expression of CNDP2 is
significantly high in interneurons.
5. The expression of serine and glycine transporters shows a distict pattern. SLC6A9 encodes
the glycine transporter 1 protein responsible for the uptake of glycine [196] and is signifi-
cantly overexpressed in oligodendrocytes and underexpressed in pyramidal CA I cells. The
same pattern is present in the expression profile for SLC1A4, encoding the Asct-1 which is
involved in the transport of serine, alanine and threonine [197]. The expression of SLC7A10,
which encodes Asc1 involved in the Na+ -independent transport of glycine, alanine, serine
and cysteine [198] is significantly high in astrocytes.
Pathways of glycine biosynthesis in different cell types
Glycine export was fixed at 0.035 µmolg−1min−1 in the background of an ATP demand at 17.7




i=1 |v| · ji
subject to

Nn,m · v = 0




As can be seen in Figure 3.7, both cell types import serine which is transported into the mito-
chondria for glycine formation via the mitochondrial SHMT2. Carbon released in this reaction is
recycled back into glycine via the reverse action of GCS, with each reaction contributing 50% to
total glycine production. The single difference between solutions is the source of N atoms used by
the reverse GCS-catalysed reaction and serine production from hydroxypyruvate. Neuronal cells






















































































































































































































































































































































































































































































































































































































































































































































take up glutamine, which undergoes deamination in the mitochondria to form glutamate by the
glutaminase enzyme. Glutamate is sunk into the TCA cycle intermediate, 2-oxoglutarate via the
glutamate dehydrogenase-catalysed reaction which releases NH4 and reduces NAD to NADH. In
the glial cells, glutamate is used as the substrate and all NH4 is provided by the glutamate dehy-
drogenase -catalysed reaction (Figure 3.7). The preferential uptake of each amino acids matches
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Figure 3.7: Pathways of glycine synthesis in different cell types Pathways of glycine
production remain the same, with the exception of the N source. Glial cells show a preference for
glutamate uptake (b), whereas neuronal cells consume glutamine which is converted to glutamate
in the mitochondria (a).
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Alternative pathways of glycine synthesis in an interneuron
In the previous solutions seen in Chapter 2, Section 2.3.2, glycine is synthesized equally via the
reverse GCS and the forward reaction of SHMT2, where reverse GCS consumes methylene-THF
generated in the mitochondria by the forward reaction of SHMT2. The implication of setting the
GCS as irreversible on the preferred pathway utilization are assessed in the next results section.
The purpose of SHMT cell compartmentalization was also assessed by analysing the effect of the
knockout of each reaction on the resulting pathways of glycine production. In each problem, the
constraints were set as in equation 3.4, and the flux of the reaction in question was set to zero.
reactions described were sequentially restricted to zero in each next problem described as follows.
1. Knockout of mitochondrial SHMT2 Glycine is synthesized via the cytoplasmic SHMT1
and reverse GCS. Serine is not directly transported across the mitochondrial membrane,
rather C atoms cleaved from serine are involved in several folate transformation reactions with
the overall effect of generating mitochondrial methylene-THF required for the GCS-catalysed
reaction. The net flux of serine and glutamate import remains the same as in Section 3.3.3,
where serine import flux is 50% of glycine export. Folates are known to be transporter across
mitochondrial membranes by mitochondrial folate transporters which are required for glycine
biosynthesis [199].
2. Setting GCS to irreversible in the glycine-degradation direction Glycine production
via SHMT in both compartments is inactive. Instead, serine is transported into the peroxisome
where it is used as a substrate in the serine-pyruvate transaminase-catalysed reaction:
1.0 Serine +1.0 Pyruvate + 1.0 H+→ 1.0 Alanine + 1.0 Hydroxypyruvate
Alanine and glyoxylate produce glycine and pyruvate via the enzyme alanine-glyoxylate amino-
transferase. Glyoxylate used in this reaction is formed from hydroxypyruvate in the peroxisome, via
a pathway which converts the latter to glycoaldehyde, and subsequently glycolate in the cytoplasm.
This pathway leads to the formation of H2O2 which is neutralised by the catalase-mediated reaction
to O2 and H2O. The serine-pyruvate transaminase reaction occurs both in the peroxisome and in
the mitochondria, thus upon the knockout of the former the latter switches on. Alanine used in
the mitochondrial alanine-glyoxylate aminotransferase-catalysed reaction is synthesized from gluta-
mate, and glyoxylate is generated in the same peroxisomal pathway as described. Knockout of both
pathways utilizing alanine causes the cell to change the amino donor. Glyoxylate is produced via the
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equal peroxisomal pathway however, glycine production occurs in the cytoplasm from glyxoylate
and glutamate in the following reaction:
1.0 Glutamate +1.0 Glyoxylate + 1.0 H+→ 1.0 Glycine + 1.0 2−Oxoglutarate
Across all solutions the import of serine is equal to the export of glycine, at 0.035 µmolg−1min−1 .
There is no net turnover of NADP in the solution. The expression of the AGXT gene encoding
the serine-pyruvate transaminase enzyme is zero across the scRNA-seq, therefore this pathway of
glycine production is unlikely to occur in brain cells.
Knockout of the glyoxylate biosynthetic pathway If none of the above pathways can be used
and GCS is set as irreversible, glycine is synthesized in the cytoplasm via SHMT1. The methylene-
THF produced which can no longer be sunk by the GCS is cycled back to THF with a release of
CO2. Upon inspection of this solution, futile cycles catalysing NAD(P)H conversions were spotted,
such as the reaction cycle:
1.0 Hydroxyacetone +1.0 NADPH + 1.0 O2 + 1.0
H+→ 1.0 Methylglyoxal + 1.0 NADP + 1.0 H2O
1.0 Hydroxyacetone + 1.0 NADPH← 1.0 Methylglyoxal + 1.0 NADP
Overall, there are no net metabolic transformations that take place in this cycle. Four equivalent
cycles were identified involving the conversions of the toxic metabolite methylglyoxal, as well as
fatty acid interconversions. Upon the removal of these cycles, glycine production occurs both via
the cytoplasmic and mitochondrial SHMT enzymes which contribute equally to the total glycine
production (Figure 3.8, a). Methylene-THF produced in the cytoplasm which can no longer be sunk
into mitochondrial glycine is used to form methionine. Further pathways of methionine degradation
switch on, utilizing S-adenosyl methionine in the pathway of choline formation from ethanolamine.
In this pathway, three S-adenosyl methionine molecules are used for the methylation reaction
producing three molecules of S-adenosyl-homocysteine (SAM) which is further cleaved to adenosine
and homocysteine. The methylene-THF produced in the mitochondria is recycled to cytoplasmic
THF via folate transformations and a release of CO2. Uptake of serine is 0.041 µmolg
−1min−1 ,
exceeding glycine export.
Knockout of cytoplasmic SHMT1 Glycine biosynthesis occurs entirely from SHMT2 in the
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mitochondria. As in the previous result, methylene-THF produced in the mitochondria is recycled
back into tetrahydrofolate with a release of the C atom as CO2. This reaction reduces NADP to
NADPH, which is balanced by the oxidation of reduced glutathione (GSH) to glutathione (GSSG) in
cysteine transfers reactions (Figure 3.8, b). There is a net formation of H2O2 which is neutralised
by GSH. Uptake of serine is equal to the export of glycine, at 0.035 µmolg−1min−1 .
Knockout of mitochondrial SHMT2 As in the case of equal glycine production from both
SHMT enzymes, there is a net production of choline via the methionine degradation pathways.
However, there is no transport of glycine into the mitochondria and production occurs entirely
by SHMT1, which can be seen in Figure 3.8, c. Apart from methylene-THF sink into 5-methyl-
THF, methylene-THF is converted into 5,10-methenyl-THF which is subsequently recycled into
tetrahydrofolate required for the SHMT1- catalyzed reaction. Net uptake of serine exceeds glycine


















































































Figure 3.8: Effect of SHMT knockouts When the GCS-catalysed reaction is set as irreversible
in the glycine degrading direction and NAD(P)H cycling reactions are removed, glycine is formed
from both SHMT enzymes equally (a). Glycine formation entirely from SHMT2 results in a stop
in methionine formation, and all of the C atoms from methylene-THF are sunk into CO2 in the
cytoplasm (b). Glycine production from SHMT1 only supports methionine formation, as in
solution (a).
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3.3.4 Amino acid uptake at increasing energy and biomass demands
In this section the preferences for amino acids uptake during cell growth were assessed. In each
FBA problem the ATPd was kept constant at 17.5 µmolg
−1min−1 and the total biomass ranged from
0.025 to 0.055 µmolg−1min−1 . Restrictions on glucose uptake remained the same, at the upper
limit of 0.6 µmolg−1min−1 , and all fatty acid uptake was restricted to 0.015 µmolg−1min−1 .
Preference of substrate in the presence of free amino acid uptake
In the first instance, the uptake of all imported amino acids including glutamate, glutamine, serine
and glycine was left unconstrained. Across all solutions the cells saturated glucose uptake and
released lactate, with a linear increase in the uptake of glutamate and export of aspartate (data
not shown). There is a small increase in the rates of glycine and serine uptake which are used in
the biosynthesis of purines and lipids via the reaction pathways seen in Chapter 2, Section 2.3.2.
In the next problem formulation, glutamate uptake was restricted to 0.01 µmolg−1min−1 which re-
sulted in increased uptake of serine and isoleucine, and a release of glycine (Figure 3.9, b). As seen
in Section 3.3.1 (increases in the demands of ATPd only), glucose uptake is saturated at all biomass
demands. It follows that as more oxygen is consumed in the pathways of amino acid oxidation
there is a linear increase in the OGI across solutions (5.58-5.82). Glucose utilization is shunted
towards the oxidative PPP thus reducing glycolytic flux, without an effect on the flux via the TCA.
Isoleucine is the biggest contributor to the total imported C moles across all solutions (Figure 3.9
a) and undergoes transamination with 2-oxoglutarate to produce glutamate and 2-keto-3-methyl-
valerate. Both of these compounds are transported into the mitochondria, where glutamate is used
to directly fuel the TCA cycle via its conversion to 2-oxoglutarate by the glutamate dehydrogenase
enzyme which releases significant NH4 .
As biomass demand increases, serine becomes a major source of C atoms via its conversion to the
glycolytic intermediate, 2-phosphoglycerate. Firstly, it exchanges an amino group with pyruvate to
form hydroxypyruvate and alanine via the serine-pyruvate transaminase reaction. Hydroxypyru-
vate is next converted to glycerate in a reaction which oxidises NADH to NAD via hydroxypyruvate
reductase. Finally, glycerate is converted to the glycolytic intermediate 2-phosphoglycerate via glyc-
erate 2-kinase which uses ATP as the phosphate donor.
Although the flux carried by this pathway as well as reactions utilizing serine and glycine for bio-
mass formation increase, the rates of increase do not correspond with the large increase in the rate
of serine uptake. Large increases in the rate of serine import correspond directly to its transport
into the mitochondria and cleavage into glycine (Figure 3.9,c). As seen in previous solutions, the
total methylene-THF produced in this reaction is sunk into glycine formation via reverse GCS, with
both reactions carrying equal flux. Glycine is next transported into the cytoplasm and released.
Since the two transport reactions do not carry equal flux and there is no import of glycine, that
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which is used for biosynthetic reactions is formed completely from serine.
If the large increase of serine uptake is directly correlated with glycine export, and all the methylene-
THF formed in the mitochondria is sunk into glycine, what is the purpose of this pathway?
Analysis of the solution shows that the reverse GCS acts as primary sink for NH4 formed as a
byproduct in the glutamate to 2-oxoglutarate conversion reaction. At higher biomass demands,
more than 90% of N is neutralised by this pathway (Figure 3.9, d), thus the primary purpose of the
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Figure 3.9: Cell uptake of isoleucine and serine for biomass production In the absence of
additional glucose or glutamate, the cell begins to use isoleucine and serine (b). Isoleucine, along
with serine are the major C donor across all solutions (a). The rate of serine uptake corresponds
to equivalent increases in the rate of its transport to the mitochondria, conversion to glycine
(reacID: R GHMT2r m), the reverse reaction of GCS (reacID: R r0295 m), and subsequent
glycine release (reacID: Gly tx), (c). This reaction cycle may be acting as a primary sink for NH4
produced in glutamate degradation pathways, as reverse GCS is the reaction with highest N
consumption across all solutions (d).
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In the next scan, both glutamate and isoleucine were constrained to 0.1 µmolg−1min−1 . In
this solution, the cell begins to uptake glutamine and continues to consume large amounts of
serine and export glycine (Figure 3.10, b). The conversions of serine to hydroxypyruvate increase
proportionally to serine uptake (Figure 3.10, c), indicating that this pathway becomes a major
contributor to energy production as can be seen in Figure 3.10, a. Glutamine also contributes to
biomass production via its deamination to glutamate in the mitochondria which – as previously –
is sunk into 2-oxoglutarate with a net production of NH4 . Reverse GCS remains the major N sink
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Figure 3.10: Cell uptake of serine and glutamine for biomass production Upon restriction
of isoleucine import, the cell begins to uptake large amounts of serine as well as glutamine (b).
The former becomes a major C donor (a) after glucose via the serine-pyruvate aminotransferase
reaction in the cytoplasm (reacID: SPA-RXN c) which leads to formation of 2-phosphoglycerate
(c). As in the previous solution, reverse GCS remains the major consumer of NH4 produced by
glutamate degradation (d).
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Production of ATP from serine and glycine
Biomass turnover requires an increase in cellular ATP consumption. The ability of each amino acid
to support energy production only was tested in the model. In each problem formulation, ATP
demand was incremented from 1-20 µmolg−1min−1 in the presence of a zero flux constraint on all
transport reactions except for O2 , CO2 , H2O , H
+ and either serine or glycine.
Out of the two amino acids only serine was able to support an ATP demand increase. Serine was
able to support ATP production in the mitochondria via a number of pathways as follows:
1. Serine conversion to cysteine via the enzyme cystathionine-β-synthase, with the latter con-
verted to pyruvate in the cytoplasm via cystathionine-γ-lyase.
2. Serine conversion to cystathione via the enzyme cystathionine-β-synthetase, which is next
sunk into 2-oxoglutarate in the cytoplasm.
3. Serine conversion to aminocrylate via the enzyme serine-dehydratase which is next converted
to pyruvate in the cytoplasm.
4. Serine conversion to 3-phosphoglycerate via the reversal of its pathway of biosynthesis from
glucose.
5. Cleavage of serine into glycine in the mitochondria, leading to the production of NADH for
use in the ETC (Figure 3.11)
.
Pathway 5, ATP production from serine via cleavage into glycine leading to the generation of
NADH in the mitochondria can be seen in Figure 3.11. Serine uptake is directly correlated with
glycine release (Figure 3.12, a). On the other hand, when the only substrate for energy production
was glycine the cell could not make ATP at any demand. This shows that these two amino acids
are not freely interconvertible.

























Figure 3.11: Serine to glycine conversion supports ATP formation via the ETC Serine
can support ATP formation by inducing NAD reduction via the reaction converting
methylene-THF to 5,10-methenyl-THF . The methylene-THF is generated by conversion of serine
to glycine via mitochondrial SHMT2. This pathway requires the cycling of folate groups across
the mitochondrial membrane.
Interconversion of serine and glycine
Reversibility of the SHMT enzymes would suggest that cells should have a capability to freely
convert serine and glycine. This is not the case given previous results which show that only serine
is capable of supporting energy increases. In this set of analyses, the export rate of each amino
acid was varied from 0.001- 0.35 µmolg−1min−1 in the background of constraints on amino acids
uptake and an unconstrained uptake of the other amino acid.
In the absence of glucose uptake, the model is capable of producing unlimited amounts of glycine
from serine only (Figure 3.12, c). In reverse, production of serine from glycine is only feasible in
the presence of glucose (Figure 3.12, b) or formate (Figure 3.12, d). In the former, glycine is used
to produce glutamate in the cytoplasm which acts as the amino donor in the pathways of serine
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Figure 3.12: Glycine alone cannot support serine synthesis Serine can support ATP and
glycine production without the use of any other substrate (a, c). On the other hand, production
of serine from glycine is not possible unless the uptake of glucose (b) or formate (d) is allowed in
the model.
production from glucose. When the model is allowed formate uptake in the absence of glucose,
serine production occurs via both the glycolytic pathway, as well as the reverse flux of both SHMT
enzymes. These contribute to serine biosynthesis in different ratios, with mitochondrial SHMT2
producing ≈ 65%, cytoplasmic SHMT1 ≈ 25% and the glycolytic pathway ≈ 8% of the total serine
biosynthesis. These ratios remain the same across all solutions.
Ability of serine and glycine to support increasing biomass demands
It is apparent that serine is one of the preferred amino acids used during biomass increase along
with glutamate, isoleucine and glutamine. Secondly, production of glycine in the mitochondria may
act as a N sink for a cell utilizing glutamate to feed the TCA cycle. However, it remains unclear
whether serine may act as a sole substrate for biomass production.
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In the next set of FBA problems the uptake of all amino acids was constrained to 0.01 µmolg−1min−1 .
Serine and glycine uptake was constrained to 1 µmolg−1min−1 , in the presence of constraints on
glucose and fatty acids uptake as described previously. Biomass was increased from 0.03 to 0.14
µmolg−1min−1 . The uptake of amino acids was allowed to a limit because the complete knockout
of amino acids import renders the solution infeasible.
Serine alone can sustain biomass increases up to ≈ 0.12 µmolg−1min−1 (Figure 3.13 a) by donating
its C atoms to 2-phosphoglycerate in the cytoplasm as described in the previous section. Knockout
of the hydroxypyruvate pathway in the presence of the same restrictions leads to the formation
of the intermediates of glycolysis and ETC as described in the presence of an ATP demand only
(Section 3.3.4). Across all solutions, glycine is exported proportionally to serine uptake and thus
remains the main sink for N atoms generated in these reactions. Setting the GCS to unidirectional
in the glycine degradation direction stops glycine export, and the cell begins to release asparagine
which becomes the N sink.
In the presence of glycine and a restriction on serine uptake, biomass increase can only be supported
up to ≈ 0.056 µmolg−1min−1 . Glycine begins to be imported only at very high demands which
causes an increase in H+ import and arginine export. Across all solutions, C atoms are acquired
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Figure 3.13: Ability of serine and glycine to sustain biomass increase Serine can support
growth up to ≈ 0.13 µmolg−1min−1 (a) and is the second C donor after glucose (b). In the
presence of glycine, solution is feasible only up to a total of ≈ 0.057 µmolg−1min−1 total biomass
flux. Glycine begins to be imported only at the very high biomass demands, which results in a
large increase of H+import (c).
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3.4 Discussion
Energy production pathways in different cell types
Expression of all glycolytic genes is widespread across the dataset and upregulated in neuronal cell
types, as can be seen in Table 3.2. This includes the gene encoding pyruvate kinase (PKM), which
catalyzes the dephoshorylation of phosphoenolpyruvate to pyruvate. Differential splicing of PKM in
human results in two isoforms, PKM1 and PKM2 where the latter has been associated with higher
expression in human cancer cells [200]. Since PKM1 is constitutively active, but the activation of
PKM2 relies on the binding of allosteric activators [201] PKM2 limits glucose oxidation and favours
biosynthetic-diverging pathways of glycolysis. However, the enhancement of PKM1 has also been
shown to favour tumour growth in tumour mouse models, thus evidence towards tumour-enhancing
overexpression of both isozymes exist. Analysis of transcriptomic data from different types of puri-
fied brain cells by Zhang et al. [202] showed that PKM1 is mostly expressed in neurons, and PKM2
in astrocytes which have a better ability to modulate their glycolytic flux, in comparison to neurons.
Although the products of the differential splicing cannot be distinguished in the scRNA-seq, the
expression of PKM is widespread across all cell types showing no specific pattern of expression.
Entry of pyruvate into the TCA cycle is regulated by pyruvate dehydrogenase, which catalyzes the
formation of acetyl-CoA from pyruvate in the mitochondria. This enzyme is regulated via phospho-
rylation by the pyruvate dehydrogenase kinase enzyme which exists in four isoenzymes, encoded by
the genes PDK1-4. Activities of each isoenzyme have been determined in vitro showing that the
isoenzymes vary in their phosphorylation rates at three serine sites [203]. Overall, PDK2 has the
highest rate of phosphorylation of serine site 1, whereas PDK3 has the highest rate of phosphory-
lating serine site 2 and serine site 3 is only phosphorylated by PDK1 [203]. In the same study by
Zhang et al. [202] it was found that the expression of PDK4 is higher in astrocytes than in neurons,
which may act to prevent pyruvate entry into the TCA cycle and promote lactate formation by
lactate dehydrogenase. In the current study it was found that PDK4 expression is indeed higher in
astrocytes, but the expression of PDK1-3 genes is higher overall and more prevalent in pyramidal
CA I thus neuronal, rather than glial cell types.
Lactate dehydrogenase, which interconverts pyruvate and lactate is encoded in humans by four
genes, LDHC. LDHA and LDHB encode the subunits which compose the heteromeric enzyme de-
fined by random combinations of the two subunits, however the affinity of LDHA to pyruvate is
higher than lactate and vice versa, which, along with the concentrations of lactate and pyruvate
present, determine in which direction the reaction will proceed [204]. The expression of LDHA
and LDHB in the scRNA-seq is widespread across the whole dataset with both genes expressed
in slightly higher numbers in neuronal cell types, as seen in Table 3.2. Overall, these expression
patters suggest that glycolysis is present in all cell types, and perhaps higher in neuronal cells in
comparison to glial.
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Methylglyoxal is a product of spontaneous breakdown of dihydroxyacetone phosphate (DHAP), an
intermediate of glycolysis and is associated with numerous health-related conditions [205]. Mag-
istretti and Allaman [25] reasoned that higher expression of GLO genes in astrocytes in comparison
to neurons better equips these cells to a high glycolytic activity which leads to methylglyoxal accu-
mulation. In this study, the GLO1 gene, which encodes the components of the glyoxylate system,
lactoylglutathione lyase and hydroxyacylglutathione hydrolase is one of the most widely expressed
genes analysed, suggesting the ubiquitous need of methyglyoxal detoxification in brain cells which
is not cell-specific.
As seen in Figure 3.3, the expression of genes encoding the enzymes of the oxidative PPP is lower
than glycolytic genes overall. There is no significant correlation between the expression patterns
of these genes. Genes of the non-oxidative PPP are more widely expressed, but there is not a
significant difference in the expression levels across cells. This further supports the notion that
glucose in all cells is mostly processed via glycolysis, rather than diverging biosynthetic pathways
such as the PPP.
Further to the expression patterns, ATP production in different cell types was analysed in an FBA
problem ATP scan (Section 3.3.1). The pathways utilized by each cell type, neuronal and glial
were the same with a difference of lactate efflux. Glial cells consumed only the amount of glucose
required for the production of ATP, at all demands. Although the conversion of pyruvate to lactate
occurred in the cytosol, all of the lactate was oxidised in the mitochondria. Suprisingly, neuronal
cells saturated glucose uptake and released lactate at all energy demands, with the proportion of
lactate release decreasing at increasing energy demands. This is in direct contrast with the ANLS
hypothesis, supported by previous studies such as that by Walz and Mukerji [206] in which higher
lactate release rates were seen from cultured astrocytes in comparison to neurons. In their study,
the rate of neuronal release reached astrocytic release rates when uncoupling of oxidative phospho-
rylation in the mitochondria was achieved by the addition of dinitrophenol, suggesting that the
difference accounts for the varying rates of glycolysis and oxidative phosphorylation in the two cell
types. Higher rates of lactate release by astrocytes were also reported by Itoh et al. [207] in vitro.
However, stimulation of PDH via the administration of dichloroacetate to conscious rats, reducing
the rate of astroglial lactate release, did not affect normal brain function, suggesting that astroglial
lactate release and cycling is not essential for neuronal function. In addition, it has been shown
by Dı́az-Garćıa, C. et al. [208] that during stimulation neuronal cells uptake glucose and process it
via glycolysis, increasing the NADH ratio without the uptake of astrocytic lactate. Thus, although
these cells may have different metabolic capabilities, neuronal cells are not dependent on astrocytic
lactate release.
So what could account for neuronal lactate release? Sobieski et al. [209] found that rat neuron-
astrocyte co-cultures can survive long-term glucose deprivation and sustain neurotransmission. Cell
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starvation induced large lactate releases which remained in the media, supporting cell survival. The
origin of lactate was likely astrocytic, although in the same study glucose-deprived neurons main-
tained neurotransmission whether grown in the presence of astrocytes or not. The authors concluded
that neuronal cells may use lactate release as a way to store energy. Given that neuronal cells have
a high ATP demand, but brain glycogen reservoir is restricted to glial cells [210], lactate efflux
could provide neurons with an energy source in the surrounding fluid. Whether this happens in
vivo, when the cell is not subjected to stress conditions which may cause it to rewire its metabol-
ism is not certain. It can be imagined that the experimental treatment of the tissue prior to the
collection of mRNA expression values in the scRNA-seq dataset used in the current study could
lead to stress-induced changes in genetic expression, leading to the results seen in this study.
In the next model analyses (Section 3.3.1), both glucose and lactate were allowed to be uptaken
and the ATP demand ranged from 1-30 µmolg−1min−1 . All cells, apart from astrocytes preferred
to consume glucose up to its saturation at ATPd ≈ 20 µmolg−1min−1 . This is in direct contrast
with substrate preference of primary cultures of astrocytes and neurons reported by Bouzier-Sore
et al. [211], although, it has been previously shown that both cell types can take up glucose and
lactate as substrates [207]. Overall, the high rate of lactate release and preferential use of lactate
by astrocytes is in direct contrast to the ANLS hypothesis
In Section 3.3.2, ATP production was used as the objective function to cluster cells based on the
solutions they produce. Overall, the heterogeneity emerging from the data was less apparent than
that resulting from clustering based on genetic expression. Two main groups of cell clusters ap-
peared, neuronal and glial cell types with the former releasing lactate. Out of the seven main classes
identified in the original publication, only microglia were separated in a distant node. Microglial
cells utilized both ketobutyrate and glucose for the production of acetyl-CoA in the mitochondria,
which was not seen in any other solution set. Lastly, a separate cluster of 65 cells composed of
mostly oligodendrocytes emerged, with a preference for GTP production via the TCA cycle reaction
catalyzed by succinate CoA synthase.
It seems obvious that the main pathways of energy production in a cell will remain similar across cell
types, given that cellular need of energy production is fundamental and constant across the lifespan
of the cells. In his book ‘What is life?’, Schrödinger [212] wrote that stochastic behaviour within a
system is a disadvantage for its existence in an ordered- at least on the macro scale- universe. For
example, the Brownian motion of a particle would make it difficult for it to plan its journey which
is trivial for bigger organisms like humans, thus defining a scale to living organisms. As energy
production is a fundamental need of cells to sustain life, stochasticity would make it less robust to
external factors, such as gene expression. In fact, the stability of the ETC machinery as a means
of energy production is proved by its emergence in bacteria about 2×109 years ago and its use in
mammals still today [213]. Rather, cellular heterogeneity is a result of the more specialised cellular
functions contained in the total genetic expression of the cell. It is therefore surmised that clustering
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based on more specific objective functions will produce a greater cell heterogeneity. Nevertheless,
the emergence of two small populations of cells in this study suggest that scRNA-seq could be used
further in metabolic modelling for the identification of rare phenotypes. In addition, it may prove
useful in the elucidation of metabolic interactions between cell types, for example energy substrate
or neurotransmitter cycling.
Glycine biosynthesis pathways in different cell types
Expression of genes related to glycine and serine metabolism and transport can be seen in Ta-
ble 3.3. Amongst metabolic enzyme genes, there was a significantly uneven distribution of genes
encoding enzymes of serine biosynthesis from the glycolytic intermediate 3-phosphoglycerate. Phos-
phoglycerate dehydrogenase (PHGDH) catalyses the conversion of 3-phosphoglycerate to phospho-
hydroxypyruvate which is the first step of glycolysis diverging pathway of serine biosynthesis from
glycine. Expression of PHGDH is significantly low in all neuronal cell types, and significantly high
in oligodendrocytes and astrocytes. Overexpression of PHGDH in astrocytes has previously been
found by Shimizu et al. [214] who found its low expression in cultured neurons and high expression
in astrocytes. In addition, it was later shown by the same group that astrocyte-derived serine
enhances the survival and growth of cultured hippocampal neurons [215]. This lead the authors to
conclude that serine is produced in the astrocytes and shuttled across to neurons. The expression
patterns in the scRNA-seq are in line with these findings.
Phosphoserine aminotransferase (PSAT1) and phosphoserine phosphatase (PSPH) catalyze the next
two steps of this pathways with the final production of serine, and the genetic expression of these
genes is significantly high in oligodendrocytes. These cells are classically attributed the role of
providing axonal insulation, and given serine is a phospholipids precursor high demands of serine
would be expected.
Expression of cytoplasmic SHMT1 is much lower than its mitochondrial counterpart, SHMT2 sug-
gesting a bigger contribution of the latter to the total glycine pool. Another possible source of
glycine is from glyoxylate, which require the peroxisomal or mitochondrial enzyme serine-pyruvate
aminotransferase, encoded by AGXT and AGXT2, respectively. These genes were not present in
the scRNA-seq dataset used, implying this pathway is inactive in the brain. According to the Allen
Brain Map, mean transcriptome expression across all cell types is zero. This is in line with findings
by Shank et al. [39], who suggested that glycine is unlikely to be derived from glyoxylate in the
brain.
Genes encoding dipeptidase enzymes prolidase (PEPD) and carnosinase (CNDP2) are highly ex-
pressed in the dataset, with numbers of cells positive in the same range as for the PHGDH gene.
Prolidase was significantly overexpressed in pyramidal CA I cells. It preferentially hydrolyzes dipep-
tides containing proline or hydroxyproline, and is important in the recycling of collagen in cells [216]
of which glycine is a major constituent. Collagen is known to be the component of structural tis-
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sues in the body, but a recent paper by Seppänen, A. et al. [217] describing immunohistochemical
staining of the human brain showed high levels of collagen expression in neuronal, but not glial
cells. The function of collagen in the brain is not known, however its presence requring production
and consumption could represent a substantial source and sink for glycine in neurons.
The dipeptidase encoded by CNDP2 is significantly overexpressed in interneurons. It has been
previously been reported that this protein has a preference for hydrolyzation of cysteine-glycine
bonds in vitro, and is involved in the degradation of glutathione [218]. High rates of oxidative
phosphorylation in neuronal cells generates oxidative stress, rendering these cells in need of a high
requirement for ROS scavenging mechanisms, thus GSH turnover which will have an effect on the
cellular glycine pools.
The expression of GCSH, encoding the glycine cleavage system H protein, is widespread in the
dataset and nearly triple that of SHMT2. Expression is consistent across the dataset, with no sig-
nificant over or under expression in any specific cell type which is in contrast with findings by Sato
et al. [47]. The number of GCSH-positive cells in comparison to SHMT2-positive cells could imply
that glycine degradation is more widespread to its biosynthesis. This would support the notion
that glycine biosynthesis occurs in one cell type and is shuttled to others. On the other hand, if
GCS is reversible in vivo, it could provide a source of glycine although subject to the availability
of methyl groups produced in cellular biosynthetic pathways.
Lastly, the expression of serine/glycine transporters is non-normal across the dataset. SLC6A9
endodes the sodium-dependant glycine transporter 1 (GlyT1) which modulates glycine concentra-
tions in glycinergic as well as glutamatergic NMDA synapses. It readily uptakes glycine but is also
capable of glycine release which is a function of the membrane voltage [219]. SLC1A4 encodes the
Asct-1 transporter which has been shown to efficiently uptake serine in vitro [220]. The expression
of these transporters was significantly high in oligodendrocytes, low in pyramidal CA I cells and
normal across all other cell types. The high expression of GlyT1 in oligodendrocytes is suprising,
since these cells are usually attributed the role of producing myelin which wraps around the neu-
ronal axon, providing insulation. However, novel evidence shows that the roles of these cells in the
CNS may extend further, for example in providing trophic support to neuronal axons [221]. It could
be possible that oligodendrocytes, along with astrocytes are the main locations of serine and glycine
biosynthesis which are shuttled into the neuronal cells, where it is required for neurotransmission.
In addition, given the close proximity of the oligodendrocyte to the neuronal axon, these cells may
have a function in the reuptake of glycine during neurotransmission, particularly in the uptake of
extra-synaptic neurotransmitter spill-over.
It is important to add that, since the number of gene copies at any given moment is related to the
stability of the protein, it is difficult to draw conclusions regarding the actual amounts of functional
protein within cells based on RNA expression only, and without the knowledge of the half-lives of
these proteins. Further evidence would ideally be supplemented by proteomics data which quanti-
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fies protein expression.
The difference in glycine production pathways across cell types was assessed via FBA in Section
3.3.3. The presence of transporters for glutamate, glutamine and serine, as well as the differential
expression of PHGDH in different cell types imply that serine and glutamate required for glycine
biosynthesis are likely recycled across different cell types as is the case in the glutamate-glutamine
shuttle. Under these conditions, glycine production in the background of an ATP demand occurs
from serine and glutamate in glial cell types, and serine and glutamine in neuronal cell types which is
in line with the preferred amino acid uptake by each cell type proposed in the glutamine-glutamate
shuttle hypothesis [222]. As in the pathways of glycine biosynthesis in Chapter 2, glycine is syn-
thesized entirely from serine via the mitochondrial SHMT2 and the reverse GCS, which utilizes the
methyl group released in that reaction.
In Section 3.3.3, the effect of knocking out the various components of serine/glycine biosynthetic
pathways was investigated. Loss of the mitochondrial SHMT2 lead to the utilization of its cytoplas-
mic counterpart, along with the reverse GCS formation. The metabolic flexibility has previously
been seen in in vitro studies in human cells, where SHMT2-knockout cell lines were capable of
supporting methyl group production in the cytoplasm, the source of which is mostly mitochondrial
before the knockout [223]. When the GCS was set as unidirectional in the glycine-catabolising direc-
tion, both SHMT enzymes became inactive altogether and glycine was synthesized from serine via
the glyoxylate pathway. This pathway requires the enzyme serine-pyruvate aminotransferase and
since genes encoding the enzyme were absent from the scRNA-seq this pathway is unlikely. Implicit
in the LP formulation is the assumption of a metabolic Occam’s razor, which is implemented by
describing the problem as one of flux minimization. Via the glyoxylate pathway, serine utilization
is higher than that produced in solutions allowing GCS reversibility. However, this pathway does
not require NADP and its reduced equivalent, and does not produce methylated groups that need
to be sunk under steady state condition. One explanation for the appearance of this pathway in
the solution is due to its disconnection from these requirements.
Glyoxylate production causes the generation of H2O2, has been shown to inhibit glucose oxidation
in rat brain slices in vitro [224] and proved toxic when applied to rats in vivo [225]. Furthermore,
significant glycine production from glyoxylate has been shown only in the human liver so far [41],
thus this pathway is unlikely to occur in the brain.
Knockout of the glyoxylate pathway in the absence of NADPH cycling reactions and a unidirec-
tional GCS causes the cell to utilize both SHMT1 and SHMT2 for glycine production. Serine uptake
exceeds glycine export, and methionine biosynthetic pathways switch on, leading to the release of
choline and production of ADP. Mitochondrial SHMT2 knockout produces a similar solution in
which glycine biosynthesis causes a switch in biosynthetic pathways. According to Meléndez-Hevia
and de Paz-Lugo [46], the stoichiometry of SHMT-catalysed reactions enforces a metabolic inflexibil-
ity in the system, where glycine formation causes an obligatory methylene-THF production posing
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an inability of the system to regulate each independently, assuming that GCS is irreversible. This is
what is seen in the model when glycine production occurs from cytoplasmic SHMT1, in the absence
of NADPH cycling reactions. It is possible that this is a result not only of the GCS irreversibility
constraint, but also of the requirement for NADPH balance. On the other hand, knockout of the
cytoplasmic SHMT1 results in a solution in which glycine biosynthesis occurs entirely by the mi-
tochondrial SHMT2, without the presence of other biosynthetic pathways. NADPH generated by
cycling is instead utilized for the reduction of GSSG to GSH, necessary for oxidative stress protec-
tion. The total serine import is equal to that of glycine export, and lower than that in the presence
of cytoplasmic SHMT1. The methylene-THF produced is transported into the cytoplasm in the
form of 10-formyl-tetrahydrofolate, which is broken down to tetrahydrofolate and CO2. Since this
pathway requires crossing of folates across the mitochondrial membrane, it would be dependent on
the rates of folate transporters in a cell- according to Wagner [226], the transport of folates across
mitochondrial membranes is slower than that of serine and glycine which may impose a constraint
on the rate of glycine biosynthesis via this pathway.
As surmised in the Discussion section of Chapter 2, modularization of metabolism gives the system
the advantage of flexibility. Glycine formation via both reversal of the GCS and forward SHMT2
proves as the most ‘economical’ pathway, since serine consumption equals half of the glycine pro-
duction flux and both glycine C atoms are derived wholly from serine. It is also advantageous
as it does not require the additional need for a methyl sink, which is also the case for glycine
biosynthesis entirely via mitochondrial SHMT2. The latter is less preferred, because it does not
allow for the incorporation of two C atoms from one serine molecule into glycine. The additional
advantage is provided by the fact that utilization of mitochondrial SHMT2 leads to the reduction
of NAD to NADH, linking glycine biosynthesis to energy production in the mitochondria. A link
between SHMT2 and energy production was seen in cultured human cells knockout of SHMT2,
which caused a decrease in the TCA cycle intermediates which was not seen on SHMT1 knockout
[223]. On the other hand, utilization of cytoplasmic SHMT1 exerts a pressure on the system which
leads to methionine formation, and higher serine consumption. If glycine, and so methylene-THF
production is less efficiently achieved by the cytoplasmic SHMT1, it is possible that depletion of
TCA intermediates in their study was caused by an increase in the channeling of glucose towards
serine biosynthesis.
Serine/glycine metabolic pathways and biomass turnover
The importance of the metabolic pathways involving serine and glycine for one-carbon metabolism
is well established. A previous metabolomics study performed in a panel of cancer cell lines showed
that an increase in glycine uptake and expression of biosynthetic genes correlated positively with cell
proliferation, and generation of methylene-THF from glycine [227]. Furthermore, increased glycine
concentrations are positively associated with the presence and stage of human gliomas [5, 6]. In
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Section 3.3.4, the preference for amino acids uptake, and the abilities of serine or glycine to support
increased biomass and ATP demands were investigated. Out of all model uptake amino acids,
glutamate, glutamine, isoleucine and serine were preferred as substrates when glucose uptake is
limited. Biomass increase requires ATP, and in a set of experiments on cultured neurons Divakaruni
et al. [228] showed that inhibition of mitochondrial MCTs, thus blocking pyruvate entry does not
decrease cell viability. Glutamate abundance was decreased, without a decrease in the levels of TCA
cycle intermediates showing that glutamate is readily oxidised to support mitochondrial energy
production. In addition, the ability of glutamine to sustain bioenergetic cellular needs and cancer
cell proliferation has been previously well established [229, 230] supporting the use of glutamate
and glutamine in the model.
The upregulation of genes related to serine and glycine metabolic pathways in a subset of cancer cell
lines including gliomas [7–10] is suggestive of the utilization of these amino acids to support cellular
growth demands. Uptake of serine and corresponding glycine efflux has been shown in cultured
colon cancer cell lines HTC116 and RKO by Labuschagne et al. [54], and later in neurosphere-
forming glioma cell lines by Kim et al. [231], in line with the model results. In the model, the
rate of serine uptake increase was proportional to its conversion to glycine in the mitochondria,
generating methylene-THF required for biosynthetic reactions. Serine was also able to support
a demand in ATP and biomass increases via a number of pathways, the feasibility of which are
described as follows:
1. Serine conversion to the glycolytic intermediate 2-phosphoglycerate requires the enzyme serine
pyruvate aminotransferase, encoded by AGXT1 enzyme which, as previously discussed, is
unlikely to be present in the brain.
2. Production of pyruvate from cysteine derived from serine requires the enzyme cystathionine-
β-synthase which is a component of the transsulfuration pathways involved in the control of
cellular methylation (via S-adenosyl methionine ) and antioxidant status (via GSH produc-
tion) [232]. Cystathionine-β-synthase in encoded by the CBS gene, which was found in 217
cells in the scRNA-seq dataset, showing a low expression of this enzyme in the brain. Knock-
out of the PKM genes in a pancreatic cancer cell line has previously been shown that cysteine
can maintain cell viability by its catabolism to pyruvate in the cytosol [233], although it is
unclear whether the upregulation of this pathway could be responsible for energy production
in the brain.
3. Another alternative pathway of serine contribution to energy production was its conversion
to pyruvate via the enzyme serine dehydrytase, encoded by the enzyme SDS which was found
in only 3 cells in the scRNA-seq dataset. Indeed, serine dehydrytase has been mostly found
in the human liver where it exhibits low activity [234], thus this pathway is unlikely to be
able to sustain energy production in the brain.
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4. Production of the glycolytic intermediate 3-phosphoglycerate from serine, via the reversal of
its phosphorylated pathway of synthesis is unlikely to occur since the reversal of the serine
phosphatase, catalysing the dephosphorylation of 3-phosphoserine to serine is highly energet-
ically unfavourable, as reported by Lund et al. [235].
5. Finally, ATP production via the catabolism of serine to glycine which leads to a transfer of
electrons from methylene-THF to NAD, producing 5,10-methenyl-THF and NADH as seen in
the model has also been shown experimentally by Yang et al. [236] via deuterium labelling
of the H atom of serine in normal and cancerous cell lines. In their study, the fractional
contribution of serine to NADH was increased in hypoxia-induced states, thus serine may act
as a source of ATP production in a context-dependent manner.
Conversion of serine to glycine is a main producer of methylene-THF necessary for biosynthetic
pathways. The model results also suggest that this reaction may play a role as a nitrogen sink.
Silencing of the GCS in cell lines expressing high levels of SHMT2 was shown by Kim et al. [231]
to be detrimental to cell proliferation. In addition, the authors found a correlation between the
level of SHMT2 expression and sensitivity to GCS knockouts, suggesting that in those cell lines the
overexpression of both enzymes is required for the high proliferation. If the GCS is a reversible
process, the model results suggest that apart from methylene-THF generation, GCS may play a
role as a nitrogen sink in a cell oxidising amino acids for its biosynthetic needs. Ammonia must be
exported from cells and excreted in the urea cycle, or otherwise deposited into a reservoir of amino
acids, for example cytosolic glutamine which is a major sink of free NH4 in the human brain [237].
As pointed out by Spinelli et al. [238], the question of how tumour cells which increase their rate
of amino acids utilization manage the surplus ammonia locally remains underdetermined. Since
the vasculature of tumours is less organised than that of normal tissue, the bulk usually contains
hypoxic areas which is less well cleared from the excess nitrogen which may disrupt the ‘normal’
pathways of nitrogen balancing in the cell. Kim et al. [231] described that that SHMT2 suppression
had a pronounced effect in glioma cell lines under hypoxic conditions, which was not the case under
normal oxygen tension. The authors suggest that the serine/glycine dependence of these tumour
may therefore be context-dependant, which is in line with the increase in mitochodrial NADH pro-
duction from serine reported by Yang et al. [236].
Although serine could sustain energy and biomass increases in the model, the same was not true for
glycine. The two amino acids were not freely convertible, as serine formation from glycine required
the addition of glucose for its production via the glycolytic pathway. Alternatively, the addition
of methylene-THF source was required as shown by the addition of formate. This is in line with
the findings by Labuschagne et al. [54], who showed that glycine media supplementation cannot
sustain cell proliferation in the same manner that serine can. Furthermore, the authors showed
that application of glycine alone lead to the inhibition of glycine flux into purines, and increase in
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its rate of conversion to serine, depleting the methylene-THF pool. It is unclear why glycine could
not sustain proliferation given it can provide methylene-THF via GCS.
It is interesting to note that in both of the described studies, the cells showed high levels of SHMT,
GCS and glycine efflux at the same time. If the GCS is unidirectional it would suggest a high rate
of glycine breakdown into CO2 and NH3 , and thus little glycine release, in contrast with what is
seen experimentally as well as in the model results.
It has been previously realised that alterations in the these biosynthetic pathways of serine/glycine
metabolism provide an attractive target for the development of cancer treatments, for example
PHGHD inhibitors [190, 239] which shows contrasting results in their effectiveness to inhibit prolif-
eration [240], which is likely context-dependent. The model results support previous experimental
observations in which serine was shown capable of supporting cellular needs of energy and biomass
demands, which does not hold true for glycine. Knockout of the pathways involved in the metabol-
ism of these amino acids highlights the flexibility of metabolism which may explain the reason for
which inhibition of individual reactions is not effective. The model could be further used in order
to aid the elucidation of the set of reactions involved in serine/glycine metabolism which may be
targeted in the treatment of cancers displaying upregulation of enzymes involved in these pathways.
3.4.1 Conclusion
In summary, the major insights of this chapter relate to the establishment of a novel method for
integration of scRNA-seq datasets with the metabolic model which was used to shed light on the
differences in ATP production pathways in different cell types, as well pathways related to meta-
bolism of glycine. Energy production in glial ad neuronal cells was assessed in the context of the
ANLS hypothesis. Both statistical analysis of gene expression as well as model simulations resulted
in findings contrary to the assumptions made by the ANLS. Expression of genes encoding enzymes
composing the glycolytic pathway suggests this pathway is active both in glial and neuronal cells.
Preferential uptake of glucose was shown for neuronal cells during model simulations. Perhaps
more suprising was the finding that neuronal cells saturated glucose uptake and released lactate,
and that astrocytes preferred lactate as an energy substrate at all ATP demands. As multiple lines
of experimental evidence exist supporting and disproving the ANLS theory (Section 3.4) it will
remain a worthy topic of further exploration and debate.
Analysis of the expression of genes related to serine and glycine metabolic pathways showed align-
ment with previous findings, supporting the notion that serine is likely produced in astrocytes and
shuttled across to neurons, following the high expression of PHGDH in astrocytes. Th breakdown
of glycine was found to be likely active in all cell types, following the ubiqutous expression of the
GCSH gene across all cell types, which contrasts with the localization of glycine catabolism to
astrocytes only [47]. This finding also further supports the theory for an inter-cellular serine and
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glycing cycling mechanism within the brain, further supporting by the high expression of genes
encoding serine and glycine transporters, GlyT-1 and Asct-1. All brain cells types were lacking
the expression of genes encoding the enzymes of the glyoxylate to glycine conversion pathway, res-
onating with previous findings (Section 3.4) thus glycine is likely not synthesized from glyoxylate
in the brain. On the other hand, the high expression of dipeptidases which decompose GSH as
well as collagen suggest that a significant pool of glycine is recycled, rather than synthesized de
novo from serine. The presence and significance of collagen in the brain is an area requiring further
exploration.
A suprising outcome of the analysis of gene expression is the finding that serine and glycine
metabolic genes are highly present in oligodendrocytes. This can be related to the most well-
known function of these cells which is the production of myelin however it may also be relevant to
novel roles being attributed to these cells. High expression of genes encoding serine and glycine
transporters could hint to potentially two areas. In the first instance, it is possible that oligo-
dendrocytes play a function in regulating neurotransmission during synaptic glycine release by the
uptake of extra-synaptic glycine, supported by high GlyT-1 gene expression. In the second case,
oligodendrocytes could also be important in providing metabolic support to neurons supported by
the high expression of the genes encoding the serine and glycine metabolic enzymes. Although
outside of the scope of this study, it is an interesting topic for further exploration.
The knockout of each SHMT subtype during glycine demand simulations lead to insights regarding
their role in the context of background metabolism. Knockout of SHMT2 led to the ’metabolic
inflexibility’ in the system as described by Meléndez-Hevia and de Paz-Lugo [46] during which
glycine and methylene-THF cannot be regulated independently. Production of glycine via SHMT2
only does not lead to an engagement of other biosynthetic pathways, although it relies on the cycling
of folate groups across the mitochondrial membrane. Since metabolic models do not incorporate
the time component, kinetics of transport proteins are not captured which is a limitation of this
type of modelling, although it is not the focus of such models.
Increase in biomass demands in the presence of different amino acids showed that serine is one of
the main preferred substrates for the support of ATP and biomass generating pathways. Analysis
of the different routes from serine to energy formation suggests that the most likely pathway to
ATP generation is via the supply of NADH to the ETC following serine to glycine breakdown. The
current study also highlighted a possible importance of the reverse GCS reaction in sinking the
nitrogen surplus in hypoxic areas of tumour, such that the nitrogen released by utilization of serine
is deposited in glycine released from the cell.
Although serine was found to support increases in biomass and energy demands, the reverse was
not true for glycine, consolidating that these two amino acids are not interchangeable and glycine
likely cannot support proliferation.
Major limitations to the above findings are related to the nature of the scRNA-seq datasets which
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in big proportion are populated with zero gene counts. This is likely due to the difficulties arising
in the experimental procedures that generate these datasets, which may lead to many false negative
hits. The complication arising from that is the statistical analysis of the dataset and pertinent to
metabolic modelling, definition of a method for the integration of the dataset with the metabolic
model such that it provides the most biologically relevant solution. Bulk transcriptomic data has
been incorporated into metabolic models for a considerate amount of time by different groups,
thus various methods exist which differ in the key parameters such as gene expression thresholds
specifying ’active’ enzymes to be allowed in the solutons. The effects of applying various methods
has been assessed in relationship to the resulting solutions. It is likely that as this field matures, a
similar comparison can be done for the method of integration of scRNA-seq with metabolic models.
Nevertheless, application of scRNA-seq can provide insights of cell specific metababolic phenotypes.
Clustering of pathways utilized by the model weighed by the genetic expression of individual cells
showed that this method can be used to assess rare and novel celullar phenotypes (Section 3.3.2).
Utilization of transcriptomic data- whether coming from single cells or bulk tissue- is limiting in a
number of ways. The number of gene copies is related to the stability of the protein in the cell, thus
copy numbers cannot be directly translated to protein expression. Furthermore, post-translational
modifications will be determinant of the actual activity of the enzymes- and although the enzyme
may be present in a given cell, the direction with which the reaction will proceed is a function of
the substrate and product concentrations, which is not taken in the account in the current study.
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Chapter 4
Kinetic model of the glycinergic
synapse
4.1 Introduction
Glycinergic neurotransmission in the human CNS is important in the regulation of excitatory sig-
nalling pathways involving the movement of skeletal muscles, control of pain perception, and others
(Introduction, Section 1.2.5). Mutations in genes encoding components of the glycinergic synapse
lead to serious, albeit rare conditions such as hyperkplexia, or the metabolic disorder nonketotic
hyperglycinemia (NKH). Moreover, there is an interest in the development of glycine transporter 1
and 2 (GlyT1 and GlyT2) inhibitors for the treatment of neuropathic pain and others, the mech-
anism of action of which is to regulate the time course of glycine in the synaptic cleft by blocking
its reuptake.
NKH is normally caused by mutations in the glycine cleavage system (GCS) leading to impaired
glycine breakdown, thus increased glycine levels in the CNS. A novel caused for NKH phenotype
in a child was reported by Alfadhel,M. et al. [80], who identified a Ser 407 → Gly point mutation
in the GlyT1 protein, responsible for reuptake of glycine following its synaptic release. Chapter 5
describes the results from functional characterization of the GlyT1 mutant via electrophysiological
recordings in X. oocyte and it was found that mutation at the position Ser 407 cause a knockout
in GlyT1 function.
The amplitude and the length of the inhibitory post-synaptic currents (IPSC) which are disrupted
in disease states are a result of the interaction between the proteins composing the glycinergic
synapse. Thus, the focus of this chapter was the development and analysis of a computational
kinetic model reproducing the processes of glycine release and reuptake across the synaptic cleft.
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Previous experimental studies have established the kinetic parameters for the GlyR, as well as
GlyT1 and GlyT2 in isolation- the kinetic model described in the current Chapter was developed
with the aim of probing the interaction between these proteins as a whole system.
In the first instance, a detailed scheme of GlyR activation was adapted from Burzomato [144] based
on the single-channel recording of α1β GlyR expressed in HEK293 cells in the ScrumPy modelling
software. This provided a starting point for the glycinergic synapse model, which was expanded by
the addition of reactions describing glycine release from the pre-synaptic cell as well as processes
which consume glycine, more specifically reactions describing its reuptake by GlyT1 and GlyT2, as
well as loss resulting from diffusion.
Firstly, the GlyR scheme and the resulting IPSC were analysed in isolation. Steady state and
dynamic currents were recorded from GlyR stimulated with varying glycine and compared to those
reported in previous studies. Secondly, the GlyR model structure and associated kinetic parameters
were assessed via the application of local sensitivity analysis, as well as the mathematical reduction
of the model to a Monod-Wyman and Changeaux (MWC) type equation (Introduction, Section
1.3.1).
One of the advantages of computational modelling is that models can be applied to probe questions
relating to events which - such as neurotransmission - happen on a millisecond scale and may oth-
erwise be difficult to control in an experimental setting. Following, the full glycine synapse model
incorporating the detailed GlyR scheme was used to assess the effects of changing the time course
and the amplitudes of neurotransmitter released during synaptic simulation. Since these parameters
are largely affected by the rate of glycine reuptake, the model was used to estimate the parameters
describing GlyT1 and GlyT2 transport incorporating previous experimental observations. Finally,
the glycinergic synapse model was used to look at the effects of modulating GlyT1 and GlyT2
reuptake on the glycinergic currents, such as that resulting from the Ser 407 mutation which causes
a functional knockout of GlyT1.
4.2 Methodology
All steps of model construction and analysis were completed in ScrumPy (Introduction, Section
1.3.4). Unless otherwise stated, rate equations following mass-action type kinetics were automati-
cally generated by the software in the following form:
V = kf × (S − P/Keq) (4.1)
Where the kf is the forward reaction rate, S and P represent substrate and product concentrations,





. All model concentrations and rates are in Ms-1or s-1.
Model curve fitting was performed in Python using the scipy.optimize.curve fit package which uses
the Levenberg-Marquardt algorithm. The concentration-response curves generated from the model
were normalized to the values of the maximum response and fitted to the one-component Hill





Where the EC50 is the concentration of substrate eliciting half-maximal response, h is the Hill
coefficient of cooperativity (Hcoeff ), and S is the substrate concentration. In order to compare the
the speed of signal decrease, 10-90% of the decay phase of glycine and IPSC responses were fitted




where A is the amplitude, Amax is the maximum amplitude, and k is the microscopic decay constant.
4.2.1 Model description
Glycine receptor model
Glycine receptor model (Figure 4.1) and the associated rate constants (Appendix B,6.2) were taken
from Burzomato [144] and are based on single-channel recordings from heteromeric rat α1β GlyR.
The receptor can reside in three global conformational states, resting (R), flipped (F), and open (O)
and binds glycine which is the agonist (A). Glycine binding affinities to each global conformational
state R and F are equal, thus the increase in substrate affinity to protein is a result of a concerted
change in the protein conformation stabilised by a higher number of ligands bound, in line with the
MWC model of ligand binding cooperativity. The model is composed of 11 reactions between 10
model species. Reactions 1-3, 7 and 8 represent glycine binding to the receptor in different global
conformations resting (R) and flipped (F). Reactions 4-6 represent receptor isomerization from the
R to F conformation which can happen in the presence any number of ligands bound. Receptor
openings (states OA - OA3) can proceed only from the flipped conformations (FA - FA3) and are
represented by reactions 9-11.
The Vmax and Keq parameters were calculated from the microscopic rate constants taking into
account the number of binding sites available in each conformation. For example, the unbound
state R contains three available binding sites, but no glycine molecules bound, therefore the Keq is
calculated as 3 × kf/kr and the Vmax = 3 × kf . The Keq associated with reactions r4 and r6
(Figure 4.1) were calculated from the Keq describing neighbouring reactions in order to respect the
constraints imposed by microscopic reversibility on the internal model cycles.












Figure 4.1: Glycine receptor scheme The scheme is described by a total of 11 reactions
describing the rate of up to three molecules of glycine (A) binding to two global conformational
states resting (R) and flipped (F) (reactions 1-3, 7-8) as well as the global conformational changes
from the R to F conformations (reactions 4-6) and from the F to the open (O) conformations
(reactions 9-11).
Inhibitory post-synaptic currents (IPSC) carried by n receptors are a product of channel con-
ductance and the reversal potential (Erev) of Cl
- ions. The equation used to calculate the current
is derived from Ohm’s law and assumes a linear current-voltage relationship of the form:
IPSC = (gmax × Popen ∗Rn)× (∆Ψ− Erev) (4.4)
where IPSC is the current through n receptors, gmax = 45.9×10−12S is the maximum channel
conductance [241], Popen is the channel open probability, Rn = 100 is an estimation of the number
of receptors, ∆Ψ = -60mV is the membrane voltage and Erev = -70mV is the reversal potential for
Cl- ions. The assumption of linear current-voltage characteristics is justified based on studies on
the electrophysiological signature of GlyR expressed in HEK293 cells showing only small amount
of current rectification due to voltage change for heteromeric GlyR [242]. Upon model simulation,
the time course of Popen which drives the IPSC is calculated from the sum of the open channel
conformations ie. Popen = OA+OA2 +OA3, driven by the binding of ligand.
Glycine synapse model
The glycinergic synapse model can be seen in Figure 4.2 and is composed of the GlyR model
described in the previous section as well as reactions associated with release and reuptake of glycine
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Table 4.1: Concentrations of Na+ and glycine in the model
Parameter Model value (mM) Reference
Glyi, astrocyte 2 [243]
Glyi, neuron 10 [66, 244]
Na+i , astrocyte 17 [245]
Na+i , neuron 30 [246]
Na+e , synaptic cleft 150 [66]
across the synapse. Reaction 12 represents glycine release from the synaptic vesicle upon its fusion
with the presynaptic membrane and its rate was calculated from a simple mass-action equation of
the form:
V = kf × S (4.5)
This equation was also used to describe simplified neurotransmitter diffusion away from the synaptic
cleft (r13), as well as the slow processes which act as a sink for the glial (r16) and neuronal (r17)
glycine. Reactions describing glycine release and diffusion were adjusted to the slower uptake
processes. Reactions 14 and 15 represent bi-directional transport by GlyT1 and GlyT2, respectively.
Rate of transport was calculated from a two-substrate Michaelis Menten equation of the form:
V =
(Vf ×Glye ×Na+e h)

















i are the extracellular
and intracellular glycine and Na+ concentrations, associated K parameters are the equilibrium
constants for each species, and h is the Hcoeff for Na
+ . Maximal forward and reverse reaction
rates, Vf or Vr, are calculated in the model from the microscopic turnover rate of the transport
cycle, k multiplied by the transporter number, T and a constant, c :
V = k × T × c (4.7)
where T= 1000, and c= 1×10−4 which were estimated in the current study. Values of the micro-
scopic turnover rates of each transporter can be seen in the Appendix B, 6.2. The equilibrium
constant of glycine binding has been shown to vary according to membrane voltage, and large rises
in the affinity of glycine to both transporters can be seen at positive voltage potentials [66, 219].
The values of parameters in the model are based on a membrane voltage of -60mV. Intracellular
concentrations of Na+ and glycine describe the astrocytic and neuronal concentrations and can be
seen in Table 4.1. Na+ concentrations were treated as model parameters thus were not allowed to
vary during model simulation. ScrumPy model file can be found in Appendix A, 6.2.
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Figure 4.2: Glycinergic synapse model Glycine is released from the presynaptic neuron (r12)
and diffuses across the synaptic cleft, binding to the glycine receptors (R) on the opposing neuron.
Termination of neurotransmission is regulated by the removal of glycine via passive diffusion (r13)
as well as uptake into the astrocyte by the GlyT1 (r14) and back into the pre-synaptic neuron by
GlyT2 (r15). Concentrations of Na+ which drive transporter uptake are based on physiological




4.3.1 Interactions of glycine with the GlyR
Characterisation of the steady state and dynamic GlyR responses
Glycine receptor model responses were analysed over a range of glycine concentrations in order to
confirm that the model implementation can realistically reproduce experimentally-recorded IPSC.
Concentration response curve of the Popen at varying glycine concentrations from 10 to 1000µmol
can be seen in Figure 4.3. The curve was fitted to a Hill equation with the resulting parameters
EC50 = 60.9µmol and Hcoeff = 1.54 which are in agreement with the values obtained in the original
study [144]. The receptor is saturated at a glycine concentration of ≈ 300µmol with a maximum
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Figure 4.3: Concentration response curve for glycine binding to GlyR Steady state
glycine open probability was calculated over a range of glycine concentration 10-1000µmol. Fit of
the Hill equation resulted in parameters EC50 = 60.9 and Hcoeff = 1.54.
Next, time courses of dynamic model occupancies calculated from the model stimulated with
1mM glycine for 10ms were compared to GlyR model stimulation from a study by Colquhoun
and Lape [88] which utilised a different method for model states calculations. Results from both
models are in close agreement, confirming that the ScrumPy GlyR implementation can accurately
reproduce the kinetic behaviour of GlyR described in the original study (data not shown).
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Sensitivity analysis of the GlyR scheme
In order to establish which receptor model parameters mostly affect the resulting glycinergic cur-
rents, local sensitivity analysis was performed on the model kinetic constants. Since the IPSC is
directly proportional to the sum of the open conformations, the sensitivities of steady state [O] to
a small change in the Keq describing reactions 1-11 were calculated over a range of glycine con-
















may vary from 0 to 1, where higher values indicate a bigger impact of changing the
independent variable, Keq , on the dependent variable, [O] . The R
[O]
Keq
calculated for each GlyR
reaction is plotted against glycine concentrations in Figure 4.4, a). It is apparent that the overall
sensitivity of [O] drops as the concentration of glycine increases, which is expected given that the
receptor experiences half saturation at ≈ 60µmol. As glycine concentration increases, the receptor
resides in the tri-liganded, open state thus the remaining states will not be occupied frequently. The
[O] is most sensitive to variations in the rates of the initial glycine binding to the R conformation
(RBind1), the binding of the second glycine to the F conformation (FBind3) as well as the opening
in the tri-liganded state (Open3). High R
[O]
Keq
over the range can also be seen for Keq describing the
rate of receptor binding the second glycine molecule (RBind2), as well as a change in the global
conformation from the double-liganded R to F states (Flip2). At low concentrations of glycine, ≤
≈20µmol, the rate of the second glycine binding to the F conformation (FBind2) as well as receptor
flipping in the single-liganded state (Flip1) also seem to have a large effect on the [O] , which be-
comes lower as the glycine input increases. On the other hand, R
[O]
Keq
of the Keq describing receptor
opening from a single-bound conformation (Open1), the binding of a third glycine molecule to the
R conformation (RBind3) as well as flipping of the triple-bound R to F (Flip3) are consistently low
across all concentration ranges.
These results raise a question regarding the occupancy of these states which are products of the
reactions with the lowest response coefficients. In order to determine if the results from the sensi-
tivity analysis identify which states are hardly occupied at all glycine concentrations, the sum of
flux via each reaction was recorded following a 10ms model simulation with ranging glycine concen-
trations from 10-300µmol (Figure 4.4, b). The sum of fluxes correlate with the R
[O]
Keq
as given by the
sensitivity analysis, thus suggesting that even at low glycine concentrations receptor states OA and
RA3 are not visited frequently. According to the kinetic parameters from the original publication,
the receptor will bind two glycine molecules before switching to the flipped conformational state,
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followed by the binding of the third glycine and subsequent opening. These results were confirmed
to match similar findings to those reported by Colquhoun and Lape [88] who identified similar
‘routes’ of GlyR transitions.
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of the all model reactions Keq at varying glycine concentration. At concentrations ≥
≈20µmol, the R[O]Keqcorrelate with the sum of flux carried by each reaction in a dynamic model
simulation with 1mM glycine for 10msec (b).
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Reduction of the GlyR scheme to a MWC-type equation
The GlyR model by Burzomato [144] is based on the Monod Wyman and Changeaux (MWC)
model which explains ligand binding cooperativity under several assumptions. However, the model
is not a complete MWC scheme thus it does not describe the rates of glycine binding to the open
conformations, nor the ratios of receptors in the different conformational states, R, F and O in
the absence of ligand. This is because the experimental data which the scheme was fit to does
not contain information about these states- openings in the absence of ligand are very rare, and
any conformational changes that are experimentally recorded are evoked in the presence of agonist;
currents are not generated through closed states in the agonist absence.
Hess’s law states that the enthalpy of a chemical process from reactant to product must remain the
same regardless of the path taken. Since the GlyR scheme is composed of internal cycles, Hess’s law
can be applied to the scheme in order to calculate missing parameters which could not be obtained
experimentally.
Treatment of the scheme as for the original MWC model allowed for the derivation of two equations
which describe the steady state fractions of receptor in each conformational state (Equation 4.14)
as well as the fractional occupancy of the receptor (Equation 4.13) which is the fraction of ligand
bound to the receptor.
The overall goal of the derivation was to express each species in terms of the substrate concentration,
[S] and substrate dissociation constants for [O],[F] and [R] ; KO, KF and KR respectively. Firstly,
all of the species were expressed in terms of the concentration of the open, unliganded state, [O],
following which it was set to 1 to allow for the elimination of concentrations from the equations
altogether.
The following constants were defined: α = [S]KO , c =
KO
KF
, d = KFKR .
Therefore: αc = [S]KF , αcd =
[S]
KR
, M = FO and L =
R
F .
Secondly, each species was re-written in terms of [O] and the concentration of substrate, [S],
as well as the dissociation constants for each global conformations which were written in terms of
individual sites available. For example; [OA1] = 3× [O]× [S]KO because there are 3 vacant substrate
sites available in the [O] conformation but only one site occupied in the [OA1] conformation therefore
the probability of the first event is three, however the second only one. This resulted in a set of
equations:
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The fractional saturation equation describes the amount of agonist bound to receptor. The
number of sites occupied by the agonist forms the numerator, where each species is multiplied by
the number of agonist it has bound. The denominator is the sum of all the agonist sites available,
regardless if the agonist is bound or not thus each species is multiplied by three.
y = [OA1]+2[OA2]+3[OA3]+[FA1]+2[FA2]+3[FA3]+[RA1]+2[RA2]+3[RA3]3×([O]+[OA1]+[OA2]+[OA3]+[F ]+[FA1]+[FA2]+[FA3]+[R]+[RA1]+[RA2]+[RA3])
(4.9)
4.3. RESULTS 135
The fraction of receptor in the open conformation,
∑
[O] is the sum of all the open conformations
divided by the sum of the total receptor, ie.:
∑
[O] = [O]+[OA1]+[OA2]+[OA3][O]+[OA1]+[OA2]+[OA3]+[F ]+[FA1]+[FA2]+[FA3]+[R]+[RA1]+[RA2]+[RA3]
(4.10)

















Which is equivalent to the following equation describing the sum of the open conformations in










































During the original model parameter fitting the model did not include reactions for agonist
binding to the open conformations thus the value for KO was not constrained by microscopic re-
versibility. Calculating the KO from the internal cycles returned two different values, disagreeing
with model assumptions that the speed of agonist binding to each conformation is the same, re-
gardless of how many agonists are bound.































Which give similar results for M (rounded to two decimal places).
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Thus the resulting set of parameters for the equations are:
 d= 0.015
 c= 0.26
 L ≈ 11×103
 M = 3.13
Values for the dissociation constants are KR = 520×10−6 and KF = 8×10−6.





KO = c×KF = 0.26× 8×10−6 = 2.07×10−6
Full scheme in terms of the MWC parameters described in the derivation can be seen in Figure
4.5. The dissociation constant for glycine open conformation, KO, equalled 2.07 × 10−6 Ms-1. As
expected, glycine binding to an already open receptor is extremely rapid. The high value for the L
parameter reveals that the fraction of receptors in the flipped conformation is extremely low in the
absence of ligand. It follows that the ratio between flipped and open conformations in ligand absence
is small, implying that there is a high energetic cost in the initial change in receptor conformation
from resting to flipped state, followed by receptor opening which is less energetically demanding.
In order to confirm these equations are good approximations for the model output at steady state,
open receptor fractions were calculated at glycine inputs ranging from 10 to 1000µmol from the
full model and Equation 4.14. The results can be seen in Figure 4.6. Fitting of a Hill equation to
both curves resulted in values of the EC50 and Hcoeff which are near identical (Full model EC50 =
71.1µmol, Hcoeff = 2.27 , Equation 1 EC50 = 69.3µmol, Hcoeff = 2.46). These results show that the
full scheme can be successfully reduced to Equation 4.14 capable of reproducing steady-state GlyR
fractions, and therefore IPSC.
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Figure 4.5: Full MWC scheme describing the glycine receptor GlyR scheme rewritten in
its full form, with the addition of unbound global conformations F and O, the occupancy of which
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Figure 4.6: Concentration response curves calculated from the MWC versus full
model Popen at steady state was calculated from the full model (blue) and Equation 4.14 (green)
over a range of glycine concentrations (10-1000µmol) resulting in near identical curves.
4.3.2 Glycine synapse model
Effect of the neurotransmitter profile on the glycinergic currents
Ca+-triggered glycine release from the presynaptic cleft is a fast event happening at the order of
milliseconds, followed by rapid neurotransmitter reuptake. Thus the activation of GlyR at the
post-synaptic density happens under non-equilibrium conditions, shaped by the duration of neuro-
transmitter transients in the synaptic cleft [248]. In the next section, the effects of changing the
kinetic parameters of glycine transporters on glycinergic transients in the synaptic cleft were as-
sessed under physiological conditions. The maximal concentration of glycine and the time constant
of its decay, τdecay, have been previously estimated in rat lumbar motorneurons by Beato [249] and
equalled 2.2-3.5mM and 0.6-0.8ms, respectively, providing a starting point for model simulations.
Figure 4.7 shows the results of model simulation with 4mM glycine for 1ms in the absence of
transport reactions. Synaptic glycine concentration reached a peak of 3.5mM and was removed by
diffusion with a τdecay= 0.5ms, resulting in an IPSC current maximum amplitude, Imax, of 413pA
with a τdecay= 8.78 ms. It can be seen in Figure 4.7 b), c) that the time course of current decay
closely follows the time course of Popen with the latter reaching a maximum value of 0.9, close to
the values achieved under saturating glycine transients seen in Section 4.3.1. The resulting IPSC
decay time is within the range of previously published values recorder from glycinergic neurons of
the spinal cord, ranging from 5 to 15ms [249–251].
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Figure 4.7: IPCS evoked by fast synaptic glycine transients The model was simulated with
a 1ms pulse of 4mM glycine in the absense of the transport reactions. Top graph (a) shows the
time course of glycine pulse, leading to a high maximum GlyR Popen of 0.9 which resulted in an
IPCS with a τdecay = 8.78 ms. The staircase effect seen in the decay phases of Popen and IPSC
amplitudes is an artefact of the solver software used.
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Effect of varying the concentration and duration of released glycine transients on IPSC
Apart from the processes which remove glycine during neurotransmission, the neurotransmitter
transients may also be affected by the rate of vesicular release, the concentration within the vesicle,
as well as the length of the release event. The model sensitivity of the IPSC to released glycine
concentration and duration of release were assessed by varying these two parameters over a range
of glycine concentrations from 0.5 to 5.0mM and durations of release between 0.2 and 3ms. The
results can be seen in Figure 4.8, where the top graphs show a variation in the resulting IPSC
τdecay(a) and maximum amplitude (b). Effects of changing the independent variables on glycine
maximum amplitude (c) can be seen in the bottom graph. Overall, there is a higher variability
in the resulting amplitudes of both glycine and IPSC which increase as the concentration and the
duration of glycine pulse increase, as expected. Maximum concentrations of glycine show a uniform
increase across the two independent variables. On the other hand, the increase in the maximal
IPSC reached is non-linear, reflecting receptor saturation. The decay time constant of the glycine
peaks does not significantly change across all of the concentrations and durations tested and remains
stable at 0.5ms, showing that the shape of the neurotransmitter decay is shaped mostly by the rate
of its consumption by diffusion, rather than the length of release. However, there is an increase in
the decay time constant of the IPSC from ≈ 6.5 to 9ms across the range. Significant differences can
be seen at the extreme values of independent variables, with the majority of the IPSC decay time
constant values falling in between 8 and 9ms. Given that the τdecayof glycine does not significantly
change, the variations in IPCS time courses and amplitudes are mostly driven by the top glycine
concentrations reached. In addition, long, low concentration glycine transients elicit currents with
a similar time course as fast, high concentration release events.


























   





















































































































Figure 4.8: Effects of varying glycine release concentration and duration on the
resulting IPSC Current amplitudes varied between 5.6- 434.1pA with a decay time constant
variation from 6.48- 8.98ms, showing a much higher differences in the top amplitudes reached.
Glycine amplitudes varied from 0.17- 4.99mM with a decay time constant remaining equal at
approximately 0.5ms.
4.3.3 Estimation of the GlyT1 and GlyT2 kinetic parameters
Glycine and sodium binding affinities in the absence of product
In the first instance, kinetics of glycine uptake by GlyT1 and GlyT2 in the absence of products
were established. Figure 4.9 shows steady state rates of Na+ (a) and glycine (b) transport by
GlyT1 and GlyT2 in the presence of extracellular glycine only. Na+ concentration response curves
were calculated in the presence of 1mM extracellular glycine over a range of Na+ concentrations
ranging from 0.1 to 150mM. Fits of the Hill equation to the Na+ binding curve for GlyT1 resulted
in transporter EC50 = 8.4mM and a Hcoeff = 1.2. This is in line with the previously reported
values of EC50 ≈ 7mM and Hcoeff mean value of 1.4 in X. oocytes expressing GlyT1 voltage held
at -70mV reported by Roux and Supplisson [66]. Glycine receptor 2 EC50 equalled 44.2mM with
a Hcoeff of 1.9, which also agrees with the EC50 ≈ 30mM and Hcoeff mean value of 2.2 reported in
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the same study. GlyT1 binds extracellular Na+ with a higher affinity than GlyT2, however with a
lower Na+ cooperativity which can be seen by the right shift of the curve.
Rate of glycine uptake (Figure 4.9, b) for each transporter was plotted in the presence of extracel-
lular Na+ = 150mM, over a range of glycine concentrations 1-1000µmol. Fits of the Hill equation
resulted in an EC50 = 21.2µmol and a Hcoeff = 1.0 for GlyT1 and an EC50 = 22.0µmol and a
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Figure 4.9: Concentration response curves of Na+ and glycine binding to GlyT1 and
GlyT2 GlyT1 has a higher affinity for Na+ than GlyT2 (a), although the latter displays higher
cooperativity of binding which is a result of the transport stoichiometry, with GlyT2 transporting
3Na+ in comparison to 2Na+ import per transport cycle for GlyT1. Bottom graph shows maximal
rates of steady state glycine transport in the presence of 150mM Na+ .
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Reverse transport of glycine by GlyT1 and GlyT2
Reversal of transporter flux is a function of the equilibrium potential of each transporter, which















Where R is the gas constant, T= 298K, F is the Faraday constant, and nNa is the number of
ions coupled to transport. Previous studies have shown that the ability of reverse transport by
each transporters differ, with GlyT1 showing a significant rate of glycine transport in the reverse
direction as the internal Na+ is increased [66, 252, 253] in comparison to GlyT2 [66], the function
of which is to ensure a high synaptic glycine concentration required for vesicular refilling (Introduc-
tion, Section 1.2.5). Aubrey et al. [252] have reported the glycine binding affinity to the internal
facing GlyT1 conformation at ≈ 4.3mM, which was the starting point for the estimation of the
kinetic parameters determining GlyTs reversal that agree with experimental observations. Figure
4.10 shows the difference in maximal reverse transport rates by each transporter in the presence
of 2mM and 10mM glycine, the estimated astrocytic and neuronal concentrations, respectively.
The rate of transport was calculated in the first instance assuming that the internal glycine Keq is
equal for each transporter at 4.3mM, and the affinity of the intracellular Na+ to the transporter
is the same as for the extracellular Na+ at 6mM and 30mM for GlyT1 and GlyT2, respectively.
Extracellular and intracellular Na+ were set to 150mM and 50mM in all calculations. It can be
seen that at both concentrations of internal glycine the maximal reverse rate is higher for GlyT1,
which has a higher affinity for Na+ in both intracellular and extracellular-facing conformations.
Assuming an astrocytic glycine concentration of 2mM, reversal of transport to the extracellular
glycine-consuming direction occurs when extracellular glycine approaches 6.5µmol , in comparison
to 3µmol for GlyT2. In the presence of higher intracellular glycine concentrations of 10mM, both
transporters show a significant reverse transport until extracellular glycine reaches concentrations
of ≈ 7µmol and 20µmol for GlyT2 and GlyT1, respectively. Across all observations, the direction of
transport at concentrations of extracellular glycine ≥ 20µmol is in the extracellular to intracellular
direction, even if the internal glycine concentration is high, which shows that the transport cycle is
mostly driven by the high Na+ gradients across the compartments.
Assuming that neuronal glycine concentration is ≈ 10mM, given the previously described param-
eters GlyT2 would show significant glycine leaks from the presynaptic neuron in the absence of
neurotransmission. This does not agree with results by Roux and Supplisson [66], who demon-
strated that GlyT2 reversal transport does not occur at a significant rate from X. oocytes. The
authors concluded that GlyT2 affinities to intracellular glycine and Na+ , or the rate of reverse
transport must be lower than those in the extracellular facing state. In order to estimate the
binding affinities of intracellular Na+ and glycine to GlyT (Equation 4.6), these parameters were
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ranged from 30-100mM and 4-20mM, respectively. The intracellular glycine concentration was set
to 10mM, in the presence of 50mM intracellular and 150mM extracellular Na+ . The results can
be seen in Figure 4.11 and show that any combination of Na+ Keq from 80-100mM, and glycine
Keq 16-20mM would produce a rate of reverse transport at less than 0.5Ms
-1. For the next model
simulations values of Na+ Keq = 80mM and glycine Keq = 15mM were chosen in order to ensure
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Figure 4.10: Maximal rates of reverse transport by GlyT1 and GlyT2 Steady state
reaction rates were calculated for each transporter at internal glycine concentrations of 2mM and
10mM, under the assumption that the affinity of internal glycine binding to each transporter is
equal. Na+ affinities to each transporter were assumed to be the same towards extracellular and
intracEllular-facing conformations. GlyT1 has a higher potential for reverse transport at both
concentrations tested.
Reverse glycine transport by GlyT1 and GlyT2 under physiological conditions
The effect of increasing intracellular glycine concentrations on the extracellular glycine levels and
subsequent GlyR activation was measured. Figure 4.12 shows the results from a 10ms model simu-
lation in the presence of extracellular Na+ at 150mM, astrocytic Na+ at 17mM, and neuronal Na+
at 30mM. Top graph, a) , shows the maximum extracellular glycine released by each transporter
at varying internal glycine concentrations, in the absence of other uptake processes. The result-
ing maximum Popen can be seen in b). The bottom graphs show results from equivalent 10ms
simulations at varying internal glycine concentrations but in the presence of all model uptake pro-
cesses. GlyT2 does not release glycine from the neuronal cell at concentrations high enough for
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Figure 4.11: Effects of changing the GlyT2 Na+ and glycine affinities on the rate of
reverse transport Affinities of intracellular Na+ and glycine were ranged in the presence of
10mM intracellular glycine to assess in which range the parameter combinations produce minimal
glycine extrusion in the absence of neurotransmission.
GlyR activation even at very high intracellular glycine concentrations ≥ 15mM. In comparison, the
model shows that as the astrocytic glycine concentration increases, there is a considerable glycine
efflux into the extracellular space, leading to low levels of GlyR openings. However, as the uptake
processes of GlyT2 and diffusion are allowed, the small concentrations of astrocytic glycine released
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Figure 4.12: Glycine release at varying intracellular concentrations under physiological
conditions In each simulation the starting intracellular astrocytic (GlyT1) or neuronal (GlyT2)
glycine concentration was increased from 2-20mM. Increases of astrocytic glycine leads to its
release via GlyT1 (a), which in the absence of GlyT2 and diffusion leads to GlyR activation (b).
In the presence of GlyT2 and diffusion processes, astrocytic glycine release is negligible due to its
fast consumption in the synapse, and does not lead to any significant GlyR activation. GlyT2
does not release glycine in concentrations high enough for GlyR activation even at very high
neuronal concentrations.
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4.3.4 Effects of GlyT1 and GlyT2 uptake on the time course of glycin-
ergic currents
Effect of changing transporter numbers on the IPSC
In order to identify the effects of changing GlyT1 and GlyT2 densities on the resulting currents,
transporter numbers were ranged from 100-2000 and the resulting maximum IPSC amplitude and
decay time constant were measured in a dynamic model simulation with 4mM glycine for 1ms given
the initial GlyT1 and GlyT2 parameters:
Table 4.2: Initial set of GlyT1 and GlyT2 kinetic parameters
Paremeter GlyT1 model value (Ms-1, s−1) GlyT2 model value (Ms-1, s−1)
kf 2.00×101 2.00×101
kr 2.00×101 2.00×101
Keq Glye 22.60×10−6 24.60×10−6







Hill Na+ 1.4 2.2
Kinetic parameters used in Equation 4.6 to describe GlyT1 and GlyT2 transport, where kf and kr
are used for the calculation of the Vf and Vr values, respectively. Keq refer to the equilibrium
constants of Na+ and glycine in the forward (extracellular, e) and reverse (intracellular, i)
reaction directions.
As can be seen in Figure 4.13, increasing the number of GlyT2 leads to a faster decaying IPSC,
decreasing its decay time constant from 12ms to 9.5ms. Increasing the number of GlyT1 had the
opposite effect, and caused a longer decay of the IPSC from 9.5ms to 10.5ms. Reduction in IPSC
decay time constant and amplitude seen upon GlyT2 increase is expected, as the higher number
of transporters leads to faster removal of the released glycine, leading to a shorter time course of
glycine across the synaptic cleft. This observation is in line with experimental results in which
the pharmacological inhibition of both GlyT1 and GlyT2 leads to a slow down in the IPSC decay,
increasing its decay time constant by ≈ 1-5 ms [249, 251, 254]. On the contrary, the increases
in the τdecay seen as GlyT1 numbers are increased do not fit with the experimental observations
described. This effect can be explained by the difference in the reverse transport abilities of each
transporter, given the parameters in Table 4.2. Figure 4.13, c), d) shows the maximal concentration
of astrocytic and neuronal glycine reached during each simulation, from a starting concentration of
2mM and 10mM, respectively. As expected, increasing the number of GlyT1 leads to an increase
in the total astrocytic glycine uptake, whereas increase in the GlyT2 leads to its decrease as the
competition between the two transporters leads to a higher accumulation of glycine in the neuron.
Similarly, increasing the number of GlyT2 increases neuronal glycine, however this effect is also
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seen when GlyT1 is increased. As the number of GlyT1 increases, there is an increase in the rate
of reverse reaction via GlyT1 leading to a higher concentration of astrocytic release followed by
GlyT2 reuptake. Figure 4.14 shows the results of a 4mM glycine, 1ms simulation in the presence
of GlyT2= 1000 and GlyT1=1000 (a) and GlyT1= 2000 (b). At the end of the 1ms simulation,
there is a large overshoot of the flux where GlyT1 is operating in the glycine-releasing direction,
which is proportional to GlyT2 uptake flux leading to the accumulation of astrocytically- released
glycine in the presynaptic cell. This effect is not seen in the absence of GlyT1, when the flux via
GlyT2 returns to zero immediately after the end of the glycine release. As the number of GlyT1 is
doubled, there is an increase in the rate of glycine uptake but also in the rate of astrocytic release
post-simulation, leading to higher rates of GlyT2 reuptake. According to these model parameters,
glycine released during synaptic activation is uptaken in higher concentrations into the astrocyte,
followed by slower release of the astrocytic glycine which is returned back to the pre-synaptic cell
by GlyT2.




















































































Figure 4.13: Effect of varying GlyT numbers on the decay time constant and maximum
amplitude of IPSC The model was simulated with 4mM glycine for 1ms at varying GlyT1 and
GlyT2 numbers. The resulting IPSC τdecay and maximum amplitudes reached can be seen in a),
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Figure 4.14: Maximal rates of GlyT1 reversal at increased GlyT1 numbers The model
was simulated with 4mM glycine for 1ms in the presence of GlyT2=1000 and GlyT1= 1000 (a),
and GlyT2=2000 (b). It can be seen that the maximal rate of GlyT1 overshoot increases at the
GlyT1 number is doubled, and the rate of release is directly proportional to GlyT2 reuptake.
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Glycinergic IPSCs in the presence of both transporters set to n=1000 leads to an IPSC with a
τdecay= 9.93ms and Imax= 321pA. Complete block of GlyT2, equivalent to experimental inhibition
leads to an increase in the τdecay to 12.47ms with an Imax= 377pA. In comparison, complete block
of GlyT1 leads to a decrease of τdecay to 9.22ms and an Imax= 379pA. This does not agree with
experimental observations of pharmacological GlyT1 block in rat spinal cord neurons [249, 251, 254],
suggesting that model rates describing the reverse reactions of GlyT1 are too fast. Thus, new model
parameters were searched for such that they reflect the experimental observations. Setting the rate
of GlyT1 reverse reaction, kr14 at values more than 5s
-1 did not lead to IPSC τdecay values lower than
those in the absence of GlyT1 than in its presence, even at very high glycine and Na+ equilibrium
constant values. Figure 4.15 shows the values of τdecay IPSC calculated across a range of glycine
and Na+ equilibrium constants at kr14 = 5s
-1, following a 4mM, 1ms glycine model simulation.
Lowest value of the decay time constant was measured at glycine Keq = 5.7mM, Na
+ Keq = 29mM
at which the τdecay= 8.7ms. Thus, these rates of GlyT1 were set in the next model simulations.
In line with previous observations that the rate of GlyT2 reverse reaction is slower than that of
GlyT1, the rate of the reverse GlyT2 reaction, kr15, was also set to 5s
-1.
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Figure 4.15: Effects of changing GlyT1 intracellular glycine and Na+ affinities on the
time course of IPSC The model was simulated with 4mM glycine for 1ms at varying
intracellular glycine Keq ranging from 4.3-8.6mM and Na
+ Keq ranging from 6-40mM at the
microscopic rate constant of 4s-1.
The effect of changing the number of transporters on the resulting glycine peaks and IPSC
amplitude and kinetics were re-calculated with the new model parameters:
Figure 4.16 shows results from model simulation with 4mM glycine for 1ms over a range of GlyT
numbers 0-3000. Figure 4.16, a) shows that increasing the number of GlyT1 causes an overall fall
in the τdecay (range 8.5 - 7.9ms) similarly to GlyT2 which causes a fall in the τdecay in the same
range. There is steady fall in the maximum amplitudes of IPSC reached for both transporters,
which is more pronounced in response to change in GlyT1 (range 379- 67pA) in comparison to
GlyT2 (range 359- 125pA) showing that GlyT1 reuptake has a stronger effect on the IPSC (Figure
4.16, b). The highest Popen reached across all simulations was 0.82 when GlyT2 n= 1000 and there
was a complete block of GlyT1 in comparison to the maximum Popen of 0.94 seen during GlyR
simulation with saturating glycine in the absence of transport in Section 4.3.1. This suggests that
transport reactions have a significant effect on GlyR activation during fast synaptic transmission.
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Table 4.3: Final set of GlyT1 and GlyT2 kinetic parameters
Paremeter GlyT1 model value (Ms-1, s−1) GlyT2 model value (Ms-1, s−1)
kf 20.00×100 20.00×100
kr 5.00×100 5.00×100
Keq Glye 22.60×10−6 24.60×10−6







Hill Na+ 1.4 2.2
Kinetic parameters used in Equation 4.6 to describe GlyT1 and GlyT2 transport, where kf and kr
are used for the calculation of the Vf and Vr values, respectively. Keq refer to the equilibrium
constants of Na+ and glycine in the forward (extracellular,e) and reverse (intracellular, i) reaction
directions.
The change in the shape of IPSC results from significant changes in the τdecay and maximum am-
plitude of glycine transients, which range from 0.02- 0.34ms and 0.6- 2.9mM (Figure 4.16, c), d).
The relatively large effects on glycine peaks contrast with the small effects on the IPSC τdecay
suggesting that the dynamics of GlyR activation play a major role in shaping the resulting IPSC.
The unstable fall in the τdecay of IPSC, in comparison to the trend seen in time constant of glycine
decay is likely due to the non-linear trends in GlyR activation due to varying glycine transients.
As expected, maximal concentrations of astrocytic and neuronal glycine reached increase as the
number of GlyT1 and GlyT2 increase (Figure 4.16, e, f). Neuronal concentrations reach up to
14.2mM at GlyT1= 1000, GlyT2= 3000, suggesting that at high GlyT2 densities nearly all of the
released neurotransmitter will be taken back up into the presynaptic cell. Overall, the concentra-
tions of glycine taken up into the astrocyte and neuron is highly dependant on the ratios of GlyT1
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Figure 4.16: Change in the decay time constant and maximum amplitude of IPSC at
varying GlyT numbers The effect of increasing the GlyT1 and GlyT2 was measured given
model parameters as in Table 4.3. The model was simulated with 4mM glycine for 1ms at varying
transporter numbers. Graphs a), b) show the effects seen in IPSC τdecay and maximal amplitudes.
Glycine transient τdecayand maximal amplitudes can be seen in c), d). The maximal astrocytic
and neuronal glycine concentrations reached in each simulation can be seen in d), e).
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Regulation of glycine reuptake by GlyT1 and GlyT2
Since GlyT1 operates close to its reversal potential, it has previously been hypothesized that the
depolarization of the astrocytic cell may lead to non-vesicular glycine releases across the synaptic
cleft [66]. This was explored in a model simulation with the intracellular Na+ concentration raised
by 25mM, an estimated concentration rise during cell depolarization [255]. The model simulations
were performed under an assumption that the astrocytic and neuronal glycine removal processes
are significantly slower than the kinetics of GlyT1 and GlyT2, ie. the system is closed. Figure
4.17 shows results of model simulation with 4mM glycine for 1ms in the presence of 17mM (a,
c) and 42mM (a, c) astrocytic Na+ , when the sink processes for astrocytic (r16) and neuronal
(r17) glycine are set to zero, allowing for the accumulation of glycine inside the compartments.
Simulation of the model in the presence of 17mM astrocytic glycine resulted in a glycine transient
reaching a maximum concentration of 2.1mM with a τdecay= 0.2ms that lead to a maximum Popen=
0.64 and IPSC with a maximum amplitude of 293pA with a τdecay= 9ms. These results are very
similar in the presence of 43mM astrocytic glycine, where glycine amplitude equalled 2.13mM
with a τdecay= 2.1ms, leading to a Popen=0.65 and an IPSC amplitude of 296pA with a τdecay=
8.9ms. Thus, raising the astrocytic Na+ does not have an effect on the GlyR activation which
happens at a fast time scale. However, it can be seen from Figure 4.17, a), b), that there is a
significant difference in the size of the GlyT1 reverse flux which happens after the fast glycine
accumulation in the astrocyte following neurotransmission. Rate of GlyT1 reversal is proportional
to glycine reuptake via GlyT2, thus increasing astrocytic Na+ affects the final concentrations of
neuronal glycine under the assumption that the processes which consume glycine in the astrocyte
are slower than the kinetics of GlyT1 reverse transport. The maximal astrocytic and neuronal
glycine concentrations reached at Na+ = 17mM are 4.6mM and 12.7mM, respectively suggesting
that even in the presence of baseline Na+ concentrations GlyT1-released glycine is taken back up
into the pre-synaptic cell. Raising the astrocytic Na+ to 43mM leads to maximal astrocytic and
neuronal glycine concentrations of 4.5mM and 13.8mM, thus although the maximal GlyT1 uptake
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Figure 4.17: Rate of GlyT1 reverse transport across different astrocytic Na+
concentrations Graphs a), c) show flux carried by GlyT1 and GlyT2 during a 4mM glycine
simulation for 1ms at astrocytic Na+ = 17mM, and the resulting intracellular accumulations of
astrocytic and neuronal glycine. Graphs b), d) show results from the same model simulation at
astrocytic Na+ = 43mM.
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4.4 Discussion
Glycine receptor model
Understanding of events which take place at the molecular level upon ligand binding to a receptor
is important in elucidating how protein structure relates to function. Development of experimental
techniques which allowed for the collection of current recordings via single channel receptors, and
subsequently theory for the analysis of the data to model receptor activation has greatly advanced
our understanding of receptor gating.
In Section 4.3.1, the overall features of the GlyR scheme activation arising from its topology and
associated kinetic parameters were analysed. Although sensitivity analysis is concerned with model
results at steady state, the trends seen for the the response coefficients over a concentration range
followed those of the total sum of flux via each reaction in a dynamic simulation. This is not supris-
ing, given that the equilibrium constant is a ratio of the microscopic rate constants for the forward
and reverse reaction which themselves can be thought of as the number of events per second, or
the probability of an event taking place. Regarded as probabilities, it is intuitive to think that the
concentration of any receptor species will be most sensitive to those reactions (events) which have
a higher probability of taking place.
These methods led to the identification of the most likely events taking place during receptor acti-
vation. Although the explanation for the protein activation provided by the MWC theory imposes
the existence of all global conformations, R F and O in all non-, single-, double- and triple-liganded
conformations, the likelihood of the receptor residing in each state differs.
According to the model results, openings of the receptor from a single-liganded state which would
be expected to take place in low, non-saturating glycine concentrations is very rare. The opening
of the receptor will happen mostly from triple- liganded states, as seen from the high total flux
carried by reactions FBind3 and Open3, whereas openings from a double-liganded state mostly
take place at below half-saturating glycine concentrations of 50µmol. At around 30µmol glycine,
there is a crossover of the response coefficient trends for two reaction pairs, Flip1 and FBind2, and
FBind3 and Open3. This would suggest that the activation of the GlyR below 30µmol will proceed
with the binding of one molecule to state R, followed by an isomerization of the protein into the F
state, to which another one or two molecules will bind leading to receptor opening. Above 30µmol,
the likely route of activation is the binding of two glycine molecules to the R state, followed by
its isomerization to the F state and subsequent opening. At all glycine concentrations, reactions
RBind3 and Flip3 are descibed by very low response coefficients and carry little flux. In contrast,
reaction FBind3 carries large flux across all concentrations. This suggests that the binding of the
third glycine molecule will nearly always happen in the global F conformation. As the equilibrium
constant is related to the standard Gibbs free energy of the reaction, it is the energy provided by
glycine binding that leads to the stabilisation of the protein in each state, thus the binding of two
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glycine molecules is predicted to provide the energy needed for the isomerization of the protein.
In the following section, the model was reduced to a three state MWC equation which was used
to reproduce steady state full model results. Reduction of the scheme led to the estimation of the
isomerization equilibrium constants between the global conformations states R and F and equalled
≈ 11×103 as well as states F and O which equalled 3.13. In addition, it allowed for the estima-
tion of glycine affinity to the open conformation which equalled 2.07×10−6M. According to these
values, in the absence of ligand the majority of the receptor will be found in the R conformation.
Once receptor isomerizes, there is a 65-fold increase in glycine affinity to the F conformation but
only a 4-fold change in affinity from the flipped to the open conformation. This suggests that the
majority of energy provided by glycine binding is used for the first step of receptor conformational
change into the F conformation, from which the second isomerization steps leading GlyR opening is
relatively less energetically costly. Given the previous results from sensitivity analysis, the binding
of two glycine molecules will provide the energy needed for the conformational ‘flip’.
Before the aplication of the MWC to GlyR by Burzomato [144], the model was applied to the
nicotinic receptors (AChRs) by Auerbach [256] who used mutant-receptor constructs to show the
applicability of the model to explain the differential effects of mutations on the ligand affinity versus
global protein isomerization, as well as to estimate the rates of AChRs openings in the absence of
ligand. As stated by the authors, the knowledge of the different MWC parameters may aim in
the engineering of receptor function by combining mutations the effects of which can be quantita-
tively measured. Apart from the advantage of model reduction, a desirable feature in the area of
mathematical modelling, the derivation of the MWC equation for the GlyR may prove useful in the
identification of the effects of mutations, as well as design of experiments. The equation provides a
clear separation between parameters which affect ligand binding (c, d) and global isomerizations of
the protein (M, L). The effects of mutations are usually predicted from their AA position based on
the crystal structures of receptors. However, in the absence of this information the equation could
potentially be used during curve fitting to predict the effect of a ligand, inhibitor, or a mutation
has on the receptor. This would require the collection of enough data point for the concentration-
response curves such that the fitting of the numerous equation parameters is feasible.
Glycine synapse model
The time course of the neurotransmitter transient in the synapse is a result of many factors, includ-
ing the maximal concentration and length of release from the vesicle, the geometry of the synaptic
cleft and density of the solution affecting the rate of diffusion, the expression and locations of the
transporter proteins and others. In Section 4.3.2, the model was simulated with peaks of glycine
varying in concentration and duration of release in the absence of transporters in order to see how
presynaptic release affects the IPSC time course. Previous estimates of neurotransmitter peak and
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length of persistence in the synapse from glutamatergic synapses resulted in values of 1-3mM with
a decay time constant of up to 1.2ms [257, 258]. A more recent estimation of glycine concentration
across inhibitory synapses by Beato [249] provided a range of values for concentrations between
2.2-3.5mM glycine with time decay constant of 0.6-0.9ms which was the starting point for model
simulations. Varying the vesicular glycine concentrations and duration of release in the model had
no effect on the decay time constant of glycine, only the maximal amplitudes reached. Since IPSC
are a result of the occupancy of the open states calculated from the kinetic model of GlyR there
is a hyperbolic increase in the maximal amplitudes and decay time constants of the IPSC upon
GlyR saturation. The model shows that vesicular glycine concentrations of 2-5mM released for
longer than 1ms would lead to IPSC which change only by ≈ 10% in amplitude and even less in
the speed of decay. On the other hand, in the region of durations of neurotransmitter transient less
than those determined experimentally (1ms) the resulting IPSC significantly vary depending on the
length and the initial concentration, agreeing with the observations that receptor activation hap-
pens under non-equilibrium [248]. The condition of non-equilibrium activation allows for a greater
flexibility in the regulation of GlyR currents such as dynamic changes in transporter expression, or
modulation via modification such as phosphorylation which affect the maximum rate of transport
[259].
It has been previously proposed that the process of diffusion is faster than active transporter re-
uptake and accounts entirely for the clearance of glycine [260]. However, numerous studies have
since shown that pharmacological inhibition of transporters in spinal cord tissues reduces IPSC,
suggesting that active reuptake significantly affects the glycine transients experienced by the GlyR.
In order to determine the effects of GlyTs on IPSC, realistic estimates for the kinetic parameters
describing their reuptake were searched for.
Two models varying in their complexity have been previously published for GlyT1 [252, 261] and
a more recent study describing the kinetics of both transporters under the same experimental
conditions was published by Erdem et al. [219]. They provide invaluable information regarding
transporter activation due to glycine, and the current study aimed to bring together kinetic param-
eters estimated in these studies as well as those from the electrophysiological analysis of currents
via GlyTs [66], highlighting further systemic constraints on these parameters that emerge from the
interactions between these proteins and the effect it has on the IPSC.
Affinity of glycine to GlyT2 in the intracellular-facing conformation must be low enough such that
glycine release is not seen even at high neuronal concentrations ≥ 10mM, as predicted to be required
for successful competition of glycine with GABA for the import into the vesicle by the low-affinity
vesicular transporters [66, 244, 262]. The model results show that values of Na+ and glycine equi-
librium constants which satisfy this condition must be more than two orders of magnitude bigger
than the affinities of the substrates to the extracellular-facing conformations.
In a similar manner, the higher limit on the rate of reverse transport by GlyT1, which is the
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summed rate of all of the protein conformational transitions including substrate binding as well as
isomerization could be estimated. According to model results, this value must be at least 4-fold
slower than that of the forward transport otherwise the reversal of flux stimulated by large glycine
astrocytic concentration increased during neurotransmission will lead to a longer glycine transient
in the synapse, and so IPSC which is not seen experimentally. The lower intracellular Na+ binding
affinities to GlyT1 estimated are in line with the model by Cherubino et al. [261] but disagree
with the predictions made by Aubrey et al. [252]. In contast, lower intracellular glycine binding
affinities to GlyT1 align with the model by Aubrey et al. [252] but disagree with the other model.
This is because the kinetic schemes described in these studies must follow microscopic reversibil-
ity, which is not imposed by the phenomenological Michaelis Menten equation used in the current
study. Detailed analysis of GlyT kinetics by Erdem et al. [219] confirm that the affinities of both
substrates are lower to the intracellular-facing transporter states who explained this feature as a
result of substrate binding cooperativity.
Estimation of the kinetic parameters for GlyTs allowed to look at the competition between the
transporters for glycine reuptake. The model results show that GlyT1 uptakes a higher proportion
of released glycine than GlyT2. If the processes which remove glycine from the astrocyte such as
its metabolic breakdown by the GCS are much slower than the kinetics of GlyT1 reversal, fast ac-
cumulation of astrocytic glycine leads to its release from the astrocyte back into the synaptic cleft.
The astrocytically-released glycine is taken back up into the presynaptic neuron by GlyT2 where it
is repackaged into the synaptic vesicles. Whether this could happen in vivo, and the importance of
GlyT1-mediated refilling of the neuronal glycine concentrations depends on the expression of each
transporter, as well as proximity of these proteins.
Apart from slow, long term glycine releases following glycine neurotransmission, glial GlyT1 glycine
release may occur due to cell depolarization, as shown by the model results. The possibility of non-
vesicular release of neurotransmitter was initially described by Attwell et al. [255], and the relevance
of GlyT1 reversal in the activation of NMDAR receptors in glutamatergic synapses suggested by
Roux and Supplisson [66]. Later on it was shown that glycine can be released from Bergmann
glial cells upon membrane depolarization [263] as well from astrocytes stimulated with dopamine
[253]. As astrocytic release of glycine via GlyT1 could have an advantage in the modulation of
NMDAR across glutamatergic synapses, the relevance of astrocyte depolarization in the inhibitory
neurons of the lower brain is less known. Expression patterns of glycine biosynthetic enzymes seen
in Chapter 4 show that astrocytes and oligodendrocytes are the main locations of initial glycine
production. Since glycine is used not only as a neurotransmitter, but is important in the formation
of glutathione needed for redox balance in neuronal cells, one carbon metabolism regulation and
others, it is likely that de novo biosynthesis is required in which case GlyT1 reversal could play a
central role in supplying neuronal glycine. Since the expression of SLC6A9 encoding GlyT1 was
high not only in astrocytes, but also in oligodendrocytes , the depolarization of both of these types
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of cells may be important in glycine homeostasis. These results could shed a light on the impli-
cation of long-term pharmacological block of GlyT1 across inhibitory synapses- if GlyT1 releases
are necessary for GlyT2- mediated accumulation of glycine in the pre-synaptic neuron, long-term
effects of persistent inhibition could overall decrease glycinergic inhibition by emptying the required
glycine pools. This should be taken into account during the design and dosage of GlyT1 inhibitors
which are developed for the treatment of numerous conditions, as related to the location of GlyT1
expression [264].
Point mutation at the position Ser 407 in GlyT1 was identified as novel cause for in a child. In
both GlyT1, as well as 46% sequence identical dopamine transporter serine at position 407 is con-
served, and in the latter was found to be located at the sodium and chloride binding pocket [80].
It was surmised in the original publication that replacement of amino acid at this site changes
the chemical properties of the protein, resulting in the disrupted functioning of the transporter.
Indeed, replacement of this amino acid in wild-type human GlyT1 expressed in X. oocyte lead to
inhibiton of currents elicited by GlyT1, as described in Chapter 5. Setting the number of trans-
porters in the glycine synapse model to zero, equivalent to the functional knockout of GlyT1 was
seen to significantly increase the maximum concentration of glycine reached, as well as lenghten its
persistance in the synapse, leading to a longer GlyR activation as seen by the increase in the IPSC
decay time constant. GlyT1 knockout mouse models have previously shown that severe disruption
of glycine clearance leads to sustained inhibition in the respiratory centers located in the brainstem
[265], causing a disruption in the development of respiratory patterns as seen in the GlyT1 mutant
patient.
Application of the synapse model allowed for the confirmation of the effects of GlyT1 mutations
on the resulting IPSC at the synapse scale. The model could be extended further to quantify the
effects of mutations which may reduce the affinities of GlyT to glycine without causing complete
inhibition. In addition, transporter equations could be expanded by terms describing inhibitor
binding and kinetic constants measured experimentally can be further integrated into the model.
Thus, the model forms a starting point which may be expanded upon to predict how the effect of
different changes in one component affect glycinergic neurotranmission overall.
4.4.1 Conclusion
In summary, the major insights of this chapter relate to single protein GlyR activation upon glycine
binding, and those pertinent to the regulation of glycine concentration across the whole glyciner-
gic synapse. Sensitivity analysis of the GlyR scheme gave insight to the sequence of events upon
GlyR activation, predicting the different activation pathways at non- and saturating glycine con-
centrations. In addition, this led to the discovery of GlyR receptor occupancies, showing that some
receptor states such as the triple bound resting state will be hardly visited at any concentrations.
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Furthermore, it was shown that the model can be reduced to fewer equations which accurately
predict time-dependant GlyR activation, as well as one MWC-type equation which can be used to
calculate steady state occupancies, and therefore IPCS. The parameters defining the MWC-type
equation are also clearly split between those which define substrate binding, and those which relate
to global protein isomerization as a result of GlyR composition. Furthermore, parameters which
are very difficult to obtain experimentally such as the binding of glycine to the open state were
determined which may provide insightful in probing the effects of mutations as well as activator
and inhibitor molecules on GlyR activation (Section 4.4).
A holistic model which combines the results of experimental kinetic studies on single proteins was
also established. The systemic constraints resulting from the model give an estimation on the
glycine transporter kinetic parameters. It was shown that in order to keep glycine concentrations
high enough for successful vesicle refilling in the neuron, the affinity of glycine to GlyT2 in the in-
tracellular facing state has to be two-fold lower than that in the extracellular facing state. A similar
finding is reported for the speed at which glycine binds the GlyT1 in different states. The rate at
which GlyT1 binds glycine to GlyT1 must be four-fold slower to the intracellular facing state than
that to the extracellular facing state, otherwise the glycine rapidly accumulating in the astrocyte
would compete with the depleting extracellular glycine, causing GlyT1 to release astrocytic glycine
back into the synapse and thus lenghtening the time course of IPCS (Section 4.4).
Under the assumption that metabolic processes sinking astrocytic glycine are slower than GlyT1
kinetics, it is possible that GlyT1-mediated astrocytic release of low concentrations of glycine may
play a role in the refilling of vesciles in the synapse, which could be a mechanism for ensuring high
neuronal concentrations required. This would take place at a longer time scale than the fast events
of vesicular release upon activation, and the concentrations should be low enough such that they
don’t cause GlyR activation.
It was also shown that depolarization of the astrocyte, in the presence of assumed 2mM concen-
trations of intracellular glycine would cause GlyT1 to rapidly release glycine across the synapse.
Whether this mechanism is important across the inhibitory synapses for the role of neuronal refill-
ing, metabolism, or other functions is a topic for further study.
Lastly, the model results show that the inhibition of GlyT1, whether resulting from mutations such
as that causing the novel NKH phenotype (Chapter 5) or via a pharmacological block would lead to
a higher concentration of glycine and its longer persistance in the synaptic cleft, leading to longer
GlyR activation. These findings can provide insights to the mechanism of GlyT1 inhibition and its
resulting phenotype, such as the persistant over-inhibition of respiratory centers in patients.
The synapse model relies on experimentally determined parameters of different proteins which were
collected under varying conditions, which is a major limitation of this study. The model also does
not show include other transporter proteins which may be regulating glycine concentrations, such
as the Asc-1 transporter which has recently been reported to regulate glycinergic neurotransmission
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[266]. Lastly, the equations do not take into account the space dimension, meaning effects such as
synapse geometry, locations of the proteins, and the diffusion processes are not represented. In the
future state, the model can be expanded upon via additional reactions and the space dimension.
Chapter 5
Effects of Ser 407 mutations on the
GlyT1 transporter
5.1 Introduction
Glycine transporter 1 (GlyT1) regulates inhibitory neurotransmission by active reuptake of glycine
into glial cells wrapping the glycinergic synapses. This ensures rapid clearance of glycine from the
synaptic cleft (Introduction, Section 1.2.5). The importance of GlyT1 for glycinergic signalling is
supported by the finding that loss of astrocytic GlyT1 results in a lethal phenotype in newborn
mice due to an over-inhibition of respiratory centers in the brain stem [265]. A similar phenotype
has been reported in a child presented with nonketotic hyperglycinema (NKH) by Alfadhel,M. et al.
[80], who identified a missense Ser 407→ Gly mutation in the GlyT1. Since nearly all cases of NKH
are a result of variants in the genes encoding the catabolic enzymes involved in glycine degrada-
tion,the glycine cleavage system (GCS) [267], the GlyT1 mutation discovered by Alfadhel,M. et al.
[80] is a novel cause for NKH.
GlyT1 is a member of the SLC6 Na+ /Cl- -dependent neurotransmitter transporters family which
also includes transporters for other amino acids such as taurine, as well as neurotransmitters
dopamine, serotonin and others [65]. All members of the SLC6 family utilize the high electro-
chemical gradients across biological membranes to couple the transport of Na+ and Cl- to ligand
translocations. Much of what is known about the structure of these transporters as well as the
locations of ligand and co-substrate binding sites is based on the resolution of the crystal struc-
ture of the bacterial leucine transporter (LeuT) which shows a high degree of sequence similarity
with mammalian SLC family members [1] in selected regions. Later, the crystal structure of the
Drosophila melanogaster dopamine transporter (DAT) was obtained which shares 46% sequence
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identity with the GlyT1, providing additional information regarding the topology of the mam-
malian transporters. Overall, the SLC6 are composed of 12 transmembrane helices (TM) with
intracellular N- and C-termini and a large extracellular loop 2 (EL2) containing a pair of cysteine
residues which form a disulfide bridge and residues containing glycosylation sites [268]. The 12 TM
regions buried within the lipid bilayer contain the site of ligand binding, and form two inverted
bundles of five TM regions which move against one another during transport [1, 269].
Serine at the position 407 in GlyT1 is located in the transmembrane helix (TM7) region. It is a
conserved residue across human GlyT1, GABA, dopamine as well as the serotonin transporters [1],
and is located in a cavity binding Na+ and Cl- ions. It is surmised that Ser407 mutation leads to
a disruption of transporter function by affecting its co-substrate binding affinities.
In this chapter, an attempt was made to characterize the effects of Ser407 on the transporter func-
tion. In the first instance, currents via the wild type GlyT1 (wtGlyT1) expressed in Xenopus laevis
oocytes were recorder to establish a positive control. Introduction of Ser 407 → Gly, and Ser 407→
Tyr mutations led to complete inhibition of currents through GlyT1. Lastly, in order to characterise
the effect of mutation a FLAG epitope tag was introduced into the extracellular loop 2 (EL2) of
wtGlyT which also caused complete abolishment of currents as compared to the wild type.
Result of GlyT1 functional disruption caused by the Ser407 mutation was incorporated into a ki-
netic model of the glycinergic synapse as described in Chapter 4, confirming that the mutation
leads to an increase in the maximum glycine peak reached across the synapse, which persists in the
synapse for a longer time period, increasing GlyR activation.
5.2 Materials and methods
5.2.1 Molecular Biology
Materials
All restriction endonucleases (RE), enzymes and buffers were purchased from New England Biolabs
(USA). The E.N.Z.A. Plasmid DNA Kit used for plasmid elution from competent E.coli was pur-
chased from Omega Bio-Tek (USA). Plasmid elution from ligation/RE reactions was done using the
Monarch PCR & DNA Cleanup Kit purchased from New England Biolabs (USA). Transcription of
cDNA was performed using the mMessage mMachine kit purchased from Thermo Fisher Scientific
(USA). All oligonucleotide primers were purchased from Eurofins Genomics (UK).
Cloning of the wild type GlyT1 sequence into the pSUNOT vector
Human glycine transporter 1 cDNA (GenBank ID:BC156979.1) was obtained from Source Bio-
science (UK). The sequence was amplified in a PCR cycle with a forward primer containing the
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XbaI recognition site and a reverse primer containing the EcoRV recognition site. The subcloning
primer sequences can be seen below:
Primer 5’-3’ oligonucleotide sequence
Forward TAA TCC TAG AGG CAC CAT GAG CGG CGG AGA CAC GCG GGC TGC
Reverse GGC GCG ATA TCT TAT ATC CGG GAG TCC TGG AGG CGG CTG GA
The reaction mixture was set up as follows:
Component Volume(µL)
GlyT1 template (50ng/µL) 1
Forward primer (125ng/µL) 1
Reverse primer (125ng/µL) 1
dNTPS(2mM) 5
Pfu buffer(10X) 5
Dimethyl Sulfoxide (DMSO) 3
High Fidelity Pfu enzyme 1
Nuclease free water 33
Total 50
Next, a PCR cycle was ran with the following conditions:
Step Number of cycles Temperature (◦C) Time
1 1 95 2 min
2 15 95 30 s
2 ↓ 60 1 min
2 72 3 min
3 1 72 10 min
The resulting product was digested with restriction enzymes XbaI and EcoRV and subcloned
into the pSUNOT vector using a standard protocol for T4 DNA ligase (Promega), using a 3:1
pSUNOT vector to GlyT1 insert ratio. pSUNOT is an in-house modified PCI (Promega) expression
vector. In order to confirm the subcloning was successful the resulting material was sequenced
(Eurofins). The resulting pSUNOT plasmid containing the wild type GlyT1 insert can be seen in
Figure 5.1.
Plasmid amplification
Plasmids were amplified in competent E.coli cells (X-Gol, Stratagene). Briefly, competent cells
were thawn on ice, then plasmid cDNA material was added and cells were returned to ice for
30min. Next, cells were heat-shocked at 42◦C for 42s, and 0.5mL of Luria Broth (LB) was added









































Figure 5.1: pSUNOT-GlyT1 plasmid map The wtGlyT1 was subcloned into the pSUNOT
vector downstream the CMV promoter site enhancing the transcription of the target gene. The
total plasmid size was 6121 base pairs including the 2122 base pairs wtGlyT1 located between the
XbaI and EcoRV restriction enzyme sites.
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to the eppendorf which was incubated at 37◦C for 45mins. The cells were plated on LB-agar plates
containing ampicillin at 100µg/mL and left to grow overnight for 16h in a 37◦C incubator. The
next day colonies were selected from the plate using a sterile pipette tip and inoculated into 10mL
of Terrific Broth (TB) media (Thermo Fisher Scientific, USA) containing ampicillin at 100µg/mL.
Cells were grown overnight for 16h in a shaking incubator at 37◦C . The next day tubes were
spun at 3000rpm for 8min, supernatant removed, and plasmid was extracted from the pellet using
the E.N.Z.A. Plasmid DNA Kit (USA) according to the kit instructions. Plasmid was collected on
the filter of a QIAprep column and eluted with 50µL of nuclease-free water (NFW). The resulting
concentration measured in a NanoDrop One spectrophotometer (Thermo Fisher Scientific, USA).
Plasmid was kept at -20◦C until needed.
Synthesis of RNA for X.oocyte injection
DNA was linearised downstream of the insert site using a unique SmiI restriction enzyme site in
a reaction incubated at 37◦C for 2.5h. Next, the linear plasmid was eluted with the Monarch
PCR DNA Cleanup Kit and was used to generate capped RNA with the mMessage mMachine
kit (Thermo Fisher Scientific,USA), according to the manufacturers instructions. Reaction mixture
was left to incubate at 37◦C for 2.5h after which 1µL of DNAse was added for 30mins to remove
the template cDNA material. Next, 25µL of lithium chloride and 30µL of NFW was added to the
resulting RNA and the reaction mix was left overnight at -20◦C. The next day, sample was spun
at -4◦C for 30mins and the supernatant carefully removed. One millilitre of 70% EtOH was added
to the sample to wash the RNA pellet, after which the sample was re-spun at 4◦C for 20 minutes.
EtOH was carefully removed and the RNA pellet resuspended in 15µL of NFW. The concentration
of RNA in the resulting sample was measured in a NanoDrop One spectrophotometer (Thermo
Fisher Scientific, USA) after which the sample was aliquoted and stored in a -80◦C freezer until the
day of injection.
Introduction of GlyT1 mutations
Nucleotide substitutions at position Ser407 were introduced into the wild type GlyT1 according
to the QuickChange Site-Directed mutagenesis kit (Stratagene, The Netherlands). The reaction
mixture was set up as follows:
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Component Volume(µL)
DNA template (50ng/µL) 1
Forward primer (125ng/µL) 1
Reverse primer (125ng/µL) 1
dNTPS(2mM) 5
Pfu buffer(10X) 5
Dimethyl Sulfoxide (DMSO) 3
High Fidelity Pfu enzyme 1
Nuclease free water 33
Total 50
Next, a PCR cycle was ran with the following conditions:
Step Number of cycles Temperature (◦C) Time
1 1 95 1 min
2 15 95 30 s
2 ↓ 55 1 min
2 68 6.5 min
3 1 68 6.5 min
In order to remove methylated parent DNA, 1µL of Dpn I was added at the end of the cycle and
the reaction was left to incubate at 37◦C for 1 hour. Two mutations were introduced overall, Ser
407 → Gly and Ser 407 → Tyr. The primers used to introduce each mutation can be seen below:
Mutation 5’-3’ oligonucleotide sequence (forward primer)
Ser 407 → Gly ACC AAC TGT GCC ACC GGC GTC TAT GCT GGC TTC
Ser 407 → Tyr ATC ACC AAC TGT GCC ACC ACT GTC TAT GCT GGC
In order to confirm the mutations were successful the resulting material was sequenced (Eu-
rofins).
Insertion of the FLAG epitope into the EL2 of GlyT1
Insertion of the FLAG- tag was performed via the PCR-driven overlap extension method following
the protocol described in Heckman and Pease [270]. Overlap PCR was ran in two steps using the
primers below:
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Mutation 5’-3’ oligonucleotide sequence
Primer A ATT ATC TAG AGC CAC CAT GAG CGG CGG AGA C
Primer B TTT ATC GTC ATC GTC TTT GTA ATC CAG TGA CAG CTT CAG CAC GT
Primer C GAT TAC AAA GAC GAT GAC GAT AAA GAC ATT GGG AAC TTT GG
Primer D ATA ATG ATA TCT TAT CCG GGA GTC CTG GAG GCG G
In the first step, two reaction mixtures containing primers A and B, and primers C and D were
set up as follows:
Component Volume(µL)
DNA template (50ng/µL) 1
Primer 1 (A or C) (125ng/µL) 1
Primer 2 (B or D) (125ng/µL) 1
dNTPS(2mM) 5
Pfu buffer(10X) 5
Dimethyl Sulfoxide (DMSO) 3
High Fidelity Pfu enzyme 1
Nuclease free water 33
Total 50
The PCR reaction was set up with the following conditions:
Step Number of cycles Temperature (◦C) Time
1 1 95 1 min
2 15 95 30 s
2 ↓ 55 1 min
2 68 6.5 min
3 1 68 6.5 min
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Products from the resulting PCR reactions containing overlapping fragments were purified and
used as the template in the next PCR step. The reaction was set up as follows:
Component Volume(µL)
AB template (78ng/µL) 0.6 (50ng)
CD template (64.8ng/µL) 0.77 (50ng)
Forward primer A (125ng/µL) 1
Reverse primer D (125ng/µL) 1
dNTPS(2mM) 5
Pfu buffer(10X) 5
Dimethyl Sulfoxide (DMSO) 3
High Fidelity Pfu enzyme 1
Nuclease free water 32.6
Total 50
The PCR was set up with the following conditions:
Step Number of cycles Temperature (◦C) Time
1 1 95 1 min
2 31 95 30 s
2 ↓ 55 1 min
2 72 1.5 min
3 1 72 10 min
Product from the second PCR reaction was digested with XbaI and EcoRV and subcloned into
the pSUNOT vector using a standard protocol for T4 DNA ligase (Promega). In order to confirm
the insertion was successful the resulting material was sequenced (Eurofins). The resulting plasmid
was used used to make RNA for injection in the X.oocytes, as described previously.
5.2.2 Electrophysiology
Materials
ORG Mg+ solution used in oocyte preparation contained 82mM NaCl, 2mM KCl, 2mM MgCl and
5mM HEPES at pH 7.6. ORG Ca2+ solution in which oocytes were stored contained 82mM NaCl,
2mM KCl, 2mM CaCl2 and 5mM at a pH of 7.6 supplemented with Antibiotic/Antimycotic Solution
x100 (10,000 units penicillin, 10 mg streptomycin and 25g amphotericin B per mL) and amikacin
purchased from Merck (Sigma-Aldrich,UK). Collagenase Type I was purchased from Merck (Sigma-
Aldrich,UK). SOS buffer used to fill the bath chamber during the electrophysiology recordings
contained 100mM NaCl, 2mM NaCl, 1.8mM CaCl2, 1mM MgCl2 and 5mM HEPES. Glycine was
obtained from Sigma-Aldrich (UK).
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Preparation and microinjection of Xenopus oocytes
Xenopus oocytes were purchased from Xenopus one (Chicago, USA) or Xenopus Express (France).
Xenopus care and experimental procedures were in accordance with the UK Home Office regulations
and were approved by the Animal Use Committee of Oxford Brookes University. Briefly, X.laevis
were housed in the animal house of Oxford University in black tanks filled with dechlorinated water
(≥ 15 L per toad) that was kept in a temperature-controlled room (18◦C). The animals were kept
under a fixed 12 h light/dark cycle. Frogs were fed twice a week with amphibian food pellets.
Ovarian lobes were harvested from aneasthesised Xenopus (MS222 solution -0.5% tricane, pH 7.4)
via surgical laparotomy and prepared as described below.
The ovarian lobes were washed in ORG Mg+ solution in a shaker at 150rpm for 10 minutes. Next
they were placed in a Petri dish containing ORG Mg+ and the oocytes were separated into smaller
groups of 5-6, after which they were placed back on a shaker for a second wash. Oocytes were then
defolliculated via the addition of ORG Mg+ solution containing collagenase at 2mg/mL to the Petri
dish, which was left on the shaker at 150rpm for approximately 1 hour. After the removal of the
extracellular membrane, healthy stage IV- V oocytes were selected based on their appearance and
placed into ORG Ca2+ solution containing Antibiotic/Antimycotic Solution x100 and amikacin,
then incubated at 17◦C.
The next day, unhealthy oocytes were removed from the plate and healthy oocytes selected for
microinjection with RNA material. The needles used for microinjection were made from Drummond
glass capillaries (Sartorius,UK) and pulled in a Narishige PC-10 micropipette puller (Narishige,
Japan). The needle was filled with mineral oil and the RNA material, and afterwards loaded
onto a Nanoject II microinjector (Drummond, USA). Oocytes were injected into the center of the
vegetal pole. The volume of RNA injected varied from 50.5nL- 119.6nL in the attempt to increase
transporter expression, however this factor did not affect amplitude of currents recorded. Next, the
oocytes were placed separately into 96 well-plates in ORG Ca2+ supplemented with kanamycin at
2 g/ml, 1x Antibiotic Antimycotic Solution and 5% horse serum, pH 7.6. and incubated at 17◦C.
Solution was changed every day until the day of experiment. Oocytes were used for recording 5-10
days after transfection on the day of the highest transporter expression.
Electrophysiological recordings of GlyT1 currents
Whole cell currents through individual oocytes expressing GlyT1 were measured via TEVC (Intro-
duction, Section 1.3.5). The oocyte was placed in a 30µL recording chamber (Digitimer Ltd, UK),
bathed in SOS buffer (100mM NaCl, 2mM NaCl, 1.8mM CaCl2, 1mM MgCl2 and 5mM HEPES)
and voltage clamped at -80mV. Electrodes used for the recording were made from borosicate cap-
illary glass (Harvard Apparatus, GC 150 TF) and pulled in a vertical electrode puller (Narishige
PP-83). Next, the electrodes were filled with 3M KCl and connected to the Oocyte Clamp OC-725C
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(Warner Instruments, USA) instrument upon which the impedance was checked. Only electrodes
with an impedance between 0.2- 2M Ω were used in the subsequent recording. Once the Vm of
the oocyte was stable, SOS buffer containing glycine at various concentrations was used to perfuse
the chamber via a gravity driven perfusion system. In order to add or remove solutions, a valve
allowing the flow of compound into the chamber was manually manipulated.
Data analysis of the concentration response curves (CRC)
All data plots and analysis were performed in the GraphPad Prism software. In order to determine
glycine affinity the maximal response was measured over a range of glycine concentrations. The
amplitude of response was normalised to the response generated by the maximum effective concen-
tration (Imax) of 1000µM. Resulting values were input into GraphPad Prism software which fitted





Where EC50 is the concentration of agonist which induces 50% of the Imax, h is the Hill coefficient
estimation of cooperativity, and [A] is the agonist concentration.
Concentration response curve was plotted based on cumulative results from a number (n) of inde-
pendent experiments chosen on the basis of the EC50 95% confidence interval (CI.) range values.
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5.3 Results
Response of the wild type GlyT1 to glycine
Five glycine concentrations ranging from 1-1000µM were applied via bath perfusion of oocytes
expressing the wtGlyT1. Representative responses can be seen in Figure 5.2. In the first instance
Imax was determined via application of 1000µM glycine. Maximal responses in individual eggs
were varied depending on the day of injection, as well as amongst oocytes injected on the same day
which is a reflection of the high variation in protein expression at the cell membrane. Oocytes were
perfused with different solutions every 3 to 6 minutes in order to ensure the removal of residual
compound between recordings thus allowing for the recovery of the transporter. Figure 5.3 shows
glycine concentration response curve from n=6 individual oocytes. Fit of the Hill equation to the
curve resulted in glycine EC50 = 25.7µmol (18.9-34.0 CI.) and Hcoeff = 0.95 (0.64-1.25 CI.) which
is in line with the previously reported value of EC50 2̄2.60µmol and Hcoeff = 0.78 [66].
Figure 5.2: Amplitudes of the wtGlyT1 responses to glycine at varying concentrations
Representative Cl- currents via the wtGlyT1 at concentration of glycine applied ranging from
1µmolto 1mM. Maximal responses upon 1mM glycine application were approximately 60nA, but
ranged from one experiment to another as determined by membrane transporter expression.
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Figure 5.3: Concentration response curve of glycine binding to the wtGlyT1 Fits of the
Hill equation to the curve resulted in an EC50 = 25.7µmol (18.9-34.0 CI.) and Hcoeff = 0.95
(0.64-1.25 CI.).
Effects of S407 mutations on GlyT1
After the establishment of the wild type GlyT1 transporter EC50 an attempt was made to deter-
mine the effect of point mutations at position Ser407 on the GlyT1 currents. In the first instance,
mutation Ser 407 → Gly was introduced. No currents could be detected in oocytes expressing this
construct. Thus a second, less dramatic mutation Ser 407 → Tyr was introduced which produced
ambiguous results. Currents collected through the Ser 407 → Tyr mutant in oocytes injected on
different days could not be resolved due to the small amplitude of the Imax, ranging from 5-20nA.
Since the baseline noise in the recordings varied up to 10nA, it was not possible to establish a stable
baseline current under these conditions.
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Insertion of FLAG epitope tag
The absence of Cl- currents through oocytes injected with the mutant transporter does not univo-
cally resolve the effect of the mutation. It remains underdetermined whether the mutation causes a
functional knockout of GlyT1 inserted in the membrane, or whether it has an effect on the correct
protein folding and delivery to the membrane in the first instance.
Electrophysiological recordings cannot resolve this issue which requires the visualization of the
protein in the membrane. Standard techniques utilizing synthetic or animal-derived antibodies
binding to the protein of interest include immunocytochemistry, wester blotting and others. How-
ever, most of these techniques require the homogenization of the cell thus the detection of intra- and
extra-cellular proteins from ruptured cells. Visualisation of membrane proteins can be achieved via
antibody binding to segments of proteins that protrude extracellularly from the membrane. A com-
monly used technique is the insertion of small peptide sequence in the protein for which strongly-
binding antibodies are available, such as the FLAG epitope which is is an eight amino acids epitope
sequence motif (DYKDDDDK) for which strongly binding antibodies are commonly available.
For the purpose of visualization of GlyT1 mutants in the membrane, the FLAG tag was inserted
into the extracellular loop of the protein. The extracellular loop 2 (EL2) is the largest across the
mammalian SLC6 family, thus to minimizes the probability of functional disruption of FLAG in-
sertion, EL2 was chosen as the site of insert. In order to predict the location of EL2, bioinformatics
tools capable of predicting the secondary structure and topology of transporters were used, as can
be seen in Table 5.1.
Once the amino acid sequence composing EL2 was estimated, the location of FLAG insertion was
chosen such that it minimizes the probability that the FLAG insert will have an effect on protein
function. Previously recorder amino acids conserved across the family members were avoided, as
well as positions close to the potential glycosylation sites (Figure 5.4). Location of insert was chosen
as Asp278, since the amino acid in itself forms the beginning of the the FLAG sequence.
Insertion of the FLAG tag was performed via the PCR-driven overlap extension method following
the protocol described in Heckman and Pease [270] (Materials and Methods, Section 5.2). Briefly,
insertion of the sequence was performed in two PCR-reaction steps. Primers were designed such
that in the first cycle, two fragments of the desired product are generated containing overlapping
sections that include the insert. In the second PCR cycle, these fragments are denatured and used
as a template in the following reaction. The single-stranded products hybridize at the overlapping
regions, leading to the amplification of the product driven by the addition of primers flanking the
5’-3’ beginning of sequence and reverse complement of the 3’-5’ end of sequence. Thus, the second
PCR reaction generates the desired product containing the amino acid sequence insert which can
be inserted into a vector of interest.
X. oocytes were injected with the GlyT1-FLAG RNA on the same day as the wtGlyT1 RNA which
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Table 5.1: Bioinformatic tools used to predict the sequence of amino acids composing EL2.








Amino acid length 71-80
Sequence of amino acids composing EL2 as predicted by each tool can be seen in the right hand
column.
was used as a positive control. The oocytes were testes 5-10 days post-injection however no currents
could be detected via the wtGlyT-FLAG construct. Given that currents could be measured via the
wtGlyT1 it is expected that the FLAG insertion caused a knockout of transporter function.
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GlyT WT seq
 10 20 30 40 50 60
MSGGDTRAAI ARPRMAAAHG PVAPSSPEQV TLLPVQRSFF LPPFSGATPS TSLAESVLKV 
70 80 90 100 110 120
WHGAYNSGLL PQLMAQHSLA MAQNGAVPSE ATKRDQNLKR GNWGNQIEFV LTSVGYAVGL 
130 140 150 160 170 180
GNVWRFPYLC YRNGGGAFMF PYFIMLIFCG IPLFFMELSF GQFASQGCLG VWRISPMFKG 
190 200 210 220 230 240
VGYGMMVVST YIGIYYNVVI CIAFYYFFSS MTHVLPWAYC NNPWNTHDCA GVLDASNLTN 
250 260 270 280 290 300
GSRPAALPSN LSHLLNHSLQ RTSPSEEYWR LYVLKLSDDI GNFGEVRLPL LGCLGVSWLV 
310 320 330 340 350 360
VFLCLIRGVK SSGKVVYFTA TFPYVVLTIL FVRGVTLEGA FDGIMYYLTP QWDKILEAKV 
370 380 390 400 410 420
WGDAASQIFY SLGCAWGGLI TMASYNKFHN NCYRDSVIIS ITNCATSVYA GFVIFSILGF 
430 440 450 460 470 480
MANHLGVDVS RVADHGPGLA FVAYPEALTL LPISPLWSLL FFFMLILLGL GTQFCLLETL 
490 500 510 520 530 540
VTAIVDEVGN EWILQKKTYV TLGVAVAGFL LGIPLTSQAG IYWLLLMDNY AASFSLVVIS 
550 560 570 580 590 600
CIMCVAIMYI YGHRNYFQDI QMMLGFPPPL FFQICWRFVS PAIIFFILVF TVIQYQPITY 
610 620 630 640 650 660
NHYQYPGWAV AIGFLMALSS VLCIPLYAMF RLCRTDGDTL LQRLKNATKP SRDWGPALLE 
670 680 690 700
HRTGRYAPTI APSPEDGFEV QPLHPDKAQI PIVGSNGSSR LQDSRI 
N – asparagine potential glycosylation
P – potential alpha helix
E – conserved as in Yamashita et al., 2005
C – disulphide bridge cysteines as in Chen et al., 2007
XYZ – predicted EL2 
XYZ – predicted extracellular loop
S - serine 407
D - insert site Asp278
Figure 5.4: Amino acids spanning extracellular loops of wtGlyT1 as predicted by
bioinformatics tools Prediction of the amino acids sequence composing EL2 is highlighted in
yellow. FLAG insertion was chosen at position Asp278 in order to avoid possible interaction with
residues that form secondary structures, as predicted by the bioinformatics tools used (Table 5.1).
Glutamate at position 267 is a conserved residue across members of the SLC6 family [1]. The two
cysteine residues are a potential site of a disulfide bridge formation as has been found in the
equivalent EL2 cysteines in Drosophila melanogaster dopamine transporter, where mutation of
either or both amino acids produced non-functional transporters [2].
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5.4 Discussion
In this chapter the effect of the Ser407 mutation in the GlyT1 was characterised. Introduction
of a mutation in this amino acid position completely abolished currents via the transporter ex-
pressed in X. oocyte. In the first instance, the polar serine was replaced with glycine which is
a non-conservative mutation. In order to establish whether a less dramatic mutation would lead
to reduced function, serine was replaced with tyrosine which has similar biochemical properties.
However, in both cases no currents could be recorder via GlyT1 mutants. Given that the maxi-
mal amplitudes of currents were very small (maximal values of ≈ 200nA) even via the wtGlyT, it
is possible that small currents, indistinguishable from the background noise were carried via the
tyrosine mutant, thus further investigation is required for complete characterisation of the Ser407
mutation.
Transmembrane helix 7 contains a number of amino acids which are conserved across the family.
In the bacterial leucine transporter, Na+ binding occurs in the unwound regions of TM1 and TM6
halfway across the lipid bilayer and is stabilised by residues in TM7. Crystal structure of the mam-
malian DAT sharing higher sequence similarity to GlyT1 further revealed that the Cl- ion binding
site is located close to the Na1 binding site and is coordinated by residues in TM6, TM2, and Ser356
of TM7 which is the conserved serine residue aligning with GlyT1 Ser407. A detailed study includ-
ing comprehensive sequence alignment between the prokaryotic LeuT and numerous other members
of the mammalian SLC6 transporters including GlyT1 showed that the residues comprising the ag-
onist binding sites are highly conserved across all members, supporting the applicability of LeuT
structure in predicting Ser407 site function [271]. Importance of amino acids comprising TM7 is
further supported by previous directed mutagenesis studies of related transporters. Replacement
of the Ser356 residue to glycine or alanine in the DAT expressed in COS cells significantly reduced
the uptake of dopamine [272]. Similarly, uptake assays in the rat serotonin transporter expressed
in HeLa cells show that mutation in the equivalent TM7 serine causes a 40% or more reduction
in serotonin transport [273]. Altogether, these findings support the results in the current study
suggesting a crucial role of Ser407 in transporter function. Replacement of the polar serine residue
with less polar glycine in the hydrophobic TM7 region likely disrupts GlyT1 function directly via
changing the chemical environment in the co-substrate binding pocket.
In the second section, a small peptide FLAG epitope was inserted into the large extracellular loop
(EL2) of the transporter in order to further examine the effect of the mutation. In ordert to estab-
lish a positive control against which currents via the FLAG-tagged mutants could be established,
the wtGlyT1-FLAG construct was expressed in X. oocyte and compared against the wtGlyT1. It
was found that FLAG insertion at the position Asp278, located at the end of EL2 sequence near
TM4 in the lipid bilayer caused a complete inhibition of currents via the transporter. What could
be the cause of functional disruption?
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As compared to the highly conserved TM7, amino acids of EL2 show a lower sequence conservation
between members of the SLC6 family [271]. Since TM7 comprises the substrate binding site, and all
the SLC6 members transport Na+ and Cl- alike, the high conservation is expected in comparison
to EL2, which is involved in post-translational modifications of the transporter. The EL2 of LeuT is
relatively small in comparison to mammalian SLC6 transporters and does not share high sequence
similarity. In the mammalian SLC6, EL2 contains residues important for proper transporter fold-
ing, trafficking and surface expression.
The SLC6 family members are subject to various post-translational modifications, with the EL2
identified as an important site for N-linked glycosylation, forming bonds with the asparagine residues
[268]. In the GlyT1 transporter EL2 there are eight potential glycosylation sites (Figure 5.4, green)
out of which Asn282 resides closest to the Asp278, location of the FLAG insert. However, only four
of these sites were postulated by Smith et al. [274] to reside in the EL2 region feasible of under-
going glycosylation (Arn237, Arn240, Arn250 and Arn256). This was later confirmed by Olivares,
L. et al. [275] who showed that progressive mutagenesis of these residues lead to reduced transport
activity via GlyT1. In their study, enzymatic deglycosylation resulted in reduced activity of the
transporter-thus N-linked glycosylation is not indispensible to GlyT1 function. As determined by
GlyT1 biotinylation, mutagenesis revealed a lower expression of transporter at the surface mem-
brane, showing that it is important in protein trafficking and stability. Reduced protein expression
at the cell membrane was also found for unglycosylated serotonin [276] and the GABA transporters
[277]. As Asn282 is located closer to the TM4 region in the hydrophobic membrane, it is less likely
that it would be involved in N-linked glycosylation, but may nevertheless affect the conformation
of EL2, affecting glycosylation of the GlyT1.
It is also possible that the location of insert was too close to the TM4 region- predictions from the
bioinformatics tools as in Table 5.1 show that the last amino acid comprising EL2 is likely glutamine
at position 285, however the SOSUI prediction estimates it at the glycine residue at position 281.
Furthermore, the Asp278 is located close to a conserved glycine (Gly284) residue across human
glycine, dopamine, norepinephrine, serotonin and GABA transporters [271]. Since glycine does not
have a side chain, it has higher confromational flexibility and is therefore often found in loops, and
regions of rigid helix formations breaks [278]. Conservation of Gly284 and its equivalents in the
other human SLC6 members may imply an important role of this amino acid in the formation of
the tertiary structure of EL2.
Altogether, these findings suggest a crucial role of the serine residue at position 407 in the human
GlyT1, which likely takes part in the binding of Na+ and Cl- ions in the ligand binding cavity.
Future investigation of the effect of this mutation could involve visualisation of the protein to es-
tablish correct folding and trafficking to the membrane. This could be achieved via insertion of
the FLAG epitope in a position which does not disrupt transporter function, such as an alternative
extracellular loop known to be less important in protein trafficking and stability. Alternative meth-
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ods of protein identification which may cause a smaller interference, such as surface biotinylation
to assess relative expressions of the mutant and wtGlyT1 may also be used.
5.4.1 Conclusion
In summary, the major insights of this chapter relate to the effects of a novel NKH-causing Ser 407
→ Gly mutation. It was found that replacement of the serine with amino acids glycine and tyrosine
leads to the inhibition of currents at all concentrations tested. Furthermore, insertion of the FLAG
epitope, which was attempted in order to establish the mechanism via which the mutation disrupts
transport, showed that FLAG insertion at position Asp 278 in the EL2 also abolishes currents.
Further investigation is required to elucidate the consequence of these genetic manipulations on the
GlyT1 structure and expression in the cell membrane.
The sensitivity of the TEVC set up used for the recording of GlyT1-mediated currents determines
the resolution with which signal is captured. Oocytes injected with the wild type GlyT1 mRNA
showed maximal transporter expression after at least five days post injection, thus maintaning the
viability of the cell in the media until the day of experiment was a difficulty. Many oocytes were
discarded, reducing the pool of material to test experimentally. In addition, since the transporter
tranfers a net one charge upon one transport cycle, the current amplitudes recorder were low, at
roughly 200nA maximal responses collected. The majority of recordings measured at maximal
glycine concentration (1mM) applications were approximately 60nA. At these low currents, good
sensitivity of the instrument is required, such that the background noise can be clearly distinguished
from responses at sub-saturating glycine concentrations. This needs to be taken into account in the
future experiments utilising X.oocytes as an expression system for glycine transporters.
Chapter 6
Conclusions
The dual function of glycine in the CNS as a central metabolite, as well as an inhibitory neu-
rotransmitter across different brain regions establish its importance in human health. Metabolic
pathways of glycine synthesis in this organ are subject to the specificity of brain metabolism in
comparison to other tissue, as determined by the restricted substrate availability as well as the
brain’s high energetic needs. Since glutamate and GABA dominate neurotransmission in the brain
overall, relatively less research has been dedicated to the study of glycine in the CNS. Recent in-
terest in the understanding of pathways of its metabolism has been sparked by numerous studies
showing increased expression of the enzymes involved in serine/glycine interconversions in a subset
of cancers, creating a novel target for the development of chemotherapeutic agents.
F Pertinent to glycine’s action as an inhibitory neurotransmitter, regulation of its concentrations
in the brain in situ has been identified as a potential new method for the treatment of numerous
conditions, as proven by the efforts towards the development of several GlyT1 inhibitors so far.
However, the effect of these compounds on glycinergic transmission is difficult to measure in the
live animal, and although in vitro experimental studies of individual proteins regulating glycine
concentrations may provide detailed descriptions of their activation mechanism, they need to be
combined in order to look at how the interactions between them determine GlyR-mediated IPSC
across a synapse.
Work presented in this thesis employed computational modelling techniques with the overall aim of
increasing the understanding of glycine metabolism, as well as glycinergic neurotransmission relayed
across a synapse. Electrophysiological methods were employed in order to elucidate the effects of
NKH-causing Ser 407 → Gly mutation in the GlyT1, which was integrated into the kinetic model
of the glycinergic synapse to assess its effects on glycinergic currents.
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6.1 Overview of the result
The main aim of Chapter 2 was the construction and curation of a metabolic model representing
CNS metabolism, built on the template of a more generic human tissue reconstruction, Recon2.2
[145]. In order to contextualise the model to represent brain metabolism, experimentally recorder
transport rates of substrates across the BBB, in combination with the well-established brain OGI
parameter were used to estimate the energy and biosynthetic demands of the brain. The response
of the model to changing ATP and biomass demands were assessed by looking at the effects on the
OGI, which establishes a model system capable of directly relating variations in the OGI to sub-
strate consumption and metabolic pathway utilization. Estimations of the background metabolic
requirements allowed for the elucidation of glycine biosynthetic pathways. Increase in the demand
for glycine was seen to slightly decrease the rate of glucose consumption, as well as the conversion
of pyruvate to lactate showing that the mitochondrial SHMT2-catalyzed reaction contributes to
ATP production in the mitochondria.
Heterogeneity in the gene expression across different CNS cell types suggests a variability in the
metabolic pathways utilized by these cells. In Chapter 3, a method for the integration of a single-
cell RNA-seq dataset was developed for the purpose of assessing the possible differences in the
metabolic pathways of energy and glycine production. The motivation for the choice of the dataset
was two-fold- in the first instance, the dataset contains the genetic signature of both excitatory
and inhibitory neurons, with the latter most likely to be glycinergic. In addition, it contains data
from astrocytes and oligodendrocytes- as previously mentioned, the majority of studies of brain
metabolism have focused on glutamatergic, excitatory neurons and the associated astrocytes, and
relatively scant research has been conducted looking at the more rare cell types contained within the
dataset. Lastly, previous studies assessing the expression of genes involved in glycine metabolism
suggested compartmentalization of these pathways across different cell types, which was addresses
in the current study.
Further to Chapter 2 results, pathways of ATP production in each cell type were evaluated. In
contrast to the ANLS hypothesis, genetic expression as well as FBA applied to the model weighted
by the median expression of each cell type suggest high glycolytic activity in the neuron, and a
preference for glucose uptake accompanied by lactate release. Suprisingly, when both substrates
were present, astrocytes showed a preference for lactate uptake, whereas oligodendrocytes utilized
glucose. Although these results require experimental validation, they show that application of
scRNA-seq data to metabolic modelling may provide useful in the investigation of the metabolism
of less studied cell types, such as oligodendrocytes.
In the background of an ATP demand, glycine biosynthesis occured via the mitochondrial SHMT2
from serine and glutamine in the neuronal cell types, and glutamate in glial cell types. Expression of
the SHMT2 enzyme was more widespread than SHMT1 across the dataset, confirming its primary
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role in glycine biosynthesis. Both SHMT2 as well as the GCSH gene expressions were normally
distributed across different cell types, which is in contrast to previous findings that located the
GCS to astrocytes only [47]. Genes encoding enzymes catalyzing the phosphorylated pathway of
serine biosynthesis from glucose were mostly expressed in astrocytes and oligodendrocytes, strongly
suggesting that de novo glycine biosynthesis is indeed compartmentalized across different CNS cell
types.
Genetic expression of enzymes related to the glyoxylate pathway of glycine biosynthesis was min-
imal in the brain, consolidating results from previous studies which suggested that this pathway
does not contribute to glycine biosynthesis in this organ [39].
Knockout of the enzymes involved in glycine metabolism in the model showed the metabolic flexi-
bility of the cell, which could provide useful in the design of a strategy for knockout targets aiming
to disrupt aberrant glycine biosynthesis, such as in cancer. In support of previous experimental
studies in cell cultures [236], model results suggest that serine catabolism to glycine may support
mitochondrial ATP production by providing the ETC with NADH, which could partially explain
the upregulation of serine consumption and large glycine releases in a subset of cancer types, espe-
cially in the context of hypoxia. This could establish the role of this pathway as not only to provide
proliferating cells with the biosynthetic precursors, but also with an associated high demand for
energy which dominates cellular metabolism. However, further experimental validation is required
in order to confirm whether serine can support high cellular ATP demands.
High rates of serine uptake and glycine export were seen in the model which utilized isoleucine and
glutamine as biomass was increased, with the reverse GCS acting as a sink for the nitrogen atoms
generated in the pathways of amino acids breakdown. This could suggest that glycine production
may occur as a method of nitrogen assimilation in cancers utilizing amino acids for energy pro-
duction, especially in hypoxic areas of tumours in which the clearance of metabolic by-products is
disrupted.
Chapter 4 and 5 results are concerned with glycine’s role as an inhibitory neurotransmitter. In
Chapter 4, detailed analysis of the GlyR scheme from Burzomato [144] led to the discovery of
the likely routes of receptor activation at sub-saturating and saturating glycine concentrations, in-
creasing the understanding of receptor dynamics. Derivation of the MWC-type equation from the
GlyR scheme allowed for the reduction of the full model to only one equation, clearly separating
the kinetic parameters related to receptor gating and affinity for substrates, which may aid in the
elucidation of the effects of mutations on receptor function, and provide a quantitative measure for
the differences in the energy provided by the binding of partial agonists [256].
Furthermore, a kinetic model integrating the detailed GlyR scheme, as well as reactions describing
the speed of reuptake by GlyT1 and GlyT2 was developed, allowing for the estimation of the up-
per limits on the rates of reverse transport by each glycine transporter. The model establishes a
system in which theoretical predictions of the effects of protein mutations, inhibitor binding, and
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ionic concentration changes across compartments can be studied. For instance, the depolarization
of the astrocyte expressing GlyT1 was shown to induce glycine release across the synapse, which
was rapidly uptaken by GlyT2 into the neuronal cell.
Suprisingly, the expression of the SLC6A9 gene encoding the GlyT1 as seen in Chapter 3 was
significantly high in oligondendrocytes, suggesting that this cell type may play a role in glycine
metabolism and/or neurotransmission, although whether this is the case requires further investiga-
tion.
The model was also used to assess the effects of varying GlyT numbers on glycine transient con-
centration and time course, as well as the resulting IPSC, showing that much larger changes can
be seen in the former in comparison to the latter. The decay time constant of resulting IPSC was
decreased upon increasing GlyT numbers, but changes were less dramatic than that on the decay
time constant of glycine, confirming that IPSC persistence is mostly dependent on the deactiva-
tion kinetics of the GlyR. This implies that the regulation of the glycinergic neurotransmission via
pharmacological inhibition of GlyTs is limited to a range within which variation in GlyT-mediated
reuptake has an effect on GlyR deactivation.
Experimental results presented in Chapter 5 confirmed that the novel NKH-causing mutation Ser
407 → Gly in the human GlyT1, as reported by Alfadhel,M. et al. [80] causes a knockout of the
transporter function, as no currents could be detected in X. oocytes expressing the mutant. This
result was integrated into the glycinergic synapse model to show that, as anticipated, disruption
of GlyT1 function causes an increase in the maximum amplitude and decay time of the resulting
IPSC via the GlyRs.
6.2 Outlook
Results presented in the current work are non-exhaustive, and both require experimental validation
and provide opportunity for further research.
With respect to the metabolic model of the CNS, improvements to the method of scRNA-seq in-
tegration method can be added. Due to the physical limitations of experimental techniques owing
to the low amount of genetic material present in the first instance, these datasets inherently suffer
from a higher number of possible false-negative values and higher noise resulting from stochasticity
of gene expression, in comparison to bulk RNA sequencing data. Up to date, integration of scRNA-
seq data into metabolic models presented in this thesis has been previously attempted by one group
only [279], thus the method is lacking rigorous assessment of the choices made during analysis. In
the current thesis, the outcome of some of these choices on the feasibility of the objective function
were assessed. For example, it was found that the difference in the results generated by the model
was minimal whether the median, or the maximal value was chosen as the single expression value
used in the objective function weights for a reaction catalyzed by an enzyme with multiple gene
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relationships. However, owing to the novelty of this technique much theoretical consideration is
still needed, which is a task certainly worth pursuing. Application of the scRNA-seq data can
increase our future understanding of the differences in the metabolic pathway utilization on a scale
of single cells, and furthermore, models can be combined in order to look at cooperation between
cell populations. Since metabolic cooperation between cells is largely dependent on the transport
systems available, more attention could be given during the model curation process to transport
reactions, which could also be weighted by their expression values which wasn’t taken into account
in the current study.
Although gene expression values analysed in the current study suggest serine/glycine metabolism
compartmentalization, this hypothesis can be further tested theoretically by analysing these path-
ways in a multi-cellular model, weighted by the expression of individual cell types, as described
previously. These results would require experimental validation, for example by looking at radi-
olabelled glucose incorporation rates into downstream metabolites involved in glycine metabolic
pathways in cellular co-cultures. In return, such experimental data could be integrated into the
metabolic model to consolidate the validity of its predictions.
Results from Chapter 3 which suggest that serine degradation to glycine via SHMT2 in the mito-
chondria may play an important role in supporting ATP production could be expanded upon by
experimental validation in cancer cell lines, increasing the understanding of the role of this amino
acids in context-specific malignancy formation. Inhibition of phosphoglycerate dehydrogenase has
previously been identified as a novel cancer treatment, and was previously found to affect the ac-
tivity of central carbon metabolic pathways such as the ETC and glycolysis [280], implying that
this pathway exhibits regulation over cellular metabolism beyond serine/glycine biosynthesis and
proliferation. The model could be used further to explain the observations from experimental stud-
ies such as the aforementioned, and supply novel hypothesis regarding the effects of serine/glycine
metabolism on the overall cell metabolism. This may help in the design of future treatment strate-
gies applicable to cancers of different human tissue cell types.
With respect to the kinetic model of the glycinergic synapse, in the first instance the model would
greatly benefit from the integration of experimental measurements of the reverse transport rates by
the GlyT1 and GlyT2. The values estimated in the current thesis provide a range within which these
parameters fall, nevertheless are approximations deduced from the estimations of glycine concen-
trations within the astrocyte and neuronal compartments, which have not been directly measures
in vivo. As ample data is available on the forward transport rates of each protein, only one study by
Aubrey et al. [252] has measured the affinity of glycine to GlyT1 in the intracellular-facing protein
conformation, which is more difficult to set up experimentally. Expression of each transporter in
a model system such as the X. oocytes, and manipulation of the internal glycine and ionic con-
centrations would allow for the calculation of dose-response curves for these proteins to ligand in
intracellular-facing states. Integration of these kinetic parameters would improve the validity of
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the current model, which could be further applied to the study of the effects of GlyT inhibitors in
development, such as bitopertin, on the resulting glycinergic currents.
Lastly, the functional knockout resulting from the Ser 407 mutation in the human GlyT1 could be
further explained via experimental validation to establish whether the mutant protein is expressed
in the membrane in the first instance. This was attempted by the insertion of the FLAG epitope,
however could not be confirmed since the insertion also led to functional disruption. These exper-
iments could by continued by the insertion of the FLAG epitope in a different region of the EL2,
or a different extracellular loop altogether. Nevertheless, disruption of transporter function via the
FLAG insertion in itself is of interest, which if further studied could increase the knowledge of the
significance of EL2 in transporter function.
Appendix A





## Sodium concentra t ions , M
x Na = 0.15 ## e x t r a c e l l u l a r Na
x NaG = 0.017 ## g l i a l Na
x NaN = 0.03 ## neuronal Na
R = 1e−12
R No = 100 ##r e c e p t o r number
T = 1e−4

















### Gly r e l e a s e and p o i n t d i f f u s i o n
##
#
V GlyDif f =2.0 e3
V GlyRel= 2 .0 e3
GlyRel :
x Gly −> Gly
( V GlyRel* x Gly )
GlyDi f f :
Gly −> x Gly
( V GlyDif f *Gly )
#
##




V GlyR kf= 0.59 e6
V GlyR kr= 300
V RBind1= V GlyR kf* 3 ##forward r a t e
constants , M−1 s−1
K RBind1 = V RBind1/V GlyR kr ##e q u i l i b r i u m cons tant
M t a k i n g i n t o account the s t a t i s t i c a l f a c t o r s
V RBind2= V GlyR kf* 2
K RBind2= V RBind1 /( V GlyR kr *2)
V RBind3= V GlyR kf
K RBind3 = V RBind3 /( V GlyR kr *3)
RBind1 :
Gly + R <> Gly1R
˜( V RBind1 , K RBind1 )
RBind2 :
Gly + Gly1R <> Gly2R
˜( V RBind2 , K RBind2 )
RBind3 :
Gly + Gly2R <> Gly3R
˜( V RBind3 , K RBind3 )
#
##
### F l i p p i n g o f the bound r e c e p t o r
##
#
V Flip1= 1 .8 e2
#K Flip1= 0.006
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V Flip2 = 6 .8 e3
K Flip2= 0.378
V Flip3 = 20 .9 e3
#K Flip3 = 23.22
Fl ip1 :
Gly1R <> Gly1F
˜( V Flip1 , K Flip1 )
F l ip2 :
Gly2R <> Gly2F
˜( V Flip2 , K Flip2 )
F l ip3 :
Gly3R <> Gly3F
˜( V Flip3 , K Flip3 )
#
##
### Gly Binding to the f l i p p e d r e c e p t o r
##
#
V FBind2= 3 .0 e8
K FBind2= 1.25 e5
V FBind3 = 1.50 e8
K FBind3= 4.17 e4
FBind2 :
Gly + Gly1F <> Gly2F
˜( V FBind2 , K FBind2 )
FBind3 :
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Gly + Gly2F <> Gly3F






V Open1 = 4 .2 e3
K Open1 = 1.235
V Open2= 2 .8 e4
K Open2 = 13 .3




˜(V Open1 , K Open1)
Open2 :
Gly2F <> Gly2Fopen
˜(V Open2 , K Open2)
Open3 :
Gly3F <> Gly3Fopen
˜(V Open3 , K Open3)
K Flip1 = K Flip2 *K RBind2/ K FBind2
K Flip3 = K Flip2 *K FBind3/K RBind3
#





## parameters from Roux and S u p p l i s s o n : Glycine t r a n s p o r t e r s have
d i f f e r e n t s t o i c h i o m e t r i e s
## GlyT1 parameters
kcat GlyT1 = 20
kcatr GlyT1 = 5
keq GlyT1 = 22 .6 e−6
keq GlyGT1 = 5.7 e−3
h NaT1 = 1 .4
h NaGT1 = 1 .4
keq NaT1 = 6e−3
keq NaGT1 = 2 .9 e−2
## GlyT2 parameters
kcat GlyT2 = 20
kcatr GlyT2= 5
keq GlyT2 = 24 .6 e−6
keq GlyNT2 = 17 .0 e−3
h NaT2 = 2 .2
h NaNT2 = 2.2
keq NaT2 = 30e−3




( ( ( kcat GlyT1 * GlyT1 * T) * Gly * ( x Na**h NaT1) ) / ( ( keq GlyT1
+ Gly ) * ( keq NaT1 + x Na ) **h NaT1) )− ( ( ( kcatr GlyT1 * GlyT1 *
T) * GlyG * (x NaG**h NaGT1) ) / ( ( keq GlyGT1 + GlyG) *
(keq NaGT1 + x NaG) **h NaGT1) )
GlyT2 tx :
Gly <> GlyN
( ( ( kcat GlyT2 * GlyT2 * T) * Gly * ( x Na**h NaT2) ) / ( ( keq GlyT2
+ Gly ) * ( keq NaT2 + x Na ) **h NaT2) )− ( ( ( kcatr GlyT2 * GlyT2 *
T) * GlyN * (x NaN**h NaNT2) ) / ( ( keq GlyNT2 + GlyN) *
(keq NaNT2 + x NaN) **h NaNT2) )
## Current v i a the t r a n s p o r t e r s
e= 1.6021766208 e−19 ## e l e c t r o n charge , C
I GlyT1 := GlyT1 tx * e
I GlyT2 := GlyT2 tx * 2 * e
#
##
### Removal o f g l i a l and neuronal g l y c i n e
##
#
G l y r e l= 1e1 ## a d j u s t e d s low p r o c e s s e s
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GlyGRelease : ## s i n k f o r g l i a l g l y c i n e
GlyG −> x Gly
( G l y r e l * GlyG)
GlyNRelease : ## s i n k f o r neuronal g l y c i n e
GlyN −> x Gly
( G l y r e l * GlyN)
Closed := (R + Gly1R + Gly2R + Gly3R + Gly1F + Gly2F + Gly3F ) * 1 e12
Open := ( Gly1Fopen + Gly2Fopen + Gly3Fopen ) * 1 e12
Fl ipped := ( Gly1F + Gly2F + Gly3F ) *1 e12
#
##
### E l e c t r o p h y s c a l c u l a t i o n s
##
#
gmax= 45 .9 e−12 ## s i n g l e channel conductance , A , from S c o t t e t
a l , 2015
V= −60e−3 ## membrane v o l t a g e , V
E rev= −70e−3 ## r e v e r s a l p o t e n t i a l f o r c h l o r i d e ions , V
g := gmax * (Open)
I := gmax * (Open) * (V− E rev ) ## Current , A
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PicoI := I * 10 e12 ## Current , pA
I patch := (gmax * R No) * (Open) * (V− E rev ) * 10 e12 ##
Current through n*GlyR , pA
I p := Open * R No











MWCOpen := (1+(Gly/Ko) **3) / ( (1+(Gly/Ko) **3) + (M*(1+(Gly/Kf ) **3) ) +
(L*M*(1+(Gly/Kr) **3) ) )
Saturat ion := ( ( Gly/Ko) *(1+(Gly/Ko) ) ˆ2 + M*( Gly/Kf ) *(1+(Gly/Kf ) ) ˆ2 +
M*L*( Gly/Kr) *(1+(Gly/Kr) ) ˆ2) / (1+(Gly/Ko) ) ˆ3 + M*(1+(Gly/Kf ) ) ˆ3 +
M*L*(1+(Gly/Kr) ) ˆ3)
MWCFlipped := (M*(1+(Gly/Kf ) **3) ) / ( (1+(Gly/Ko) **3) +
(M*(1+(Gly/Kf ) **3) ) + (L*M*(1+(Gly/Kr) **3) ) )
MWCResting := (L*M*(1+(Gly/Kr) **3) ) / ( (1+(Gly/Ko) **3) +
(M*(1+(Gly/Kf ) **3) ) + (L*M*(1+(Gly/Kr) **3) ) )
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Appendix B
List of kinetic parameters used in the glycinergic synapse model.
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Reaction Parameter Model value (M , Ms-1) Reference
Glycine receptor activation
r1 (RBind1) Vmax 1 1.77×106 [144]
Keq 1 5.9×103 [144]
r2 (RBind2) Vmax 2 1.18×106 [144]
Keq 2 2.95×103 [144]
r3 (RBind3) Vmax 3 5.9×105 [144]
Keq 3 6.55×102 [144]
r4 (Flip1) Vmax 4 1.80×102 [144]
Keq 4 Keq 5×Keq 2/Keq 7 [144]
r5 (Flip2) Vmax 5 6.80×103 [144]
Keq 5 0.0378 [144]
r6 (Flip3) Vmax 6 20.90×103 [144]
Keq 6 Keq 5×Keq 3/Keq 8 [144]
r7 (FBind2) Vmax 7 3.00×108 [144]
Keq 7 1.25×105 [144]
r8 (FBind3) Vmax 8 1.50×108 [144]
Keq 8 4.17×104 [144]
r9 (Open1) Vmax 9 4.20×103 [144]
Keq 9 1.235 [144]
r10 (Open2) Vmax 10 2.80×104 [144]
Keq 10 1.33×101 [144]
r11 (Open3) Vmax 11 1.29×105 [144]
Keq 11 1.84×101 [144]
Glycine release
r12 kf12 2.00×103 [281]
Glycine diffusion
r13 kf13 2.00×103 -
Glycine Transporter 1
r14 kf14 20.00 [219, 282]
kr14 5.00 -
Keq Glye14 22.60×10−6 [66]
Keq Glyi14 5.7×10−3 [252]
Keq Na
+




Hill Na+14 1.4 [66]
Glycine Transporter 2
r15 kf 15 20.00 [219, 282]
kr 15 5.00 -
Keq Glye15 24.60×10−6 [66]
Keq Glyi15 17.00×10−3 -
Keq Na
+
e 15 30.00×10−3 [66, 219]
Keq Na
+
i 15 8.00×10−2 -
Hill Na+15 2.2 [66]
Glial and neuronal glycine removal processes
r16 kf 16 1.00×101 -
r17 kf 17 1.00×101 -
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